

## References (1995)

- Abimiku AG; Franchini G; Aldrich K; Myagkikh M; Markham P; Gard E; Gallo RC; Robert-Guroff M  
Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2.  
*AIDS Res Hum Retroviruses* 11: 383-93 (1995)
- Abravaya K; Carrino JJ; Muldoon S; Lee HH  
Detection of point mutations with a modified ligase chain reaction (Gap-LCR).  
*Nucleic Acids Res* 23: 675-82 (1995)
- Adu-Sarkodie Y  
Antimicrobial susceptibility of *Neisseria gonorrhoeae*, the essential drug list, and HIV/AIDS control [letter]  
*Trop Doct* 25: 45 (1995)
- Aggarwal BB; Totpal K; LaPushin R; Chaturvedi MM; Pereira-Smith OM; Smith JR  
Diminished responsiveness of senescent normal human fibroblasts to TNF-dependent proliferation and interleukin production is not due to its effect on the receptors or on the activation of a nuclear factor NF-kappa B.  
*Exp Cell Res* 218: 381-8 (1995)
- Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW  
Inhibition of HIV-1 by a double transdominant fusion gene.  
*Gene Ther* 2: 181-6 (1995)
- Ahmad N; Baroudy BM; Baker RC; Chappey C  
Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.  
*J Virol* 69: 1001-12 (1995)
- Aiken C; Trono D  
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.  
*J Virol* 69: 5048-56 (1995)
- Aiken C; Trono D  
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.  
*J Virol* 69: 5048-56 (1995)
- Akolkar PN; Chirmule N; Gulwani-Akolkar B; Pahwa S; Kalyanaraman VS; Pergolizzi R; Macphail S; Silver J  
V beta-specific activation of T cells by the HIV glycoprotein gp 160.  
*Scand J Immunol* 41: 487-98 (1995)
- Akolkar PN; Gulwani-Akolkar B; Chirmule N; Pahwa S; Kalyanaraman VS; Pergolizzi R; Macphail S; Silver J  
V beta-specific activation of T-cells by the HIV glycoprotein gp160.  
*Ann N Y Acad Sci* 756: 447-9 (1995)
- Albini A; Barillari G; Benelli R; Gallo RC; Ensoli B  
Angiogenic properties of human immunodeficiency virus type 1 Tat protein.  
*Proc Natl Acad Sci U S A* 92: 4838-42 (1995)
- Alcami J; Lain de Lera T; Folgueira L; Pedraza MA; Jacque JM; Bachelier F; Noriega AR; Hay RT; Harrich D; Gaynor RB; et al  
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes.  
*EMBO J* 14: 1552-60 (1995)
- Ali SA; Steinkasserer A  
PCR-ligation-PCR mutagenesis: a protocol for creating gene fusions and mutations.  
*Biotechniques* 18: 746-50 (1995)
- Allan JS; Ray P; Broussard S; Whitehead E; Hubbard G; Butler T; Brasky K; Luciw P; Cheng-Mayer C; Levy JA; et al  
Infection of baboons with simian/human immunodeficiency viruses.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 429-41 (1995)
- Allan JS; Ray P; Broussard S; Whitehead E; Hubbard G; Butler T; Brasky K; Luciw P; Cheng-Mayer C; Levy JA; et al  
Infection of baboons with simian/human immunodeficiency viruses.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 429-41 (1995)
- Allen P; Worland S; Gold L  
Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool.  
*Virology* 209: 327-36 (1995)
- Almond N; Kent K; Cranage M; Rud E; Clarke B; Stott EJ  
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells [see comments]  
*Lancet* 345: 1342-4 (1995)
- Altuvia Y; Schueler O; Margalit H  
Ranking potential binding peptides to MHC molecules by a computational threading approach.  
*J Mol Biol* 249: 244-50 (1995)
- Amacker M; Hottiger M; Hubscher U  
Feline immunodeficiency virus reverse transcriptase: expression, functional characterization, and reconstitution of the 66- and 51-kilodalton subunits.  
*J Virol* 69: 6273-9 (1995)

- Amendt BA; Si ZH; Stoltzfus CM  
Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors.  
*Mol Cell Biol* 15: 4606-15 (1995)
- Amir M; Paul J; Batchelor B; Kariuki S; Ojoo J; Waiyaki P; Gilks C  
Nasopharyngeal carriage of *Staphylococcus aureus* and carriage of tetracycline-resistant strains associated with HIV-seropositivity.  
*Eur J Clin Microbiol Infect Dis* 14: 34-40 (1995)
- Anazodo MI; Wainberg MA; Friesen AD; Wright JA  
Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.  
*J Virol* 69: 1794-801 (1995)
- Andeweg AC; Boers PH; Osterhaus AD; Bosch ML  
Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis.  
*J Gen Virol* 76 ( Pt 8): 1901-7 (1995)
- Andris JS; Capra JD  
The molecular structure of human antibodies specific for the human immunodeficiency virus.  
*J Clin Immunol* 15: 17-26 (1995)
- Angarano G; Carbonara D; Costa D  
Drug resistance of *Mycobacterium tuberculosis* strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. The Italian Tuberculosis Drug Resistance Study Group.  
*Microbiologica* 18: 69-72 (1995)
- Ansardi DC; Pal-Ghosh R; Porter D; Morrow CD  
Encapsidation and serial passage of a poliovirus replicon which expresses an inactive 2A proteinase.  
*J Virol* 69: 1359-66 (1995)
- Ansari-Lari MA; Donehower LA; Gibbs RA  
Analysis of human immunodeficiency virus type 1 integrase mutants.  
*Virology* 211: 332-5 (1995)
- Antonioli IM; Baumberger C; Yerly S; Perrin L  
V3 sequences in primary HIV-1 infection.  
*AIDS* 9: 11-7 (1995)
- Arad G; Chorev M; Shtorch A; Goldblum A; Kotler M  
Point mutation in avian sarcoma leukaemia virus protease which increases its activity but impairs infectious virus production.  
*J Gen Virol* 76 ( Pt 8): 1917-25 (1995)
- Araujo JC; Doniger J; Kashanchi F; Hermonat PL; Thompson J; Rosenthal LJ  
Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters.  
*J Virol* 69: 4933-40 (1995)
- Arendrup M; Akerblom L; Heegaard PM; Nielsen JO; Hansen JE  
The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.  
*Arch Virol* 140: 655-70 (1995)
- Arnaiz-Villena A; Rodriguez-Gallego C; Timon M; Corell A; Pacheco A; Alvarez-Zapata D; Madrono A; Iglesias P; Regueiro JR  
Diseases involving the T-cell receptor/CD3 complex.  
*Crit Rev Oncol Hematol* 19: 131-47 (1995)
- Arnold C; Balfe P; Clewley JP  
Sequence distances between env genes of HIV-1 from individuals infected from the same source: implications for the investigation of possible transmission events.  
*Virology* 211: 198-203 (1995)
- Arnold C; Barlow KL; Parry JV; Clewley JP  
At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England.  
*AIDS Res Hum Retroviruses* 11: 427-9 (1995)
- Arnold E; Ding J; Hughes SH; Hostomsky Z  
Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates.  
*Curr Opin Struct Biol* 5: 27-38 (1995)
- Arrigo SJ; Haines JK; Huffman KM  
Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.  
*DNA Cell Biol* 14: 15-23 (1995)
- Arrigo SJ; Huffman K  
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.  
*J Virol* 69: 5988-94 (1995)

## References (1995)

- Arroyo J; Boceta M; Gonzalez ME; Michel M; Carrasco L  
Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41.  
*J Virol* 69: 4095-102 (1995)
- Artenstein AW; VanCott TC; Mascola JR; Carr JK; Hegerich PA; Gaywee J; Sanders-Buell E; Robb ML; Dayhoff DE; Thivichianlert S; et al  
Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.  
*J Infect Dis* 171: 805-10 (1995)
- Arthur LO; Bess JW Jr; Urban RG; Strominger JL; Morton WR; Mann DL; Henderson LE; Benveniste RE  
Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.  
*J Virol* 69: 3117-24 (1995)
- Artico M; Silvestri R; Stefancich G; Massa S; Pagnozzi E; Musu D; Scintu F; Pinna E; Tinti E; La Colla P  
Synthesis of pyrrol aryl sulfones targeted at the HIV-1 reverse transcriptase.  
*Arch Pharm (Weinheim)* 328: 223-9 (1995)
- Asano N; Kizu H; Oseki K; Tomioka E; Matsui K; Okamoto M; Baba M  
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.  
*J Med Chem* 38: 2349-56 (1995)
- Aubin JT; Boulay D; Chapus A; Brechot C; Laure F; Agut H  
Evaluation of a new non-isotopic sandwich hybridization for the detection of HIV1-specific PCR products.  
*Res Virol* 146: 75-9 (1995)
- Autiero M; Houlgatte R; Martin M; Auffray C; Guardioli J; Piatier-Tonneau D  
Competition of HLA-DR and a beta 2 domain peptide for HIV envelope glycoprotein gp120 binding to CD4.  
*Int Immunol* 7: 191-7 (1995)
- Avril LE; di Martino-Ferrer M; Brillard-Bourdet M; Gauthier F  
Inhibition of U-937 membrane-associated cathepsin G by GP120 (IIIB) and V3 loop-derived peptides from several strains of HIV-1.  
*FEBS Lett* 367: 251-6 (1995)
- Ayisi NK; Mensah M; Ishikawa K; Sata T  
Serological, virological, and polymerase chain reaction studies of HIV type 1 and HIV type 2 infections in Ghanaian patients with AIDS and AIDS-related complex.  
*AIDS Res Hum Retroviruses* 11: 319-21 (1995)
- Baba TW; Jeong YS; Pennick D; Bronson R; Greene MF; Ruprecht RM  
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.  
*Science* 267: 1820-5 (1995)
- Bachelder RE; Bilancieri J; Lin W; Letvin NL  
A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4.  
*J Virol* 69: 5734-42 (1995)
- Bagetta G; Corasaniti MT; Berliocchi L; Navarra M; Finazzi-Agro A; Nistico G  
HIV-1 gp120 produces DNA fragmentation in the cerebral cortex of rat.  
*Biochem Biophys Res Commun* 211: 130-6 (1995)
- Bagnarelli P; Menzo S; Valenza A; Paolucci S; Petroni S; Scalise G; Sampaolesi R; Manzin A; Varaldo PE; Clementi M  
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.  
*J Clin Microbiol* 33: 16-23 (1995)
- Baier G; Baier-Bitterlich G; Looney DJ; Altman A  
Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.  
*J Virol* 69: 2357-65 (1995)
- Baldari CT; Milia E; Di Somma MM; Baldoni F; Valitutti S; Telford JL  
Distinct signaling properties identify functionally different CD4 epitopes.  
*Eur J Immunol* 25: 1843-50 (1995)
- Baldwin ET; Bhat TN; Liu B; Pattabiraman N; Erickson JW  
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.  
*Nat Struct Biol* 2: 244-9 (1995)
- Baltimore D  
Lessons from people with nonprogressive HIV infection [editorial; comment]  
*N Engl J Med* 332: 259-60 (1995)
- Baltimore D  
The enigma of HIV infection.  
*Cell* 82: 175-6 (1995)

- Balzarini J; Baba M; De Clercq E  
Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.  
*Antimicrob Agents Chemother* 39: 998-1002 (1995)
- Balzarini J; Perez-Perez MJ; Velazquez S; San-Felix A; Camarasa MJ; De Clercq E; Karlsson A  
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).  
*Proc Natl Acad Sci U S A* 92: 5470-4 (1995)
- Balzarini J; Verstuyf A; Hatse S; Goebels J; Sobis H; Vandeputte M; De Clercq E  
The human immunodeficiency virus(HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines.  
*Int J Cancer* 61: 130-7 (1995)
- Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K  
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.  
*Biochem Biophys Res Commun* 211: 850-6 (1995)
- Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K  
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.  
*Biochem Biophys Res Commun* 211: 850-6 (1995)
- Bandres JC; Shaw AS; Ratner L  
HIV-1 Nef protein downregulation of CD4 surface expression: relevance of the Ick binding domain of CD4.  
*Virology* 207: 338-41 (1995)
- Barbas SM; Ditzel HJ; Salonen EM; Yang WP; Silverman GJ; Burton DR  
Human autoantibody recognition of DNA.  
*Proc Natl Acad Sci U S A* 92: 2529-33 (1995)
- Barksdale SK; Baker CC  
The human immunodeficiency virus type 1 Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5' splice site in a 3' untranslated region.  
*Mol Cell Biol* 15: 2962-71 (1995)
- Barlow KL; Tosswill JH; Clewley JP  
Analysis and genotyping of PCR products of the Amplicor HIV-1 kit.  
*J Virol Methods* 52: 65-74 (1995)
- Barrow WW; Davis TL; Wright EL; Labrousse V; Bachelet M; Rastogi N  
Immunomodulatory spectrum of lipids associated with *Mycobacterium avium* serovar 8.  
*Infect Immun* 63: 126-33 (1995)
- Batchu RB; Hermonat PL  
The trans-inhibitory Rep78 protein of adeno-associated virus binds to TAR region DNA of the human immunodeficiency virus type 1 long terminal repeat.  
*FEBS Lett* 367: 267-71 (1995)
- Bawa N; Broor S; Seth P  
A nonradioisotopic reverse phase dipstick hybridization method for detection of polymerase chain reaction amplified product.  
*Indian J Med Res* 101: 142-6 (1995)
- Bayer P; Kraft M; Ejchart A; Westendorp M; Frank R; Rosch P  
Structural studies of HIV-1 Tat protein.  
*J Mol Biol* 247: 529-35 (1995)
- Bazarbachi A; Canivet M; Peries J  
[Role of retroviruses in human cancerogenesis]  
*Bull Cancer (Paris)* 82 Suppl 2: 85s-92s (1995)
- Beale J  
An attenuated vaccine for AIDS? [comment]  
*Lancet* 345: 1318-9 (1995)
- Bebenek K; Beard WA; Casas-Finet JR; Kim HR; Darden TA; Wilson SH; Kunkel TA  
Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain.  
*J Biol Chem* 270: 19516-23 (1995)
- Becker Y  
An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "peplotion" transepidermal transfer and HLA class I presentation to CD8+ CTLs—an approach to immunization of humans.  
*Virus Genes* 9: 133-47 (1995)
- Bendinelli M; Pistello M; Lombardi S; Poli A; Garzelli C; Matteucci D; Ceccherini-Nelli L; Malvaldi G; Tozzini F  
Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.  
*Clin Microbiol Rev* 8: 87-112 (1995)
- Benjouad A; Chapuis F; Fenouillet E; Gluckman JC  
Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.  
*Virology* 206: 457-64 (1995)

## References (1995)

- Berchtold S; Hornung U; Aepinus C  
The activation domain of simian immunodeficiency virus SIVmac239 Rev protein is structurally and functionally analogous to the HIV-1 Rev activation domain.  
*Virology* 211: 285-9 (1995)
- Berchtold S; Hornung U; Aepinus C  
The activation domain of simian immunodeficiency virus SIVmac239 Rev protein is structurally and functionally analogous to the HIV-1 Rev activation domain.  
*Virology* 211: 285-9 (1995)
- Berkhout B; Klaver B; Das AT  
A conserved hairpin structure predicted for the poly(A) signal of human and simian immunodeficiency viruses.  
*Virology* 207: 276-81 (1995)
- Berkhout B; van Wamel J; Klaver B  
Requirements for DNA strand transfer during reverse transcription in mutant HIV-1 virions.  
*J Mol Biol* 252: 59-69 (1995)
- Berkhout B; van Wamel JL  
Inhibition of human immunodeficiency virus expression by sense transcripts encoding the retroviral leader RNA.  
*Antiviral Res* 26: 101-15 (1995)
- Berkowitz RD; Ohagen A; Høglund S; Goff SP  
Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polypeptides during RNA packaging in vivo.  
*J Virol* 69: 6445-56 (1995)
- Bernier R; Tremblay M  
Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1.  
*J Virol* 69: 291-300 (1995)
- Bernstein HB; Tucker SP; Kar SR; McPherson SA; McPherson DT; Dubay JW; Lebowitz J; Compans RW; Hunter E  
Oligomerization of the hydrophobic heptad repeat of gp41.  
*J Virol* 69: 2745-50 (1995)
- Berzofsky JA  
Designing peptide vaccines to broaden recognition and enhance potency.  
*Ann N Y Acad Sci* 754: 161-8 (1995)
- Bevan MJ; Braciale TJ  
Why can't cytotoxic T cells handle HIV? [comment]  
*Proc Natl Acad Sci U S A* 92: 5765-7 (1995)
- Bilello JA; Bilello PA; Prichard M; Robins T; Drusano GL  
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.  
*J Infect Dis* 171: 546-51 (1995)
- Billich A; Hammerschmid F; Peichl P; Wenger R; Zenke G; Quesniaux V; Rosenwirth B  
Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.  
*J Virol* 69: 2451-61 (1995)
- Billich A; Hammerschmid F; Peichl P; Wenger R; Zenke G; Quesniaux V; Rosenwirth B  
Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.  
*J Virol* 69: 2451-61 (1995)
- Blasco E; Barra A; Nicolas M; Lecron JC; Wijdenes J; Preud'homme JL  
Proliferative response of human CD4+ T lymphocytes stimulated by the lectin jacalin.  
*Eur J Immunol* 25: 2010-8 (1995)
- Blazquez MV; Madueno JA; Jurado R; Fernandez-Arcas N; Munoz E  
Human herpesvirus-6 and the course of human immunodeficiency virus infection.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 389-94 (1995)
- Bochkarev AV; Zavgorodnii SG; Zhdanov AS; Gurskaia GV  
[X-ray structural study of 3'-O-methylthiomethylthymidine and 3'-O-methylsulfinylmethylthymidine-potential inhibitors of HIV]  
*Bioorg Khim* 21: 206-11 (1995)
- Bochkov NP; Ivanov VI; Petrov RV; Khaitov RM  
[Genetics and immunology in medicine]  
*Vestn Ross Akad Med Nauk* 6: 23-32 (1995)
- Bodeus M; Marie-Cardine A; Bougeret C; Ramos-Morales F; Benarous R  
In vitro binding and phosphorylation of human immunodeficiency virus type 1 Nef protein by serine/threonine protein kinase.  
*J Gen Virol* 76 ( Pt 6): 1337-44 (1995)
- Boerlin P; Boerlin-Petzold F; Durussel C; Addo M; Pagani JL; Chave JP; Bille J  
Cluster of oral atypical *Candida albicans* isolates in a group of human immunodeficiency virus-positive drug users.  
*J Clin Microbiol* 33: 1129-35 (1995)

- Bogaerts J; Kestens L; Martinez Tello W; Akingeneye J; Mukantabana V; Verhaegen J; Van Dyck E; Piot P  
Failure of treatment for chancroid in Rwanda is not related to human immunodeficiency virus infection: in vitro resistance of *Haemophilus ducreyi* to trimethoprim-sulfamethoxazole. *Clin Infect Dis* 20: 924-30 (1995)
- Bogerd HP; Fridell RA; Madore S; Cullen BR  
Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. *Cell* 82: 485-94 (1995)
- Bonhoeffer S; Holmes EC; Nowak MA  
Causes of HIV diversity [letter] *Nature* 376: 125 (1995)
- Borghi P; Fantuzzi L; Varano B; Gessani S; Puddu P; Conti L; Capobianchi MR; Ameglio F; Belardelli F  
Induction of interleukin-10 by human immunodeficiency virus type 1 and its gp120 protein in human monocytes/macrophages. *J Virol* 69: 1284-7 (1995)
- Boriskin YuS; Booth JC; Fernando S; Carrington D; Evans MR; Hay P; Coates AR  
The detection of HIV-1 proviral DNA by PCR in clotted blood specimens. *J Virol Methods* 52: 87-94 (1995)
- Borman AM; Quillent C; Charneau P; Dauguet C; Clavel F  
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. *J Virol* 69: 2058-67 (1995)
- Borman AM; Quillent C; Charneau P; Kean KM; Clavel F  
A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G→A hypermutation during negative-strand viral DNA synthesis. *Virology* 208: 601-9 (1995)
- Borvak J; Chou CS; Bell K; Van Dyke G; Zola H; Ramilo O; Vitetta ES  
Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. *J Immunol* 155: 3196-204 (1995)
- Boshoff C; Whitby D; Hatzioannou T; Fisher C; van der Walt J; Hatzakis A; Weiss R; Schulz T  
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma [letter] *Lancet* 345: 1043-4 (1995)
- Boudet F; Keller H; Kieny MP; Theze J  
Single peptide and anti-idiotypic based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice. *Mol Immunol* 32: 449-57 (1995)
- Boullier S; Cochet M; Poccia F; Gougeon ML  
CDR3-independent gamma delta V delta 1+ T cell expansion in the peripheral blood of HIV-infected persons. *J Immunol* 154: 1418-31 (1995)
- Bour S; Geleziunas R; Wainberg MA  
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. *Microbiol Rev* 59: 63-93 (1995)
- Bour S; Schubert U; Strebel K  
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. *J Virol* 69: 1510-20 (1995)
- Bourinbaier AS; Lee-Huang S  
Anti-HIV effect of beta subunit of human chorionic gonadotropin (beta hCG) in vitro. *Immunol Lett* 44: 13-8 (1995)
- Boyle MJ; Connors M; Flanagan ME; Geiger SP; Ford H Jr; Baseler M; Adelsberger J; Davey RT Jr; Lane HC  
The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. *J Immunol* 154: 6612-23 (1995)
- Brakch N; Dettin M; Scarinci C; Seidah NG; Di Bello C  
Structural investigation and kinetic characterization of potential cleavage sites of HIV GP160 by human furin and PC1. *Biochem Biophys Res Commun* 213: 356-61 (1995)
- Brand D; Mallet F; Truong C; Roingeard P; Goudeau A; Barin F  
A simple procedure to generate chimeric Pr55gag virus-like particles expressing the principal neutralization domain of human immunodeficiency virus type 1. *J Virol Methods* 51: 153-68 (1995)
- Brand D; Srinivasan K; Sodroski J  
Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein. *J Virol* 69: 166-71 (1995)
- Brander C; Pichler WJ; Corradin G  
Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine. *Clin Exp Immunol* 101: 107-13 (1995)

## References (1995)

- Bravo R; Soriano V; Martin R; del Romero J; Dronda F; Gutierrez M; Martinez P; Valencia E; Moreno V; Laguna F; et al  
[The quantification of human immunodeficiency virus viremia in patients with rapid and slow progression of the disease]  
Med Clin (Barc) 104: 530-4 (1995)
- Brennan CA; Christianson K; La Fleur MA; Mandecki W  
A molecular sensor system based on genetically engineered alkaline phosphatase.  
Proc Natl Acad Sci U S A 92: 5783-7 (1995)
- Breslin HJ; Kukla MJ; Ludovici DW; Mohrbacher R; Ho W; Miranda M; Rodgers JD; Hitchens TK; Leo G; Gauthier DA; et al  
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3.  
J Med Chem 38: 771-93 (1995)
- Breuer J; Douglas NW; Goldman N; Daniels RS  
Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype.  
J Gen Virol 76 ( Pt 2): 333-45 (1995)
- Breuer J; Douglas NW; Goldman N; Daniels RS  
Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype.  
J Gen Virol 76 ( Pt 2): 333-45 (1995)
- Briant L; Wade CM; Puel J; Brown AJ; Guyader M  
Analysis of envelope sequence variants suggests multiple mechanisms of mother-to-child transmission of human immunodeficiency virus type 1.  
J Virol 69: 3778-88 (1995)
- Bridger GJ; Skerlj RT; Thornton D; Padmanabhan S; Martellucci SA; Henson GW; Abrams MJ; Yamamoto N; De Vreese K; Pauwels R; et al  
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.  
J Med Chem 38: 366-78 (1995)
- Bridges CG; Taylor DL; Kang MS; Brennan TM; Tynms AS  
Treatment with the alpha-glucosidase 1 inhibitor 6-O-butanoyl castanospermine reduces the detection of LFA-1 (CD18/CD11a) by monoclonal antibodies.  
Glycobiology 5: 243-7 (1995)
- Bristow CL; Fiscus SA; Flood PM; Arnold RR  
Inhibition of HIV-1 by modification of a host membrane protease.  
Int Immunol 7: 239-49 (1995)
- Brockman JA; Scherer DC; McKinsey TA; Hall SM; Qi X; Lee WY; Ballard DW  
Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation.  
Mol Cell Biol 15: 2809-18 (1995)
- Broom AD; Agrawal VK; Tutonda MG; Fain HD; Buckheit RW Jr  
Unusual single-stranded polyribonucleotides as potent anti-HIV agents.  
J Med Chem 38: 3253-7 (1995)
- Brossard Y; Aubin JT; Mandelbrot L; Bignozzi C; Brand D; Chapat A; Roume J; Mulliez N; Mallet F; Agut H; et al  
Frequency of early in utero HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses.  
AIDS 9: 359-66 (1995)
- Brostrom C; Sonnerberg A; Sallberg M  
Human immunodeficiency virus type 1-infected patients with no disease progression display high-avidity antibody production to autologous V3 sequences [letter]  
J Infect Dis 171: 509-11 (1995)
- Brown LE; White DO; Agius C; Kemp BE; Yatzakis N; Pombourios P; McPhee DA; Jackson DC  
Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.  
Arch Virol 140: 635-54 (1995)
- von Brunn A; von Brunn B; Eberle J; Biryahwaho B; Downing RG; Gurtler L  
New crown motif of an HIV-1 V3 loop sequence from a Ugandan AIDS patient.  
AIDS Res Hum Retroviruses 11: 183-4 (1995)
- Brumeanu TD; Zaghouni H; Elahi E; Daian C; Bona CA  
Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements.  
J Immunol 154: 3088-95 (1995)
- Bryan CS  
Toward a post-antibiotic era? [editorial]  
J S C Med Assoc 91: 35-7 (1995)
- Bryson YJ; Pang S; Wei LS; Dickover R; Diagne A; Chen IS  
Clearance of HIV infection in a perinatally infected infant [see comments]  
N Engl J Med 332: 833-8 (1995)

- Buchsachacher GL Jr; Freed EO; Panganiban AT  
Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant.  
*J Virol* 69: 1344-8 (1995)
- Buckheit RW Jr; Fliakas-Boltz V; Decker WD; Roberson JL; Stup TL; Pyle CA; White EL; McMahon JB; Currens MJ; Boyd MR; et al  
Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.  
*Antiviral Res* 26: 117-32 (1995)
- Buckheit RW Jr; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP  
Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.  
*Virology* 210: 186-93 (1995)
- Budt KH; Peyman A; Hansen J; Knolle J; Meichsner C; Paessens A; Ruppert D; Stowasser B  
HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols.  
*Bioorg Med Chem* 3: 559-71 (1995)
- Bujia J; Wilmes E; Gurtler L  
[Analysis of the possibility of transmitting the human immunodeficiency virus when using cartilage grafts]  
*Acta Otorrinolaringol Esp* 46: 75-81 (1995)
- Bukrinsky MI; Nottet HS; Schmidtmayerova H; Dubrovsky L; Flanagan CR; Mullins ME; Lipton SA; Gendelman HE  
Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.  
*J Exp Med* 181: 735-45 (1995)
- van der Burg SH; Klein MR; van de Velde CJ; Kast WM; Miedema F; Melief CJ  
Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase.  
*AIDS* 9: 121-7 (1995)
- Burgess EM; Ruell JA; Zalkow LH; Haugwitz RD  
Molecular similarity from atomic electrostatic multipole comparisons. Application to anti-HIV drugs.  
*J Med Chem* 38: 1635-40 (1995)
- Burioni R; Plaisant P; Riccio ML; Rossolini GM; Santangelo R; Vannini A; Satta G  
Engineering human monoclonal antibody fragments: a recombinant enzyme-linked Fab.  
*Microbiologica* 18: 127-33 (1995)
- Burioni R; Plaisant P; Riccio ML; Rossolini GM; Satta G  
A new plasmid cloning vector for direct detection of recombinant clones, based on inactivation of a bacterial acid phosphatase-encoding gene.  
*Microbiologica* 18: 201-6 (1995)
- Burn TC; Connors TD; Klinger KW; Landes GM  
Increased exon-trapping efficiency through modifications to the pSPL3 splicing vector.  
*Gene* 161: 183-7 (1995)
- Bushman F  
Targeting retroviral integration [comment]  
*Science* 267: 1443-4 (1995)
- Buzy JM; Lindstrom LM; Zink MC; Clements JE  
HIV-1 in the developing CNS: developmental differences in gene expression.  
*Virology* 210: 361-71 (1995)
- Cagnon L; Cucchiari M; Lefebvre JC; Doglio A  
Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule.  
*J Acquir Immune Defic Syndr Hum Retrovir* 9: 349-58 (1995)
- Calabro ML; Zanutto C; Calderazzo F; Crivellaro C; Del Mistro A; De Rossi A; Chieco-Bianchi L  
HIV-1 infection of the thymus: evidence for a cytopathic and thymotropic viral variant in vivo.  
*AIDS Res Hum Retroviruses* 11: 11-9 (1995)
- Camp NP; Perrey DA; Kinchington D; Hawkins PC; Gani D  
Synthesis of peptide analogues containing phosphoramidate methyl ester functionality: HIV-1 proteinase inhibitors possessing unique cell uptake properties.  
*Bioorg Med Chem* 3: 297-12 (1995)
- Campbell S; Vogt VM  
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.  
*J Virol* 69: 6487-97 (1995)
- Canque B; Marandin A; Rosenzweig M; Louache F; Vainchenker W; Gluckman JC  
Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV).  
*Virology* 208: 779-83 (1995)
- Cao JG; Firtel RA  
Growth and developmental functions of a human immunodeficiency virus Tat-binding protein/26S protease subunit homolog from *Dictyostelium discoideum*.  
*Mol Cell Biol* 15: 1725-36 (1995)



## References (1995)

- Cao Y; Ho DD; Todd J; Kokka R; Urdea M; Lifson JD; Piatak M Jr; Chen S; Hahn BH; Saag MS; et al  
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.  
*AIDS Res Hum Retroviruses* 11: 353-61 (1995)
- Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G  
The tat gene and protein of the human immunodeficiency virus type 1.  
*Microbiologica* 18: 87-110 (1995)
- Carey I; Glauser MP; Bille J  
[Pneumococcal bacteremia: what is new?]  
*Schweiz Med Wochenschr* 125: 952-8 (1995)
- Carmichael AJ; Sissons JG  
Vaccines against HIV [editorial]  
*QJM* 88: 77-9 (1995)
- Carre V; Mbemba E; Letourneur D; Jozefonvicz J; Gattegno L  
Interactions of HIV-1 envelope glycoproteins with derivatized dextrans.  
*Biochim Biophys Acta* 1243: 175-80 (1995)
- Carriere C; Gay B; Chazal N; Morin N; Boulanger P  
Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles.  
*J Virol* 69: 2366-77 (1995)
- Caruso M; Salomon B; Zhang S; Brisson E; Clavel F; Lowy I; Klatzmann D  
Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription.  
*Virology* 206: 495-503 (1995)
- Catasti P; Fontenot JD; Bradbury EM; Gupta G  
Local and global structural properties of the HIV-MN V3 loop.  
*J Biol Chem* 270: 2224-32 (1995)
- Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K; et al  
Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.  
*AIDS* 9: 223-8 (1995)
- Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K; et al  
Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.  
*AIDS* 9: 223-8 (1995)
- Chang LJ; Zhang C  
Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.  
*Virology* 211: 157-69 (1995)
- Chang YN; Kenan DJ; Keene JD; Gatignol A; Jeang KT  
Direct interactions between autoantigen La and human immunodeficiency virus leader RNA.  
*J Virol* 69: 618-9 (1995)
- Chao CC; Gekker G; Hu S; Sheng WS; Portoghese PS; Peterson PK  
Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by dynorphin.  
*Biochem Pharmacol* 50: 715-22 (1995)
- Chao CC; Gekker G; Sheng WS; Hu S; Portoghese PS; Peterson PK  
Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1.  
*Adv Exp Med Biol* 373: 65-72 (1995)
- Chao SF; Chan VL; Juranka P; Kaplan AH; Swanstrom R; Hutchinson CA 3rd  
Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.  
*Nucleic Acids Res* 23: 803-10 (1995)
- Chargui J; Dye D; Blomberg J; Desgranges C; Touraine JL  
The humanized severe combined immunodeficient mouse as a model for primary human humoral response against HIV1 peptides.  
*J Immunol Methods* 181: 91-100 (1995)
- Chatte G; Panteix G; Perrin-Fayolle M; Pacheco Y  
Aerosolized interferon gamma for Mycobacterium avium-complex lung disease.  
*Am J Respir Crit Care Med* 152: 1094-6 (1995)
- Chazal N; Gay B; Carriere C; Tournier J; Boulanger P  
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway.  
*J Virol* 69: 365-75 (1995)

- Checroune F; Yao XJ; Gottlinger HG; Bergeron D; Cohen EA  
Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 10: 1-7 (1995)
- Chelucci C; Hassan HJ; Locardi C; Bulgarini D; Pelosi E; Mariani G; Testa U; Federico M; Valtieri M; Peschle C  
In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture.  
*Blood* 85: 1181-7 (1995)
- Chen CH; Matthews TJ; McDanal CB; Bolognesi DP; Greenberg ML  
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.  
*J Virol* 69: 3771-7 (1995)
- Chen L; Frankel AD  
A peptide interaction in the major groove of RNA resembles protein interactions in the minor groove of DNA.  
*Proc Natl Acad Sci U S A* 92: 5077-81 (1995)
- Chen LL; Frankel AD; Harder JL; Fawell S; Barsoum J; Pepinsky B  
Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin.  
*Anal Biochem* 227: 168-75 (1995)
- Chen SY; Zani C; Khouri Y; Marasco WA  
Design of a genetic immunotoxin to eliminate toxin immunogenicity.  
*Gene Ther* 2: 116-23 (1995)
- Chen X; Tropsha A  
Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state.  
*J Med Chem* 38: 42-8 (1995)
- Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC  
Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.  
*J Biol Chem* 270: 21433-6 (1995)
- Chen ZW; Kou ZC; Lekutis C; Shen L; Zhou D; Halloran M; Li J; Sodroski J; Lee-Parritz D; Letvin NL  
T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus.  
*J Exp Med* 182: 21-31 (1995)
- Chen ZW; Kou ZC; Lekutis C; Shen L; Zhou D; Halloran M; Li J; Sodroski J; Lee-Parritz D; Letvin NL  
T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus.  
*J Exp Med* 182: 21-31 (1995)
- Chin LT; Duenas M; Levi M; Hinkula J; Wahren B; Borrebaeck CA  
Molecular characterization of a human anti-HIV 1 monoclonal antibody revealed a CD26-related motif in CDR2.  
*Immunol Lett* 44: 25-30 (1995)
- Chin LT; Malmberg AC; Kristensson K; Hinkula J; Wahren B; Borrebaeck CA  
Mimicking the humoral immune response in vitro results in antigen-specific isotype switching supported by specific autologous T helper cells: generation of human HIV-1-neutralizing IgG monoclonal antibodies from naive donors.  
*Eur J Immunol* 25: 657-63 (1995)
- Chirmule N; Goonewardena H; Pahwa S; Pasieka R; Kalyanaraman VS; Pahwa S  
HIV-1 envelope glycoproteins induce activation of activated protein-1 in CD4+ T cells.  
*J Biol Chem* 270: 19364-9 (1995)
- Chirmule N; Than S; Khan SA; Pahwa S  
Human immunodeficiency virus Tat induces functional unresponsiveness in T cells.  
*J Virol* 69: 492-8 (1995)
- Cho SJ; Tropsha A  
Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results.  
*J Med Chem* 38: 1060-6 (1995)
- Choe HR; Sodroski J  
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid).  
*J Virol* 69: 2801-10 (1995)
- Chronister CL  
Serologic confirmation of HIV infection.  
*Optom Vis Sci* 72: 299-301 (1995)
- Chuang LF; Chuang TK; Killam KF Jr; Qiu Q; Wang XR; Lin JJ; Kung HF; Sheng W; Chao C; Yu L; et al  
Expression of kappa opioid receptors in human and monkey lymphocytes.  
*Biochem Biophys Res Commun* 209: 1003-10 (1995)

## References (1995)

- Chuang RY; Chuang LF; Li Y; Kung HF; Killam KF Jr  
SIV mutations detected in morphine-treated *Macaca mulatta* following SIVmac239 infection.  
*Adv Exp Med Biol* 373: 175-81 (1995)
- Churcher MJ; Lowe AD; Gait MJ; Karn J  
The RNA element encoded by the trans-activation-responsive region of human immunodeficiency virus type 1 is functional when displaced downstream of the start of transcription.  
*Proc Natl Acad Sci U S A* 92: 2408-12 (1995)
- Cirillo JD; Stover CK; Bloom BR; Jacobs WR Jr; Barletta RG  
Bacterial vaccine vectors and bacillus Calmette-Guerin.  
*Clin Infect Dis* 20: 1001-9 (1995)
- Cirino NM; Cameron CE; Smith JS; Rausch JW; Roth MJ; Benkovic SJ; Le Grice SF  
Divalent cation modulation of the ribonuclease functions of human immunodeficiency virus reverse transcriptase.  
*Biochemistry* 34: 9936-43 (1995)
- Clark NM; Hannibal MC; Markovitz DM  
The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells.  
*J Virol* 69: 4854-62 (1995)
- Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP; et al  
Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.  
*J Virol* 69: 2737-44 (1995)
- Clever J; Sasseti C; Parslow TG  
RNA secondary structure and binding sites for gag gene products in the 5' packaging signal of human immunodeficiency virus type 1.  
*J Virol* 69: 2101-9 (1995)
- Coffin JM  
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.  
*Science* 267: 483-9 (1995)
- Cohen JH; Guetard D; Philbert F; Chamaret S; Tabary T; Deleys R; Montagnier L  
Atypical HIV serological profile of novel HIV-1 variant distinct from subtype O [letter]  
*Lancet* 345: 856 (1995)
- Collins JR; Burt SK; Erickson JW  
Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics.  
*Nat Struct Biol* 2: 334-8 (1995)
- Collins ML; Zayati C; Detmer JJ; Daly B; Kolberg JA; Cha TA; Irvine BD; Tucker J; Urdea MS  
Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays.  
*Anal Biochem* 226: 120-9 (1995)
- Condra JH; Schleif WA; Blahy OM; Gabryelski LJ; Graham DJ; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M; et al  
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors [see comments]  
*Nature* 374: 569-71 (1995)
- Confalonieri F; Duguet M  
A 200-amino acid ATPase module in search of a basic function.  
*Bioessays* 17: 639-50 (1995)
- Connor RI; Chen BK; Choe S; Landau NR  
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.  
*Virology* 206: 935-44 (1995)
- Constantine KL; Friedrichs MS; Detlefsen D; Nishio M; Tsunakawa M; Furumai T; Ohkuma H; Oki T; Hill S; Brucoleri RE; et al  
High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion.  
*J Biomol NMR* 5: 271-86 (1995)
- Copeland KF; Hendrikx PJ; Haaksma AG; Fiering S; Van Lier R; Goudsmit J; Heeney JL  
Comparison of the response to T-cell activation by integrated HIV-1 and HTLV-1 LTR-lacZ vectors.  
*Virology* 209: 633-6 (1995)
- Corbeil J; Evans LA; McQueen PW; Vasak E; Edward PD; Richman DD; Penny R; Cooper DA  
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1.  
*Immunol Cell Biol* 73: 140-5 (1995)
- Corbeil J; Richman DD  
Productive infection and subsequent interaction of CD4-gp120 at the cellular membrane is required for HIV-induced apoptosis of CD4+ T cells.  
*J Gen Virol* 76 ( Pt 3): 681-90 (1995)

- Cornelissen M; Mulder-Kampinga G; Veenstra J; Zorgdrager F; Kuiken C; Hartman S; Dekker J; van der Hoek L; Sol C; Coutinho R; et al  
Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.  
*J Virol* 69: 1810-8 (1995)
- Couillin I; Connan F; Culmann-Penciolelli B; Gomard E; Guillet JG; Choppin J  
HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding.  
*Eur J Immunol* 25: 728-32 (1995)
- Courcoul M; Patience C; Rey F; Blanc D; Harmache A; Sire J; Vigne R; Spire B  
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.  
*J Virol* 69: 2068-74 (1995)
- Coutlee F; He Y; Saint-Antoine P; Olivier C; Kessous A  
Coamplification of HIV type 1 and beta-globin gene DNA sequences in a nonisotopic polymerase chain reaction assay to control for amplification efficiency.  
*AIDS Res Hum Retroviruses* 11: 363-71 (1995)
- Crandall KA  
Intraspecific phylogenetics: support for dental transmission of human immunodeficiency virus.  
*J Virol* 69: 2351-6 (1995)
- Cryz SJ Jr; Goldstein H; Pettoello-Mantovani M; Kim A; Furer E; Que JU; Hasler T; Rubinstein A  
Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine.  
*Vaccine* 13: 67-71 (1995)
- Cucchiaroni M; Cagnon L; Giordanengo V; Doglio A; Lefebvre JC  
Induction by human immunodeficiency viruses types 1 and 2 of degradation of CD4 but not of a CD4 mutant unable to bind viral envelope glycoproteins.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 427-36 (1995)
- Cupelli LA; Hsu MC  
The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter.  
*J Virol* 69: 2640-3 (1995)
- Cushman M; Golebiewski WM; Pommier Y; Mazumder A; Rey-men D; De Clercq E; Graham L; Rice WG  
Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase.  
*J Med Chem* 38: 443-52 (1995)
- D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumacker CS; Kahn JO; et al  
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.  
*Ann Intern Med* 122: 401-8 (1995)
- Da Cunha A; Rausch DM; Eiden LE  
An early increase in somatostatin mRNA expression in the frontal cortex of rhesus monkeys infected with simian immunodeficiency virus.  
*Proc Natl Acad Sci U S A* 92: 1371-5 (1995)
- Das AT; Berkhout B  
Efficient extension of a misaligned tRNA-primer during replication of the HIV-1 retrovirus.  
*Nucleic Acids Res* 23: 1319-26 (1995)
- Das AT; Klaver B; Berkhout B  
Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).  
*J Virol* 69: 3090-7 (1995)
- David D; Demaison C; Bani L; Zouali M; Theze J  
Selective variations in vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection.  
*Eur J Immunol* 25: 1524-8 (1995)
- David D; Zouali M  
Variable region light chain genes encoding human antibodies to HIV-1.  
*Mol Immunol* 32: 77-88 (1995)
- De Clercq E  
Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections.  
*J Med Chem* 38: 2491-517 (1995)
- De Clercq E  
Antiviral therapy for human immunodeficiency virus infections.  
*Clin Microbiol Rev* 8: 200-39 (1995)

## References (1995)

- De Loof A; Bylemans D; Schoofs L; Janssen I; Spittaels K; Vanden Broeck J; Huybrechts R; Borovsky D; Hua YJ; Koolman J; et al  
Folliculostatins, gonadotropins and a model for control of growth in the grey fleshfly, *Neobellieria* (sarcophaga) *bulbata*.  
*Insect Biochem Mol Biol* 25: 661-7 (1995)
- De Mareuil J; Guettari N; Bolmont C; Salaun D; Baillon JG; Hostomsky Z; Hirsch I  
Restriction of HIV-1 replication in intestinal cells is genetically controlled by the gag-pol region of the HIV-1 genome.  
*Virology* 207: 160-7 (1995)
- De Mareuil J; Salaun D; Chermann JC; Hirsch I  
Fusogenic determinants of highly cytopathic subtype D Zairian isolate HIV-1 NDK.  
*Virology* 209: 649-53 (1995)
- De Milito A; Catucci M; Iannelli F; Romano L; Zazzi M; Valensin PE  
Increased reliability of selective PCR by using additionally mutated primers and a commercial Taq DNA polymerase enhancer.  
*Mol Biotechnol* 3: 166-9 (1995)
- Delacourt C; Poveda JD; Chureau C; Beydon N; Mahut B; de Blic J; Scheinmann P; Garrigue G  
Use of polymerase chain reaction for improved diagnosis of tuberculosis in children.  
*J Pediatr* 126: 703-9 (1995)
- Delforge ML; Liesnard C; Debaisieux L; Tchetcheroff M; Farber CM; Van Vooren JP  
In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine [letter]  
*AIDS* 9: 89-90 (1995)
- Demirhan I; Hasselmayer O; Hofmann D; Chandra A; Svinarchuk FP; Vlassov VV; Engels J; Chandra P  
Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.  
*Virus Genes* 9: 113-9 (1995)
- Deprez B; Gras-Masse H; Martinon F; Gomard E; Levy JP; Tartar A  
Pimelaute or trimexaute as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response.  
*J Med Chem* 38: 459-65 (1995)
- Desai-Yajnik V; Hadzic E; Modlinger P; Malhotra S; Gechlik G; Samuels HH  
Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator.  
*J Virol* 69: 5103-12 (1995)
- Devergne O; Raphael M; Autran B; Leger-Ravet MB; Coumbaras J; Crevon MC; Galanaud P; Emilie D  
Intratumoral activation of CD8-positive cytotoxic lymphocytes in acquired immunodeficiency syndrome lymphomas.  
*Hum Pathol* 26: 284-90 (1995)
- Dezube BJ; Lederman MM; Spritzler JG; Chapman B; Korvick JA; Flexner C; Dando S; Mattiacci MR; Ahlers CM; Zhang L; et al  
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.  
*J Infect Dis* 171: 1628-32 (1995)
- Dhawan S; Weeks BS; Soderland C; Schnaper HW; Toro LA; Asthana SP; Hewlett IK; Stetler-Stevenson WG; Yamada SS; Yamada KM; et al  
HIV-1 infection alters monocyte interactions with human microvascular endothelial cells.  
*J Immunol* 154: 422-32 (1995)
- Di Luca D; Mirandola P; Ravaioli T; Dolcetti R; Frigatti A; Bovenzi P; Sighinolfi L; Monini P; Cassai E  
Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals.  
*J Med Virol* 45: 462-8 (1995)
- Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F  
Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.  
*J Clin Microbiol* 33: 352-5 (1995)
- Dianzani U; Bragardo M; Buonfiglio D; Redoglia V; Funaro A; Portoles P; Rojo J; Malavasi F; Pileri A  
Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120.  
*Eur J Immunol* 25: 1306-11 (1995)
- Diaz RS; Sabino EC; Mayer A; Mosley JW; Busch MP  
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.  
*J Virol* 69: 3273-81 (1995)

- Diehl LJ; Mathiason-DuBard CK; O'Neil LL; Hoover EA  
Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR.  
*J Virol* 69: 2328-32 (1995)
- Dietrich U; Maniar JK; Rubsamen-Waigmann H  
The epidemiology of HIV in India.  
*Trends Microbiol* 3: 17-21 (1995)
- Ding J; Das K; Moereels H; Koymans L; Andries K; Janssen PA; Hughes SH; Arnold E  
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.  
*Nat Struct Biol* 2: 407-15 (1995)
- Ding J; Das K; Tantillo C; Zhang W; Clark AD Jr; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K; et al  
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution.  
*Structure* 3: 365-79 (1995)
- Distler O; McQueen PW; Tsang ML; Byrne C; Neilan BA; Evans L; Penny R; Cooper DA; Delaney SF  
Characterization of the V3 region of HIV-1 isolates from Sydney, Australia.  
*AIDS Res Hum Retroviruses* 11: 423-5 (1995)
- Dittmar MT; Cichutek K; Fultz PN; Kurth R  
The U3 promoter region of the acutely lethal simian immunodeficiency virus clone smmPBj1.9 confers related biological activity on the apathogenic clone agm3mc.  
*Proc Natl Acad Sci U S A* 92: 1362-6 (1995)
- Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Luke W; Fuchs D; Bodemer W; Petry H; Hunsmann G  
Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.  
*J Gen Virol* 76 ( Pt 6): 1307-15 (1995)
- Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF 3rd; Burton DR  
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.  
*J Immunol* 154: 893-906 (1995)
- Divita G; Rittinger K; Geourjon C; Deleage G; Goody RS  
Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process.  
*J Mol Biol* 245: 508-21 (1995)
- Dobrescu D; Kabak S; Mehta K; Suh CH; Asch A; Cameron PU; Hodtsev AS; Posnett DN  
Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets.  
*Proc Natl Acad Sci U S A* 92: 5563-7 (1995)
- Dobrescu D; Ursea B; Pope M; Asch AS; Posnett DN  
Enhanced HIV-1 replication in V beta 12 T cells due to human cytomegalovirus in monocytes: evidence for a putative herpesvirus superantigen.  
*Cell* 82: 753-63 (1995)
- Dolan J; Desselberger U  
Construction of gag, pol, and env specific riboprobes for confirmation of HIV-1 specific polymerase chain reaction products [corrected and republished article originally printed in *J Virol Methods* 1994 Jul;48(2-3):167-75]  
*J Virol Methods* 51: 131-9 (1995)
- Doyle CB; Bhattacharyya U; Kent KA; Stott JE; Jones IM  
Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus.  
*J Virol* 69: 1256-60 (1995)
- Doyle CB; Bhattacharyya U; Kent KA; Stott JE; Jones IM  
Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus.  
*J Virol* 69: 1256-60 (1995)
- Drew WL; Anderson R; Lang W; Miner RC; Davis G; Lalezari J  
Failure of high-dose oral acyclovir to suppress CMV viraemia or induce ganciclovir-resistant CMV in HIV antibody positive patients.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 289-91 (1995)
- Druce JD; Locarnini SA; Birch CJ  
Isolation of HIV-1 from experimentally contaminated multi-dose local anaesthetic vials [see comments]  
*Med J Aust* 162: 513-5 (1995)
- Du Z; Lang SM; Sasseville VG; Lackner AA; Ilyinskii PO; Daniel MD; Jung JU; Desrosiers RC  
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys.  
*Cell* 82: 665-74 (1995)
- Dubay JW; Dubay SR; Shin HJ; Hunter E  
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation.  
*J Virol* 69: 4675-82 (1995)

## References (1995)

- Dukes CS; Yu Y; Rivadeneira ED; Sauls DL; Liao HX; Haynes BF; Weinberg JB  
Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism.  
*J Virol* 69: 4000-5 (1995)
- Dumois JA; VanderVegt FP; Kopp JB; Marinos NJ; Rooney JF; Notkins AL  
Transplantation of skin from human immunodeficiency virus type 1-transgenic mice to normal congenic mice results in graft rejection.  
*J Infect Dis* 172: 232-4 (1995)
- Dunn CS; Mehtali M; Houdebine LM; Gut JP; Kirn A; Aubertin AM  
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits.  
*J Gen Virol* 76 ( Pt 6): 1327-36 (1995)
- Dupon M; Texier-Maugein J; Leroy V; Sentilhes A; Pellegrin JL; Morlat P; Ragnaud JM; Chene G; Dabis F  
Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine.  
*AIDS* 9: 577-83 (1995)
- Dupuis M; Kundu SK; Merigan TC  
Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein.  
*J Immunol* 155: 2232-9 (1995)
- Dyson HJ; Wright PE  
Antigenic peptides.  
*FASEB J* 9: 37-42 (1995)
- Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J  
Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 264-73 (1995)
- Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF  
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.  
*J Infect Dis* 171: 1623-7 (1995)
- Elder JH; Phillips TR  
Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections.  
*Adv Virus Res* 45: 225-47 (1995)
- Ellison V; Gerton J; Vincent KA; Brown PO  
An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer.  
*J Biol Chem* 270: 3320-6 (1995)
- Enarson DA  
The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes [editorial]  
*Tuber Lung Dis* 76: 95-9 (1995)
- Endres CL; Bergquam EP; Axthelm MK; Wong SW  
Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.  
*J Virol* 69: 5164-6 (1995)
- Endres CL; Bergquam EP; Axthelm MK; Wong SW  
Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.  
*J Virol* 69: 5164-6 (1995)
- Engelman A; Craigie R  
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity.  
*J Virol* 69: 5908-11 (1995)
- Engelman A; Englund G; Orenstein JM; Martin MA; Craigie R  
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.  
*J Virol* 69: 2729-36 (1995)
- Englund G; Theodore TS; Freed EO; Engleman A; Martin MA  
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1.  
*J Virol* 69: 3216-9 (1995)
- Ensoli F; Cafaro A; Fiorelli V; Vannelli B; Ensoli B; Thiele CJ  
HIV-1 infection of primary human neuroblasts.  
*Virology* 210: 221-5 (1995)
- Epperson ES; Tyrer HW  
Use of computer algorithms to reduce viral quasispecies sequence space.  
*Biomed Sci Instrum* 31: 83-8 (1995)
- Erickson JW  
The not-so-great escape [news] [see comments]  
*Nat Struct Biol* 2: 523-9 (1995)

- Eriksson S; Xu B; Clayton DA  
Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase.  
*J Biol Chem* 270: 18929-34 (1995)
- Eroshkin AM; Karginova EA; Gileva IP; Lomakin AS; Lebedev LR; Kamyinina TP; Pereboev AV; Ignat'ev GM  
Design of four-helix bundle protein as a candidate for HIV vaccine.  
*Protein Eng* 8: 167-73 (1995)
- Esnouf R; Ren J; Ross C; Jones Y; Stammers D; Stuart D  
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.  
*Nat Struct Biol* 2: 303-8 (1995)
- di Fagagna FD; Marzio G; Gutierrez MI; Kang LY; Falaschi A; Giacca M  
Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1.  
*J Virol* 69: 2765-75 (1995)
- Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK  
Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.  
*FEBS Lett* 359: 233-8 (1995)
- Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK  
Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.  
*FEBS Lett* 370: 59-62 (1995)
- Fan N; Rank KB; Leone JW; Heinrikson RL; Bannow CA; Smith CW; Evans DB; Poppe SM; Tarpley WG; Rothrock DJ; et al  
The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases.  
*J Biol Chem* 270: 13573-9 (1995)
- Fan ST; Mackman N; Cui MZ; Edgington TS  
Integrin regulation of an inflammatory effector gene. Direct induction of the tissue factor promoter by engagement of beta 1 or alpha 4 integrin chains.  
*J Immunol* 154: 3266-74 (1995)
- Fang H; Pincus SH  
Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells.  
*J Virol* 69: 75-81 (1995)
- Farhood H; Gao X; Barsoum J; Huang L  
Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes.  
*Anal Biochem* 225: 89-93 (1995)
- Faure E; Cavard C; Zider A; Guillet JP; Resbeut M; Champion S  
X irradiation-induced transcription from the HIV type 1 long terminal repeat.  
*AIDS Res Hum Retroviruses* 11: 41-3 (1995)
- Federico M; Nappi F; Bona R; D'Aloja P; Verani P; Rossi GB  
Full expression of transfected nonproducer interfering HIV-1 proviral DNA abrogates susceptibility of human He-La CD4+ cells to HIV.  
*Virology* 206: 76-84 (1995)
- Feijoo E; Subira D; Fernandez-Guerrero M; Garcia R; Ortiz F  
Anti-CD4 activity in circulating immune complexes in HIV-infected patients.  
*Int Arch Allergy Immunol* 106: 366-71 (1995)
- Fenouillet E; Blanes N; Benjouad A; Gluckman JC  
Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity.  
*Clin Exp Immunol* 99: 419-24 (1995)
- Fenouillet E; Jones IM  
The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.  
*J Gen Virol* 76 ( Pt 6): 1509-14 (1995)
- Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C  
Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.  
*C R Acad Sci III* 318: 329-37 (1995)
- Fernandez MH; Faith A; Higgins JA; Weber J; Rees AD  
The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition.  
*Immunology* 85: 176-83 (1995)
- Fillet AM; Raphael M; Visse B; Audouin J; Poirel L; Agut H  
Controlled study of human herpesvirus 6 detection in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. The French Study Group for HIV-Associated Tumors.  
*J Med Virol* 45: 106-12 (1995)



## References (1995)

- Fiorelli V; Gendelman R; Samaniego F; Markham PD; Ensoli B  
Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.  
*J Clin Invest* 95: 1723-34 (1995)
- Fischer D; Lin SL; Wolfson HL; Nussinov R  
A geometry-based suite of molecular docking processes.  
*J Mol Biol* 248: 459-77 (1995)
- Fischer U; Huber J; Boelens WC; Mattaj JW; Luhrmann R  
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.  
*Cell* 82: 475-83 (1995)
- Fletcher RS; Arion D; Borkow G; Wainberg MA; Dmitrienko GI; Parniak MA  
Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.  
*Biochemistry* 34: 10106-12 (1995)
- Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA  
Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.  
*Biochemistry* 34: 4346-53 (1995)
- Flotte TR; Barraza-Ortiz X; Solow R; Afione SA; Carter BJ; Guggino WB  
An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.  
*Gene Ther* 2: 29-37 (1995)
- Fontenot JD; Gatewood JM; Mariappan SV; Pau CP; Parekh BS; George JR; Gupta G  
Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.  
*Proc Natl Acad Sci U S A* 92: 315-9 (1995)
- Fouchier RA; Brouwer M; Broersen SM; Schuitemaker H  
Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR.  
*J Clin Microbiol* 33: 906-11 (1995)
- Franchini G; Tartaglia J; Markham P; Benson J; Fullen J; Wills M; Arp J; Dekaban G; Paoletti E; Gallo RC  
Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.  
*AIDS Res Hum Retroviruses* 11: 307-13 (1995)
- Franke EK; Chen BX; Tatsis I; Diamanduros A; Erlanger BF; Luban J  
Cyclophilin binding to the human immunodeficiency virus type 1 Gag polyprotein is mimicked by an anti-cyclosporine antibody.  
*J Virol* 69: 5821-3 (1995)
- Franks RR; Ray PE; Babbott CC; Bryant JL; Notkins AL; Santoro TJ; Klotman PE  
Maternal-fetal interactions affect growth of human immunodeficiency virus type 1 transgenic mice.  
*Pediatr Res* 37: 56-63 (1995)
- Franzusoff A; Volpe AM; Josse D; Pichuanes S; Wolf JR  
Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing.  
*J Biol Chem* 270: 3154-9 (1995)
- Freed EO; Englund G; Martin MA  
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection.  
*J Virol* 69: 3949-54 (1995)
- Freed EO; Martin MA  
Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.  
*J Virol* 69: 1984-9 (1995)
- Frenkel LM; Wagner LE 2nd; Atwood SM; Cummins TJ; Dewhurst S  
Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.  
*J Clin Microbiol* 33: 342-7 (1995)
- Frenkel LM; Wagner LE 2nd; Demeter LM; Dewhurst S; Coombs RW; Murante BL; Reichman RC  
Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1.  
*Clin Infect Dis* 20: 1321-6 (1995)
- Freund J; Vertesy L; Koller KP; Wolber V; Heintz D; Kalbitzer HR  
Complete 1H nuclear magnetic resonance assignments and structural characterization of a fusion protein of the alpha-amylase inhibitor tendamistat with the activation domain of the human immunodeficiency virus type 1 Tat protein.  
*J Mol Biol* 250: 672-88 (1995)
- Fridell RA; Harding LS; Bogerd HP; Cullen BR  
Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins.  
*Virology* 209: 347-57 (1995)

- Friedman CR; Stoeckle MY; Kreiswirth BN; Johnson WD Jr; Manoach SM; Berger J; Sathianathan K; Hafner A; Riley LW  
Transmission of multidrug-resistant tuberculosis in a large urban setting.  
*Am J Respir Crit Care Med* 152: 355-9 (1995)
- Fritz CC; Zapp ML; Green MR  
A human nucleoporin-like protein that specifically interacts with HIV Rev.  
*Nature* 376: 530-3 (1995)
- Fujihashi T; Sakata T; Kaji A; Kaji H  
Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus type 1.  
*AIDS Res Hum Retroviruses* 11: 461-71 (1995)
- Furtado MR; Kingsley LA; Wolinsky SM  
Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals.  
*J Virol* 69: 2092-2100 (1995)
- Furuta RA; Kubota S; Maki M; Miyazaki Y; Hattori T; Hatanaka M  
Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy.  
*J Virol* 69: 1591-9 (1995)
- Gaedigk-Nitschko K; Schon A; Wachinger G; Erfle V; Kohleisen B  
Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease.  
*FEBS Lett* 357: 275-8 (1995)
- Gagnon L; Nordstrom PA; Duchaine J; Jutras D; Hamel M; Barbeau D; Hooker E; Ashman C; Cammack N; Tse A; et al  
Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine.  
*Immunopharmacol Immunotoxicol* 17: 17-32 (1995)
- Galeano Jimenez AH  
[Tuberculosis and AIDS in Paraguay]  
*Bol Oficina Sanit Panam* 118: 248-53 (1995)
- Gallaher WR; Ball JM; Garry RF; Martin-Amedee AM; Montelaro RC  
A general model for the surface glycoproteins of HIV and other retroviruses.  
*AIDS Res Hum Retroviruses* 11: 191-202 (1995)
- Gallay P; Swingler S; Aiken C; Trono D  
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator.  
*Cell* 80: 379-88 (1995)
- Gao WY; Johns DG; Chokekuchai S; Mitsuya H  
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.  
*Proc Natl Acad Sci U S A* 92: 8333-7 (1995)
- Garcia-Ferrer FJ; Laycock KA; Buerger DG; Flowers BE; Foos RY; Pepose JS  
Screening corneas for human immunodeficiency virus type 1 proviral DNA by polymerase chain reaction [see comments]  
*Am J Ophthalmol* 119: 7-13 (1995)
- Garzino-Demo A; Gallo RC; Arya SK  
Human immunodeficiency virus type 2 (HIV-2): packaging signal and associated negative regulatory element.  
*Hum Gene Ther* 6: 177-84 (1995)
- Gawrisch K; Barry JA; Holte LL; Sinnwell T; Bergelson LD; Ferretti JA  
Role of interactions at the lipid-water interface for domain formation.  
*Mol Membr Biol* 12: 83-8 (1995)
- Gaynor RB  
Regulation of HIV-1 gene expression by the transactivator protein Tat.  
*Curr Top Microbiol Immunol* 193: 51-77 (1995)
- Gazzinelli RT; Bala S; Stevens R; Baseler M; Wahl L; Kovacs J; Sher A  
HIV infection suppresses type 1 lymphokine and IL-12 responses to *Toxoplasma gondii* but fails to inhibit the synthesis of other parasite-induced monokines.  
*J Immunol* 155: 1565-74 (1995)
- Geissler RG; Muth J; Maurer A; Mentzel U; Mag M; Engels JW; Hoelzer D; Ganser A  
Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.  
*Ann Hematol* 71: 89-95 (1995)
- Ghosh M; Howard KJ; Cameron CE; Benkovic SJ; Hughes SH; Le Grice SF  
Truncating alpha-helix E' of p66 human immunodeficiency virus reverse transcriptase modulates RNase H function and impairs DNA strand transfer.  
*J Biol Chem* 270: 7068-76 (1995)
- Gibbs JS; Lackner AA; Lang SM; Simon MA; Sehgal PK; Daniel MD; Desrosiers RC  
Progression to AIDS in the absence of a gene for vpr or vpx.  
*J Virol* 69: 2378-83 (1995)

## References (1995)

- Gibellini D; Caputo A; Celeghini C; Bassini A; La Placa M; Capitani S; Zauli G  
Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection.  
*Br J Haematol* 89: 24-33 (1995)
- Gilmartin GM; Fleming ES; Oetjen J; Graveley BR  
CPSF recognition of an HIV-1 mRNA 3'-processing enhancer: multiple sequence contacts involved in poly(A) site definition.  
*Genes Dev* 9: 72-83 (1995)
- Girard M  
Present status of vaccination against HIV-1 infection.  
*Int J Immunopharmacol* 17: 75-8 (1995)
- Girard M; Meignier B; Barre-Sinoussi F; Kiény MP; Matthews T; Muchmore E; Nara PL; Wei Q; Rimsky L; Weinhold K; et al  
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.  
*J Virol* 69: 6239-48 (1995)
- Goff DA; Koletar SL; Buesching WJ; Barnishan J; Fass RJ  
Isolation of fluconazole-resistant *Candida albicans* from human immunodeficiency virus-negative patients never treated with azoles.  
*Clin Infect Dis* 20: 77-83 (1995)
- Golankiewicz B; Januszczyk P; Ikeda S; Balzarini J; De Clercq E  
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.  
*J Med Chem* 38: 3558-65 (1995)
- Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H  
Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.  
*J Virol* 69: 3299-307 (1995)
- Golding H; Dimitrov DS; Manischewitz J; Broder CC; Robinson J; Fabian S; Littman DR; Lapham CK  
Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.  
*J Virol* 69: 6140-8 (1995)
- Goldsmith MA; Warmerdam MT; Atchison RE; Miller MD; Greene WC  
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.  
*J Virol* 69: 4112-21 (1995)
- Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P; et al  
Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm<sup>3</sup>: a double-blind placebo-controlled trial.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 279-88 (1995)
- Goldstein S; Hague B; Montefiori D; Hirsch VM  
A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody.  
*J Virol Methods* 53: 139-48 (1995)
- Goletti D; Kinter AL; Biswas P; Bende SM; Poli G; Fauci AS  
Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression.  
*J Virol* 69: 2540-6 (1995)
- Gonzalez SA; Affranchino JL  
Mutational analysis of the conserved cysteine residues in the simian immunodeficiency virus matrix protein.  
*Virology* 210: 501-7 (1995)
- Gonzalez SA; Affranchino JL  
Mutational analysis of the conserved cysteine residues in the simian immunodeficiency virus matrix protein.  
*Virology* 210: 501-7 (1995)
- Goobar-Larsson L; Luukkonen BG; Unge T; Schwartz S; Utter G; Strandberg B; Oberg B  
Enhancement of HIV-1 proteinase activity by HIV-1 reverse transcriptase.  
*Virology* 206: 387-94 (1995)
- Goodarzi G; Im GJ; Brackmann K; Grandgenett D  
Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase.  
*J Virol* 69: 6090-7 (1995)
- Gotte M; Fackler S; Hermann T; Perola E; Cellai L; Gross HJ; Le Grice SF; Heumann H  
HIV-1 reverse transcriptase-associated RNase H cleaves RNA/RNA in arrested complexes: implications for the mechanism by which RNase H discriminates between RNA/RNA and RNA/DNA.  
*EMBO J* 14: 833-41 (1995)
- Graf von Stosch A; Kinzel V; Pipkorn R; Reed J  
Investigation of the structural components governing the polarity-dependent refolding of a CD4-binding peptide from gp120.  
*J Mol Biol* 250: 507-13 (1995)

- Grandadam M; Cesbron JY; Candotti D; Vinatier D; Pauchard M; Capron A; Debre P; Huraux JM; Autran B; Agut H  
Dose-dependent systemic human immunodeficiency virus infection of SCID-hu mice after intraperitoneal virus injection. *Res Virol* 146: 101-12 (1995)
- Green I; Espiritu E; Ladanyi M; Chaponda R; Wiczorek R; Gallo L; Feiner H  
Primary lymphomatous effusions in AIDS: a morphological, immunophenotypic, and molecular study. *Mod Pathol* 8: 39-45 (1995)
- Green L; Waugh S; Binkley JP; Hostomska Z; Hostomsky Z; Tuerk C  
Comprehensive chemical modification interference and nucleotide substitution analysis of an RNA pseudoknot inhibitor to HIV-1 reverse transcriptase. *J Mol Biol* 247: 60-8 (1995)
- Greenway A; Azad A; McPhee D  
Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. *J Virol* 69: 1842-50 (1995)
- Griffith JD; Makhov A; Zawel L; Reinberg D  
Visualization of TBP oligomers binding and bending the HIV-1 and adeno promoters. *J Mol Biol* 246: 576-84 (1995)
- Grimison B; Laurence J  
Immunodominant epitope regions of HIV-1 reverse transcriptase: correlations with HIV-1+ serum IgG inhibitory to polymerase activity and with disease progression. *J Acquir Immune Defic Syndr Hum Retrovirol* 9: 58-68 (1995)
- Grmek MD  
Some unorthodox views and a selection hypothesis on the origin of the AIDS viruses. *J Hist Med Allied Sci* 50: 253-73 (1995)
- Groenink M; Moore JP; Broersen S; Schuitemaker H  
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. *J Virol* 69: 523-7 (1995)
- Gu M; Rappaport J; Leppla SH  
Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1. *FEBS Lett* 365: 95-7 (1995)
- Gu Z; Arts EJ; Parniak MA; Wainberg MA  
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. *Proc Natl Acad Sci U S A* 92: 2760-4 (1995)
- Gualberto A; Baldwin AS Jr  
p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. *J Biol Chem* 270: 19680-3 (1995)
- Gualberto A; Hixon ML; Finco TS; Perkins ND; Nabel GJ; Baldwin AS Jr  
A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. *Mol Cell Biol* 15: 3450-9 (1995)
- Gulnik SV; Suvorov LI; Liu B; Yu B; Anderson B; Mitsuya H; Erickson JW  
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. *Biochemistry* 34: 9282-7 (1995)
- Gunkel N; Braddock M; Thorburn AM; Muckenthaler M; Kingsman AJ; Kingsman SM  
Promoter control of translation in *Xenopus* oocytes. *Nucleic Acids Res* 23: 405-12 (1995)
- Gunnery S; Mathews MB  
Functional mRNA can be generated by RNA polymerase III. *Mol Cell Biol* 15: 3597-607 (1995)
- Guo WX; Gill PS; Antakly T  
Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. *Cancer Res* 55: 823-9 (1995)
- Gupta P; Ding M; Cottrill M; Rinaldo C; Kingsley L; Wolinsky S; Mellors J  
Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay. *J Clin Microbiol* 33: 1670-3 (1995)
- Hadida F; Haas G; Zimmermann N; Hosmalin A; Spohn R; Samri A; Jung G; Debre P; Autran B  
CTLs from lymphoid organs recognize an optimal HLA-A2-restricted and HLA-B52-restricted nonapeptide and several epitopes in the C-terminal region of HIV-1 Nef. *J Immunol* 154: 4174-86 (1995)

## References (1995)

- Hammond SA; Johnson RP; Kalams SA; Walker BD; Takiguchi M; Safrit JT; Koup RA; Siliciano RF  
An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL.  
*J Immunol* 154: 6140-56 (1995)
- Hanke T; Young DF; Doyle C; Jones I; Randall RE  
Attachment of an oligopeptide epitope to the C-terminus of recombinant SIV gp160 facilitates the construction of SMAA complexes while preserving CD4 binding.  
*J Virol Methods* 53: 149-56 (1995)
- Harmache A; Vitu C; Russo P; Bouyac M; Hieblot C; Peveri P; Vigne R; Suzan M  
The caprine arthritis encephalitis virus tat gene is dispensable for efficient viral replication in vitro and in vivo.  
*J Virol* 69: 5445-54 (1995)
- Harmsen MC; Swart PJ; de Bethune MP; Pauwels R; De Clercq E; The TH; Meijer DK  
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.  
*J Infect Dis* 172: 380-8 (1995)
- Harrich D; Mavankal G; Mette-Snyder A; Gaynor RB  
Human immunodeficiency virus type 1 TAR element revertant viruses define RNA structures required for efficient viral gene expression and replication.  
*J Virol* 69: 4906-13 (1995)
- Harrowe G; Cheng-Mayer C  
Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.  
*Virology* 210: 490-4 (1995)
- Hart CE; Saltreli MJ; Galphin JC; Schochetman G  
A human chromosome 12-associated 83-kilodalton cellular protein specifically binds to the loop region of human immunodeficiency virus type 1 trans-activation response element RNA.  
*J Virol* 69: 6593-9 (1995)
- Hatta T; Takai K; Yokoyama S; Nakashima H; Yamamoto N; Takaku H  
Phosphorothioate oligonucleotides block reverse transcription by the RNase H activity associated with the HIV-1 polymerase.  
*Biochem Biophys Res Commun* 211: 1041-6 (1995)
- Hawkins ME; Pfeleiderer W; Mazumder A; Pommier YG; Balis FM  
Incorporation of a fluorescent guanosine analog into oligonucleotides and its application to a real time assay for the HIV-1 integrase 3'-processing reaction.  
*Nucleic Acids Res* 23: 2872-80 (1995)
- Haynes BF; Moody MA; Heinley CS; Korber B; Millard WA; Searce RM  
HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen.  
*AIDS Res Hum Retroviruses* 11: 211-21 (1995)
- Haynes KA; Sullivan DJ; Coleman DC; Clarke JC; Emilianus R; Atkinson C; Cann KJ  
Involvement of multiple *Cryptococcus neoformans* strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting.  
*J Clin Microbiol* 33: 99-102 (1995)
- He J; Landau NR  
Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor.  
*J Virol* 69: 4587-92 (1995)
- Hein J; Stovlbaek J  
A maximum-likelihood approach to analyzing nonoverlapping and overlapping reading frames.  
*J Mol Evol* 40: 181-9 (1995)
- Heinzinger N; Baca-Regen L; Stevenson M; Gendelman HE  
Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1.  
*Virology* 206: 731-5 (1995) van Hemert FJ; Berkhout B  
The tendency of lentiviral open reading frames to become A-rich: constraints imposed by viral genome organization and cellular tRNA availability.  
*J Mol Evol* 41: 132-40 (1995)
- Henderson AJ; Zou X; Calame KL  
C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes.  
*J Virol* 69: 5337-44 (1995)
- Heneine W; Yamamoto S; Switzer WM; Spira TJ; Folks TM  
Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1.  
*J Infect Dis* 171: 1210-6 (1995)

- Henkel T; Westervelt P; Ratner L  
HIV-1 V3 envelope sequences required for macrophage infection [letter]  
AIDS 9: 399-401 (1995)
- von Herrath M; Oldstone MB; Fox HS  
Simian immunodeficiency virus (SIV)-specific CTL in cerebrospinal fluid and brains of SIV-infected rhesus macaques.  
J Immunol 154: 5582-9 (1995)
- Herrmann CH; Rice AP  
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.  
J Virol 69: 1612-20 (1995)
- Hirsch VM; Dapolito G; Johnson PR; Elkins WR; London WT; Montali RJ; Goldstein S; Brown C  
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication.  
J Virol 69: 955-67 (1995)
- Ho JL; He S; Hu A; Geng J; Basile FG; Almeida MG; Saito AY; Laurence J; Johnson WD Jr  
Neutrophils from human immunodeficiency virus (HIV)-seronegative donors induce HIV replication from HIV-infected patients' mononuclear cells and cell lines: an in vitro model of HIV transmission facilitated by Chlamydia trachomatis.  
J Exp Med 181: 1493-505 (1995)
- Ho W; Kukla MJ; Breslin HJ; Ludovici DW; Grous PP; Diamond CJ; Miranda M; Rodgers JD; Ho CY; De Clercq E; et al  
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. 4.  
J Med Chem 38: 794-802 (1995)
- Hoch J; Lang SM; Weeger M; Stahl-Hennig C; Coulibaly C; Dittmer U; Hunsmann G; Fuchs D; Muller J; Sopper S; et al  
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys.  
J Virol 69: 4807-13 (1995)
- Hodge DR; Chen YM; Samuel KP  
Oligomerization of the HIV type 2 Nef protein: mutational analysis of the heptad leucine repeat motif and cysteine residues.  
AIDS Res Hum Retroviruses 11: 65-79 (1995)
- Hoeben RC; Fallaux FJ; Cramer SJ; van den Wollenberg DJ; van Ormondt H; Briet E; van der Eb AJ  
Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region.  
Blood 85: 2447-54 (1995)
- van der Hoek L; Boom R; Goudsmit J; Snijders F; Sol CJ  
Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum.  
J Clin Microbiol 33: 581-8 (1995)
- Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F; et al  
Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.  
J Infect Dis 171: 811-21 (1995)
- Hogervorst E; de Jong J; van Wijk A; Bakker M; Valk M; Nara P; Goudsmit J  
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.  
J Virol 69: 6342-51 (1995)
- Holloway MK; Wai JM; Halgren TA; Fitzgerald PM; Vacca JP; Dorsey BD; Levin RB; Thompson WJ; Chen LJ; deSolms SJ; et al  
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.  
J Med Chem 38: 305-17 (1995)
- Holmes EC; Zhang LQ; Robertson P; Cleland A; Harvey E; Simmonds P; Leigh Brown AJ  
The molecular epidemiology of human immunodeficiency virus type 1 in Edinburgh.  
J Infect Dis 171: 45-53 (1995)
- Holodniy M; Mole L; Margolis D; Moss J; Dong H; Boyer E; Urdea M; Kolberg J; Eastman S  
Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.  
J Virol 69: 3510-6 (1995)
- Honda A; Nakamura T; Nishimura S  
RNA signals for translation frameshift: influence of stem size and slippery sequence.  
Biochem Biophys Res Commun 213: 575-82 (1995)

## References (1995)

- Honda M; Kitamura K; Okamoto Y; Watanabe K; Yoshizaki H; Fukushima Y; Naganawa S; Miyamoto G; Someya K; Yamada K; et al  
[Induction of protective immune responses by a chimeric soluble protein from a recombinant BCG vector candidate vaccine to HIV-1]  
*Rinsho Ketsueki* 36: 435-41 (1995)
- Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF; et al  
A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.  
*J Med Chem* 38: 3246-52 (1995)
- Hope T; Pomerantz RJ  
The human immunodeficiency virus type 1 Rev protein: a pivotal protein in the viral life cycle.  
*Curr Top Microbiol Immunol* 193: 91-105 (1995)
- Horlacher J; Hottiger M; Podust VN; Hubscher U; Benner SA  
Recognition by viral and cellular DNA polymerases of nucleosides bearing bases with nonstandard hydrogen bonding patterns.  
*Proc Natl Acad Sci U S A* 92: 6329-33 (1995)
- Horsfield JA; Wilson DN; Mannering SA; Adamski FM; Tate WP  
Prokaryotic ribosomes recode the HIV-1 gag-pol-1 frameshift sequence by an E/P site post-translocation simultaneous slippage mechanism.  
*Nucleic Acids Res* 23: 1487-94 (1995)
- Hosono K; Kuwasaki T; Tsukahara S; Takai K; Takaku H  
Properties of base-pairing in the stem region of hairpin anti-sense oligonucleotides containing 2'-methoxynucleosides.  
*Biochim Biophys Acta* 1244: 339-44 (1995)
- Hottiger M; Gramatikoff K; Georgiev O; Chaponnier C; Schaffner W; Hubscher U  
The large subunit of HIV-1 reverse transcriptase interacts with beta-actin.  
*Nucleic Acids Res* 23: 736-41 (1995)
- Howcroft TK; Palmer LA; Brown J; Rellahan B; Kashanchi F; Brady JN; Singer DS  
HIV Tat represses transcription through Sp1-like elements in the basal promoter.  
*Immunity* 3: 127-38 (1995)
- Hruskova-Heidingsfeldova O; Andreansky M; Fabry M; Blaha I; Strop P; Hunter E  
Cloning, bacterial expression, and characterization of the Mason-Pfizer monkey virus proteinase.  
*J Biol Chem* 270: 15053-8 (1995)
- Hsu ML; Chen SW; Lin KH; Liao SK; Chang KS  
Cytokine regulation of HIV-1 LTR transactivation in human hepatocellular carcinoma cell lines.  
*Cancer Lett* 94: 41-8 (1995)
- Huang Y; Zhang L; Ho DD  
Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection.  
*J Virol* 69: 93-100 (1995)
- Huber J; Hell W; Wolf H  
A non-radioactive multiprime sequencing method for HIV genomes.  
*J Virol Methods* 51: 259-66 (1995)
- Huber W; Bautz W; Classen M; Schepp W  
[Pyrimethamine-sulfadiazine resistant cerebral toxoplasmosis in AIDS]  
*Dtsch Med Wochenschr* 120: 60-4 (1995)
- Hubert P; Bismuth G; Korner M; Debre P  
HIV-1 glycoprotein gp120 disrupts CD4-p56lck/CD3-T cell receptor interactions and inhibits CD3 signaling.  
*Eur J Immunol* 25: 1417-25 (1995)
- Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD  
Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).  
*J Virol* 69: 6289-96 (1995)
- Husson RN; Lan Y; Kojima E; Venzon D; Mitsuya H; McIntosh K  
Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.  
*J Pediatr* 126: 865-71 (1995)
- Imberti L; Sottini A; Quiros E; Mattioli S; Prati E; Albertini A; Primi D  
Construction of a superantigen through a structural modification of an inactive protein.  
*Ann N Y Acad Sci* 756: 117-9 (1995)
- Imberti L; Sottini A; Quiros Roldan E; Albertini A; Mattioli S; Prati E; Primi D  
Insertion of a short human immunodeficiency virus (HIV)-2 gp36 sequence into an HIV-1 p24 recombinant protein results in a polypeptide with potent and TCRBV-restricted T cell triggering activity.  
*Eur J Immunol* 25: 218-25 (1995)

- Isel C; Ehresmann C; Keith G; Ehresmann B; Marquet R  
Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer).  
*J Mol Biol* 247: 236-50 (1995)
- Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M; et al  
[An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain]  
*Rinsho Ketsueki* 36: 193-9 (1995)
- Isobe K; Imoto M; Fukuda Y; Koyama Y; Nakano I; Hayakawa T; Takamatsu J  
Hepatitis C virus infection and genotypes in Japanese hemophiliacs.  
*Liver* 15: 131-4 (1995)
- Itescu S; Rose S; Dwyer E; Winchester R  
Grouping HLA-B locus serologic specificities according to shared structural motifs suggests that different peptide-anchoring pockets may have contrasting influences on the course of HIV-1 infection.  
*Hum Immunol* 42: 81-9 (1995)
- Iversen AK; Shpaer EG; Rodrigo AG; Hirsch MS; Walker BD; Sheppard HW; Merigan TC; Mullins JI  
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.  
*J Virol* 69: 5743-53 (1995)
- Jabbar MA  
The human immunodeficiency virus type 1 Vpu protein: roles in virus release and CD4 downregulation.  
*Curr Top Microbiol Immunol* 193: 107-20 (1995)
- Jackson JB; Hanson MR; Johnson GM; Spahlinger TG; Polesky HF; Bowman RJ  
Long-term follow-up of blood donors with indeterminate human immunodeficiency virus type 1 results on Western blot.  
*Transfusion* 35: 98-102 (1995)
- Jacobsen H; Yasargil K; Winslow DL; Craig JC; Krohn A; Duncan IB; Mous J  
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.  
*Virology* 206: 527-34 (1995)
- Jaju M; Beard WA; Wilson SH  
Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer.  
*J Biol Chem* 270: 9740-7 (1995)
- James W; al-Shamkhani A  
RNA enzymes as tools for gene ablation.  
*Curr Opin Biotechnol* 6: 44-9 (1995)
- Jamieson BD; Pang S; Aldrovandi GM; Zha J; Zack JA  
In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates.  
*J Virol* 69: 6259-64 (1995)
- Janssens W; Fransen K; Loussert-Ajaka I; Heyndrickx L; Ivens T; Eberle J; Nkengasong J  
Diagnosis of HIV-1 group O infection by polymerase chain reaction [letter]  
*Lancet* 346: 451-2 (1995)
- Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR  
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.  
*J Infect Dis* 171: 1172-9 (1995)
- Jasko MV; Semizarov DG; Victorova LS; Mozzherin DJu; Krayevsky AA; Kukhanova MK  
New modified substrates for discriminating between human DNA polymerases alpha and epsilon.  
*FEBS Lett* 357: 23-6 (1995)
- al-Jaufy AY; King SR; Jackson MP  
Purification and characterization of a Shiga toxin A subunit-CD4 fusion protein cytotoxic to human immunodeficiency virus-infected cells.  
*Infect Immun* 63: 3073-8 (1995)
- Jean F; Bourcier B; Lebec S; Delaage M; Barbet J  
A novel protein immunoassay with predetermined specificity using monoclonal antibodies against tryptic fragments: application to HIV P24 antigen.  
*J Immunol Methods* 185: 103-14 (1995)
- Jelonek MT; Maskrey JL; Steimer KS; Potts BJ; Higgins KW; Keller MA  
Inhibition of the offspring anti-recombinant gp120 antibody response to a human immunodeficiency virus vaccine by maternal immunization in a murine model.  
*J Infect Dis* 172: 539-42 (1995)
- Jenkins TM; Hickman AB; Dyda F; Ghirlando R; Davies DR; Craigie R  
Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues.  
*Proc Natl Acad Sci U S A* 92: 6057-61 (1995)



## References (1995)

- Jensen TH; Leffers H; Kjems J  
Intermolecular binding sites of human immunodeficiency virus type 1 Rev protein determined by protein footprinting.  
*J Biol Chem* 270: 13777-84 (1995)
- Joag SV; Stephens EB; Galbreath D; Zhu GW; Li Z; Foresman L; Zhao LJ; Pinson DM; Narayan O  
Simian immunodeficiency virus SIVmac chimeric virus whose env gene was derived from SIV-encephalitic brain is macrophage-tropic but not neurovirulent.  
*J Virol* 69: 1367-9 (1995)
- Johnson CM; Sellese DW; Ellis MN; Childers TA; Tompkins MB; Tompkins WA  
Reduced provirus burden and enhanced humoral immune function in AZT-treated SCID-feline mice inoculated with feline immunodeficiency virus.  
*Vet Immunol Immunopathol* 46: 169-80 (1995)
- Johnson EJ; Sizemore RC; Gottlieb AA  
HIV retrotransposon activity and the immunopathogenesis of AIDS.  
*Trends Microbiol* 3: 115-7 (1995)
- Johnson EM; Warnock DW; Luker J; Porter SR; Scully C  
Emergence of azole drug resistance in *Candida* species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.  
*J Antimicrob Chemother* 35: 103-14 (1995)
- Jolliffe LK; Middleton SA; Barbone FP; Johnson DL; McMahon FJ; Lee WH; Gruninger RH; Mulcahy LS  
Erythropoietin receptor: application in drug development.  
*Nephrol Dial Transplant* 10 Suppl 2: 28-34 (1995)
- Jowett JB; Planelles V; Poon B; Shah NP; Chen ML; Chen IS  
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.  
*J Virol* 69: 6304-13 (1995)
- Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B  
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.  
*AIDS Res Hum Retroviruses* 11: 473-9 (1995)
- Jurriaans S; de Ronde A; Dekker J; Cornelissen M; Goudsmit J  
Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.  
*J Med Virol* 45: 91-8 (1995)
- Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F  
Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.  
*J Infect Dis* 171: 1343-7 (1995)
- Kanaya S; Ikehara M  
Functions and structures of ribonuclease H enzymes.  
*Subcell Biochem* 24: 377-422 (1995)
- Kandimalla ER; Agrawal S  
Single strand targeted triplex-formation. Destabilization of guanine quadruplex structures by foldback triplex-forming oligonucleotides.  
*Nucleic Acids Res* 23: 1068-74 (1995)
- Kang CY  
Molecular approaches to AIDS vaccine development using baculovirus expression vectors.  
*Methods Mol Biol* 39: 295-315 (1995)
- Kang YS; Boado RJ; Pardridge WM  
Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.  
*Drug Metab Dispos* 23: 55-9 (1995)
- Kanner SB; Haffar OK  
HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p56lck dissociation.  
*J Immunol* 154: 2996-3005 (1995)
- Kantanen ML; Leinikki P; Kuismanen E  
Endoproteolytic cleavage of HIV-1 gp160 envelope precursor occurs after exit from the trans-Golgi network (TGN).  
*Arch Virol* 140: 1441-9 (1995)
- Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS  
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.  
*Blood* 85: 1727-35 (1995)
- Kappes JC  
Viral protein X.  
*Curr Top Microbiol Immunol* 193: 121-32 (1995)
- Kappes JC  
Viral protein X.  
*Curr Top Microbiol Immunol* 193: 121-32 (1995)

- Katahira J; Ishizaki T; Sakai H; Adachi A; Yamamoto K; Shida H  
Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.  
*J Virol* 69: 3125-33 (1995)
- Katzman M; Sudol M  
Mapping domains of retroviral integrase responsible for viral DNA specificity and target site selection by analysis of chimeras between human immunodeficiency virus type 1 and visna virus integrases.  
*J Virol* 69: 5687-96 (1995)
- Kaye JF; Richardson JH; Lever AM  
cis-acting sequences involved in human immunodeficiency virus type 1 RNA packaging.  
*J Virol* 69: 6588-92 (1995)
- Keck JL; Marqusee S  
Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity.  
*Proc Natl Acad Sci U S A* 92: 2740-4 (1995)
- Kellam P; Larder BA  
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.  
*J Virol* 69: 669-74 (1995)
- Kempf W; Adams V; Pfaltz M; Briner J; Schmid M; Moos R; Hassam S  
Human herpesvirus type 6 and cytomegalovirus in AIDS-associated Kaposi's sarcoma: no evidence for an etiological association.  
*Hum Pathol* 26: 914-9 (1995)
- Kikuchi S  
[Study on transgenic mice growing into craniofacial anomaly]  
*Kokubyo Gakkai Zasshi* 62: 56-77 (1995)
- Kim B; Loeb LA  
Human immunodeficiency virus reverse transcriptase substitutes for DNA polymerase I in *Escherichia coli*.  
*Proc Natl Acad Sci U S A* 92: 684-8 (1995)
- Kim B; Loeb LA  
A screen in *Escherichia coli* for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase.  
*J Virol* 69: 6563-6 (1995)
- Kim FM; Kolson DL; Balliet JW; Srinivasan A; Collman RG  
V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate.  
*J Virol* 69: 1755-61 (1995)
- Kingsman AJ; Burns NR; Layton GT; Adams SE  
Yeast retrotransposon particles as antigen delivery systems.  
*Ann N Y Acad Sci* 754: 202-13 (1995)
- Kirchhoff F; Greenough TC; Brettler DB; Sullivan JL; Desrosiers RC  
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection [see comments]  
*N Engl J Med* 332: 228-32 (1995)
- Kishi M; Tokunaga K; Zheng YH; Bahmani MK; Kakinuma M; Nonoyama M; Lai PK; Ikuta K  
Superinfection of a defective human immunodeficiency virus type 1 provirus-carrying T cell clone with vif or vpu mutants gives cytopathic virus particles by homologous recombination.  
*AIDS Res Hum Retroviruses* 11: 45-53 (1995)
- Klenerman P; Meier UC; Phillips RE; McMichael AJ  
The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus.  
*Eur J Immunol* 25: 1927-31 (1995)
- Klinman DM; Haynes BF; Conover J  
Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides.  
*AIDS Res Hum Retroviruses* 11: 97-105 (1995)
- Knox KK; Harrington DP; Carrigan DR  
Fulminant human herpesvirus six encephalitis in a human immunodeficiency virus-infected infant.  
*J Med Virol* 45: 288-92 (1995)
- Ko YF; Bentley WE; Weigand WA  
The effect of cellular energetics on foreign protein production.  
*Appl Biochem Biotechnol* 50: 145-59 (1995)
- Koenig BW; Bergelson LD; Gawrisch K; Ward J; Ferretti JA  
Effect of the conformation of a peptide from gp41 on binding and domain formation in model membranes.  
*Mol Membr Biol* 12: 77-82 (1995)
- Koito A; Stamatatos L; Cheng-Mayer C  
Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.  
*Virology* 206: 878-84 (1995)

## References (1995)

- Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H  
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy [see comments]  
*J Infect Dis* 171: 1152-8 (1995)
- Kok-Jensen A  
[When can tuberculosis be eradicated in Denmark?]  
*Ugeskr Laeger* 157: 273-9 (1995)
- Koka P; He K; Camerini D; Tran T; Yashar SS; Merrill JE  
The mapping of HIV-1 gp160 epitopes required for interleukin-1 and tumor necrosis factor alpha production in glial cells.  
*J Neuroimmunol* 57: 179-91 (1995)
- Koller G; Graumann K; Kramer W; Sara M; Jungbauer A  
Laboratory-scale production and purification of recombinant HIV-1 reverse transcriptase.  
*J Chromatogr B Biomed Appl* 664: 107-18 (1995)
- Kondo E; Mammano F; Cohen EA; Gottlinger HG  
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.  
*J Virol* 69: 2759-64 (1995)
- Konopka K; Pretzer E; Duzgunes N  
Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.  
*Biochem Biophys Res Commun* 208: 75-81 (1995)
- Kostrikis LG; Bagdades E; Cao Y; Zhang L; Dimitriou D; Ho DD  
Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I.  
*J Virol* 69: 6122-30 (1995)
- Koval V; Jault FM; Pal PG; Moreno TN; Aiken C; Trono D; Spector SA; Spector DH  
Differential effects of human cytomegalovirus on integrated and unintegrated human immunodeficiency virus sequences.  
*J Virol* 69: 1645-51 (1995)
- Kozak CA; Gatignol A; Graham K; Jeang KT; McBride OW  
Genetic mapping in human and mouse of the locus encoding TRBP, a protein that binds the TAR region of the human immunodeficiency virus (HIV-1).  
*Genomics* 25: 66-72 (1995)
- Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Merigan TC  
Clarification of a method to reverse transcribe human immunodeficiency virus RNA [letter]  
*J Infect Dis* 171: 1072 (1995)
- Krausslich HG; Facke M; Heuser AM; Konvalinka J; Zentgraf H  
The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity.  
*J Virol* 69: 3407-19 (1995)
- Krieger JN; Coombs RW; Collier AC; Ho DD; Ross SO; Zeh JE; Corey L  
Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission.  
*J Urol* 154: 1035-40 (1995)
- Kroner BL; Goedert JJ; Blattner WA; Wilson SE; Carrington MN; Mann DL  
Concordance of human leukocyte antigen haplotype-sharing, CD4 decline and AIDS in hemophilic siblings. Multicenter Hemophilia Cohort and Hemophilia Growth and Development Studies.  
*AIDS* 9: 275-80 (1995)
- Kuiken CL; Goudsmit J; Weiller GF; Armstrong JS; Hartman S; Portegies P; Dekker J; Cornelissen M  
Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex.  
*J Gen Virol* 76 ( Pt 1): 175-80 (1995)
- Kulkosky J; Katz RA; Merkel G; Skalka AM  
Activities and substrate specificity of the evolutionarily conserved central domain of retroviral integrase.  
*Virology* 206: 448-56 (1995)
- Kunzi MS; Farzadegan H; Margolick JB; Vlahov D; Pitha PM  
Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression.  
*J Infect Dis* 171: 822-8 (1995)
- Kuroda MJ; el-Farrash MA; Choudhury S; Harada S  
Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro.  
*Virology* 210: 212-6 (1995)
- Kuznetsova EV; Kukhanova MK; Gurskaia GV; Fedorov II; Ias'ko MV; Chattopadhyaya J; Kraevskii AA  
[Conformation of crystalline 3'-nitro-2',3'-dideoxythymidine and properties of its 5'-triphosphate as a terminator substrate of retroviral reverse transcriptase]  
*Mol Biol (Mosk)* 29: 407-14 (1995)

- LaBranche CC; Sauter MM; Haggarty BS; Vance PJ; Romano J; Hart TK; Bugelski PJ; Marsh M; Hoxie JA  
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.  
*J Virol* 69: 5217-27 (1995)
- LaFemina RL; Graham PL; LeGrow K; Hastings JC; Wolfe A; Young SD; Emini EA; Hazuda DJ  
Inhibition of human immunodeficiency virus integrase by bis-catechols.  
*Antimicrob Agents Chemother* 39: 320-4 (1995)
- Lamhamedi-Cherradi S; Culmann-Penciolelli B; Guy B; Ly TD; Goujard C; Guillet JG; Gomard E  
Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection.  
*AIDS* 9: 421-6 (1995)
- Lapadat-Tapolsky M; Pernelle C; Borie C; Darlix JL  
Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1.  
*Nucleic Acids Res* 23: 2434-41 (1995)
- Lapidot A; Ben-Asher E; Eisenstein M  
Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro.  
*FEBS Lett* 367: 33-8 (1995)
- Larder BA; Kemp SD; Harrigan PR  
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.  
*Science* 269: 696-9 (1995)
- Laroche C; Drouet EB; Brousset P; Pain C; Boibieux A; Biron F; Icart J; Denoyel GA; Niveleau A  
Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas.  
*J Med Virol* 46: 66-74 (1995)
- Laufer DS; Starr SE  
Resistance to antivirals.  
*Pediatr Clin North Am* 42: 583-99 (1995)
- Laughlin MA; Chang GY; Oakes JW; Gonzalez-Scarano F; Pomerantz RJ  
Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 332-9 (1995)
- Laurent-Crawford AG; Coccia E; Krust B; Hovanessian AG  
Membrane-expressed HIV envelope glycoprotein heterodimer is a powerful inducer of cell death in uninfected CD4+ target cells.  
*Res Virol* 146: 5-17 (1995)
- Lawoko A; Johansson B; Dash R; Falck L; Dietrich U; Pipkorn R; Nilehn B; Blomberg J  
Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.  
*J Infect Dis* 172: 682-90 (1995)
- Lederman MM; Georges D; Dando S; Schmelzer R; Averill L; Goldberg D  
L-2-oxothiazolidine-4-carboxylic acid (procysteine) inhibits expression of the human immunodeficiency virus and expression of the interleukin-2 receptor alpha chain.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 107-15 (1995)
- Lee JH; Klein HG  
Cellular gene therapy.  
*Hematol Oncol Clin North Am* 9: 91-113 (1995)
- Lee PP; Linial ML  
Inhibition of wild-type HIV-1 virus production by a matrix deficient Gag mutant.  
*Virology* 208: 808-11 (1995)
- Lee SP; Censullo ML; Kim HG; Han MK  
Substrate-length-dependent activities of human immunodeficiency virus type 1 integrase in vitro: differential DNA binding affinities associated with different lengths of substrates.  
*Biochemistry* 34: 10215-23 (1995)
- Lee SP; Kim HG; Censullo ML; Han MK  
Characterization of Mg(2+)-dependent 3'-processing activity for human immunodeficiency virus type 1 integrase in vitro: real-time kinetic studies using fluorescence resonance energy transfer.  
*Biochemistry* 34: 10205-14 (1995)
- Lee-Huang S; Huang PL; Chen HC; Huang PL; Bourinbaier A; Huang HI; Kung HF  
Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.  
*Gene* 161: 151-6 (1995)
- Lefebvre S; Hubert B; Tekaia F; Brahic M; Bureau JF  
Isolation from human brain of six previously unreported cDNAs related to the reverse transcriptase of human endogenous retroviruses.  
*AIDS Res Hum Retroviruses* 11: 231-7 (1995)

## References (1995)

- Legrand-Poels S; Bours V; Piret B; Pflaum M; Epe B; Rentier B; Piette J  
Transcription factor NF-kappa B is activated by photosensitization generating oxidative DNA damages.  
*J Biol Chem* 270: 6925-34 (1995)
- Leitner T; Escanilla D; Marquina S; Wahlberg J; Brostrom C; Hansson HB; Uhlen M; Albert J  
Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden.  
*Virology* 209: 136-46 (1995)
- Lembo D; Angeretti A; Gaboli M; Cavallo R; Landolfo S  
Modulation of HIV-LTR activity by ras oncogenes.  
*Microbiologica* 18: 111-6 (1995)
- Lener D; Benarous R; Calogero RA  
Use of a constrain phage displayed-peptide library for the isolation of peptides binding to HIV-1 nucleocapsid protein (NCp7).  
*FEBS Lett* 361: 85-8 (1995)
- Letvin NL; Li J; Halloran M; Cranage MP; Rud EW; Sodroski J  
Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus.  
*J Virol* 69: 4569-71 (1995)
- Leung DW; Peterson PK; Weeks R; Gekker G; Chao CC; Kaplan AH; Balantac N; Tompkins C; Underiner GE; Bursten S; et al  
CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus.  
*Proc Natl Acad Sci U S A* 92: 4813-7 (1995)
- Lever AM  
Gene therapy for HIV infection.  
*Br Med Bull* 51: 149-66 (1995)
- Levy DN; Refaeli Y; Weiner DB  
The vpr regulatory gene of HIV.  
*Curr Top Microbiol Immunol* 193: 209-36 (1995)
- Levy DN; Refaeli Y; Weiner DB  
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency.  
*J Virol* 69: 1243-52 (1995)
- Li CJ; Friedman DJ; Wang C; Metelev V; Pardee AB  
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.  
*Science* 268: 429-31 (1995)
- Li CJ; Wang C; Friedman DJ; Pardee AB  
Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.  
*Proc Natl Acad Sci U S A* 92: 5461-4 (1995)
- Li QG; Zhang YJ; Liang Y; Feng CQ; Li YZ; Sjoberg R; Jiang Y; Wang NF; Wadell G  
The morphogenesis of a Chinese strain of HIV-1 forming inclusion bodies in Jurkat-tat III cells.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 103-13 (1995)
- Li SL; Kaaya EE; Ordonez C; Ekman M; Feichtinger H; Putkonen P; Bottiger D; Biberfeld G; Biberfeld P  
Thymic immunopathology and progression of SIVsm infection in cynomolgus monkeys.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 1-10 (1995)
- Li SL; Kaaya EE; Ordonez C; Ekman M; Feichtinger H; Putkonen P; Bottiger D; Biberfeld G; Biberfeld P  
Thymic immunopathology and progression of SIVsm infection in cynomolgus monkeys.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 1-10 (1995)
- Licinio J; Gold PW; Wong ML  
A molecular mechanism for stress-induced alterations in susceptibility to disease.  
*Lancet* 346: 104-6 (1995)
- Lieberman J; Fabry JA; Shankar P; Beckett L; Skolnik PR  
Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects.  
*AIDS Res Hum Retroviruses* 11: 257-71 (1995)
- Lin HJ; Siwak EB; Lauder IJ; Hollinger FB  
Single-strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologic cultures.  
*J Infect Dis* 171: 1619-22 (1995)
- Lin R; Gewert D; Hiscott J  
Differential transcriptional activation in vitro by NF-kappa B/Rel proteins.  
*J Biol Chem* 270: 3123-31 (1995)
- Lin Y; Lin X; Hong L; Foundling S; Henrikson RL; Thaisrivongs S; Leelamanit W; Raterman D; Shah M; Dunn BM; et al  
Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance.  
*Biochemistry* 34: 1143-52 (1995)
- Lindberg AA  
The history of live bacterial vaccines.  
*Dev Biol Stand* 84: 211-9 (1995)

- Linenberger ML; Abkowitz JL  
Haematological disorders associated with feline retrovirus infections.  
Baillieres Clin Haematol 8: 73-112 (1995)
- Linenberger ML; Beebe AM; Pedersen NC; Abkowitz JL; Dandekar S  
Marrow accessory cell infection and alterations in hematopoiesis accompany severe neutropenia during experimental acute infection with feline immunodeficiency virus.  
Blood 85: 941-51 (1995)
- Lisziewicz J; Sun D; Lisziewicz A; Gallo RC  
Antitax gene therapy: a candidate for late-stage AIDS patients.  
Gene Ther 2: 218-22 (1995)
- Lisziewicz J; Sun D; Trapnell B; Thomson M; Chang HK; Ensoli B; Peng B  
An autoregulated dual-function antitax gene for human immunodeficiency virus type 1 gene therapy.  
J Virol 69: 206-12 (1995)
- Liu M; Martinez-Maza O; Johnson MT; Fan J; Kishimoto T; Plaeger S  
IL-6 induces target cell resistance to HIV-specific cytotoxic lysis.  
J Acquir Immune Defic Syndr Hum Retrovirol 9: 321-31 (1995)
- Liuzzi G; Bagnarelli P; Chirianni A; Clementi M; Nappa S; Tullio Cataldo P; Valenza A; Piazza M  
Quantitation of HIV-1 genome copy number in semen and saliva [letter]  
AIDS 9: 651-3 (1995)
- Lodi PJ; Ernst JA; Kuszewski J; Hickman AB; Engelman A; Craigie R; Clore GM; Gronenborn AM  
Solution structure of the DNA binding domain of HIV-1 integrase.  
Biochemistry 34: 9826-33 (1995)
- Long KS; Crothers DM  
Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA.  
Biochemistry 34: 8885-95 (1995)
- Longo F; Marchetti MA; Castagnoli L; Battaglia PA; Gigliani F  
A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins.  
Biochem Biophys Res Commun 206: 326-34 (1995)
- Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL  
Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.  
J Acquir Immune Defic Syndr Hum Retrovirol 10: 13-26 (1995)
- Louie S; Cai J; Law R; Lin G; Lunardi-Iskandar Y; Jung B; Masood R; Gill P  
Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi's sarcoma.  
J Acquir Immune Defic Syndr Hum Retrovirol 8: 455-60 (1995)
- Loussert-Ajaka I; Chaix ML; Korber B; Letourneur F; Gomas E; Allen E; Ly TD; Brun-Vezinet F; Simon F; Saragosti S  
Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France.  
J Virol 69: 5640-9 (1995)
- Louwagie J; Janssens W; Mascola J; Heyndrickx L; Hegerich P; van der Groen G; McCutchan FE; Burke DS  
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin.  
J Virol 69: 263-71 (1995)
- Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS  
HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.  
Lancet 345: 820-4 (1995)
- Loya S; Bakhanashvili M; Kashman Y; Hizi A  
Peyssonols A and B, two novel inhibitors of the reverse transcriptases of human immunodeficiency virus types 1 and 2.  
Arch Biochem Biophys 316: 789-96 (1995)
- Loya S; Bakhanashvili M; Kashman Y; Hizi A  
Mechanism of inhibition of HIV reverse transcriptase by toxiusol, a novel general inhibitor of retroviral and cellular DNA polymerases.  
Biochemistry 34: 2260-6 (1995)
- Lu HH; Alexander L; Wimmer E  
Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120.  
J Virol 69: 4797-806 (1995)
- Lu S; Santoro JC; Fuller DH; Haynes JR; Robinson HL  
Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.  
Virology 209: 147-54 (1995)

## References (1995)

- Luciw PA; Pratt-Lowe E; Shaw KE; Levy JA; Cheng-Mayer C  
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).  
Proc Natl Acad Sci U S A 92: 7490-4 (1995)
- Luciw PA; Pratt-Lowe E; Shaw KE; Levy JA; Cheng-Mayer C  
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).  
Proc Natl Acad Sci U S A 92: 7490-4 (1995)
- Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F  
Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.  
AIDS 9: 435-9 (1995)
- Lusso P; Cocchi F; Balotta C; Markham PD; Louie A; Farci P; Pal R; Gallo RC; Reitz MS Jr  
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.  
J Virol 69: 3712-20 (1995)
- Lusso P; Gallo RC  
Human herpesvirus 6.  
Baillieres Clin Haematol 8: 201-23 (1995)
- Lusso P; Garzino-Demo A; Crowley RW; Malnati MS  
Infection of gamma/delta T lymphocytes by human herpesvirus 6: transcriptional induction of CD4 and susceptibility to HIV infection.  
J Exp Med 181: 1303-10 (1995)
- Luukkonen BG; Fenyo EM; Schwartz S  
Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.  
Virology 206: 854-65 (1995)
- Luukkonen BG; Tan W; Schwartz S  
Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance.  
J Virol 69: 4086-94 (1995)
- Luznik L; Kraus G; Guatelli J; Richman D; Wong-Staal F  
Tat-independent replication of human immunodeficiency viruses.  
J Clin Invest 95: 328-32 (1995)
- Mabrouk K; Van Rietschoten J; Rochat H; Loret EP  
Correlation of antiviral activity with beta-turn types for V3 synthetic multibranching peptides from HIV-1 gp120.  
Biochemistry 34: 8294-8 (1995)
- Machado AA; Bakpabua M; Salaun D; de Mareuil J; Krchnak V; MacGregor RR; Chermann JC; Hirsch I  
Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa.  
Vaccine 13: 321-5 (1995)
- Mackewicz CE; Blackburn DJ; Levy JA  
CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription.  
Proc Natl Acad Sci U S A 92: 2308-12 (1995)
- Macreadie IG; Castelli LA; Hewish DR; Kirkpatrick A; Ward AC; Azad AA  
A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.  
Proc Natl Acad Sci U S A 92: 2770-4 (1995)
- Madore SJ; Cullen BR  
Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators.  
Virology 206: 1150-4 (1995)
- Maggirwar SB; Harhaj E; Sun SC  
Activation of NF-kappa B/Rel by Tax involves degradation of I kappa B alpha and is blocked by a proteasome inhibitor.  
Oncogene 11: 993-8 (1995)
- Magnani M; Gazzanelli G; Brandi G; Casabianca A; Fraternali A; Chiarantini L; Rossi L  
2',3'-Dideoxycytidine induced drug resistance in human cells.  
Life Sci 57: 881-7 (1995)
- Mahalingam S; Collman RG; Patel M; Monken CE; Srinivasan A  
Role of the conserved dipeptide Gly75 and Cys76 on HIV-1 Vpr function.  
Virology 210: 495-500 (1995)
- Mahalingam S; Collman RG; Patel M; Monken CE; Srinivasan A  
Role of the conserved dipeptide Gly75 and Cys76 on HIV-1 Vpr function.  
Virology 210: 495-500 (1995)
- Mahalingam S; Khan SA; Jabbar MA; Monken CE; Collman RG; Srinivasan A  
Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation.  
Virology 207: 297-302 (1995)

- Mahalingam S; Khan SA; Murali R; Jabbar MA; Monken CE; Collman RG; Srinivasan A  
Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.  
*Proc Natl Acad Sci U S A* 92: 3794-8 (1995)
- Mahieu M; Hendrix C; Ooms J; Herdewijn P; Content J  
In vitro NCp7 enhancement of ribozyme-mediated cleavage of full-length human IL-6 mRNA.  
*Biochem Biophys Res Commun* 214: 36-43 (1995)
- Mai A; Artico M; Sbardella G; Massa S; Loi AG; Tramontano E; Scano P; La Colla P  
Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzylloxypyrimidines.  
*J Med Chem* 38: 3258-63 (1995)
- Majid A; Holmes R; Desselberger U; Simmonds P; McKee TA  
Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities.  
*J Med Virol* 46: 48-51 (1995)
- Maki AH  
Optically detected magnetic resonance of photoexcited triplet states.  
*Methods Enzymol* 246: 610-38 (1995)
- Maldarelli F; Sato H; Berthold E; Orenstein J; Martin MA  
Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency virus type 1.  
*J Virol* 69: 6457-65 (1995)
- Mallet F; Oriol G; Mary C; Verrier B; Mandrand B  
Continuous RT-PCR using AMV-RT and Taq DNA polymerase: characterization and comparison to uncoupled procedures.  
*Biotechniques* 18: 678-87 (1995)
- Malykh A; Reitz MS Jr; Louie A; Hall L; Lori F  
Multiple determinants for growth of human immunodeficiency virus type 1 in monocyte-macrophages.  
*Virology* 206: 646-50 (1995)
- Mammano F; Kondo E; Sodroski J; Bukovsky A; Gottlinger HG  
Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.  
*J Virol* 69: 3824-30 (1995)
- Mammano F; Salvatori F; Ometto L; Panozzo M; Chieco-Bianchi L; De Rossi A  
Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1.  
*J Virol* 69: 82-92 (1995)
- Mamounas M; Looney DJ; Talbott R; Wong-Staal F  
An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.  
*J Virol* 69: 6424-9 (1995)
- Manca F; Fenoglio D; Valle MT; Li Pira G; Kunkl A; Balderas RS; Baccala RG; Kono DH; Ferraris A; Saverino D; et al  
Human T helper cells specific for HIV reverse transcriptase: possible role in intrastuctural help for HIV envelope-specific antibodies.  
*Eur J Immunol* 25: 1217-23 (1995)
- Manca F; Fenoglio D; Valle MT; Li Pira G; Kunkl A; Ferraris A; Saverino D; Lancia F; Mortara L; Lozzi L; et al  
Human CD4+ T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 227-37 (1995)
- Mancuso LC; Correa MM; Vieira CA; Cunha OA; Lachat JJ; de Araujo HS; Ownby CL; Giglio JR  
Fractionation of Bothrops pirajai snake venom: isolation and characterization of piratoxin-I, a new myotoxic protein.  
*Toxicon* 33: 615-26 (1995)
- Mandel AM; Akke M; Palmer AG 3rd  
Backbone dynamics of Escherichia coli ribonuclease HI: correlations with structure and function in an active enzyme.  
*J Mol Biol* 246: 144-63 (1995)
- Mansky LM; Temin HM  
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.  
*J Virol* 69: 5087-94 (1995)
- Marcus H; David M; Canaan A; Kulova L; Lubin I; Segall H; Denes L; Erlich P; Galun E; Gan J; et al  
Human/mouse radiation chimera are capable of mounting a human primary humoral response.  
*Blood* 86: 398-406 (1995)
- Marino S; Kretschmer C; Brandner S; Cavard C; Zider A; Briand P; Isenmann S; Wagner EF; Aguzzi A  
Activation of HIV transcription by human foamy virus in transgenic mice.  
*Lab Invest* 73: 103-10 (1995)
- Markham RB; Yu X; Farzadegan H; Ray SC; Vlahov D  
Human immunodeficiency virus type 1 env and p17gag sequence variation in polymerase chain reaction-positive, seronegative injection drug users.  
*J Infect Dis* 171: 797-804 (1995)



## References (1995)

- Markowitz M; Mo H; Kempf DJ; Norbeck DW; Bhat TN; Erickson JW; Ho DD  
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.  
*J Virol* 69: 701-6 (1995)
- Martinez MA; Sala M; Vartanian JP; Wain-Hobson S  
Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction.  
*Nucleic Acids Res* 23: 2573-8 (1995)
- Maschera B; Furfine E; Blair ED  
Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.  
*J Virol* 69: 5431-6 (1995)
- Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ  
Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 330-4 (1995)
- Matheson PB; Abrams EJ; Thomas PA; Hernan MA; Thea DM; Lambert G; Krasinski K; Bamji M; Rogers MF; Heagarty M  
Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group.  
*J Infect Dis* 172: 353-8 (1995)
- Matsumi S; Matsushita S; Yoshimura K; Javaherian K; Takatsuki K  
Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.  
*AIDS Res Hum Retroviruses* 11: 501-8 (1995)
- Matsumi S; Matsushita S; Yoshimura K; Javaherian K; Takatsuki K  
Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.  
*AIDS Res Hum Retroviruses* 11: 501-8 (1995)
- Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K  
Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.  
*J Virol* 69: 3333-40 (1995)
- Matsuzaki K; Tanaka H; Omura S  
Isochromophilones I and II, novel inhibitors against gp120-CD4 binding produced by *Penicillium multicolor* FO-2338. II. Structure elucidation.  
*J Antibiot (Tokyo)* 48: 708-13 (1995)
- Mayers DL; Mikovits JA; Joshi B; Hewlett IK; Estrada JS; Wolfe AD; Garcia GE; Doctor BP; Burke DS; Gordon RK; et al  
Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.  
*Proc Natl Acad Sci U S A* 92: 215-9 (1995)
- Mazumder A; Gupta M; Perrin DM; Sigman DS; Rabinovitz M; Pommier Y  
Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation: the phenanthroline-cuprous complex.  
*AIDS Res Hum Retroviruses* 11: 115-25 (1995)
- Mazumder A; Pommier Y  
Processing of deoxyuridine mismatches and abasic sites by human immunodeficiency virus type-1 integrase.  
*Nucleic Acids Res* 23: 2865-71 (1995)
- Mazumder A; Raghavan K; Weinstein J; Kohn KW; Pommier Y  
Inhibition of human immunodeficiency virus type-1 integrase by curcumin.  
*Biochem Pharmacol* 49: 1165-70 (1995)
- McAdam S; Klenerman P; Tussey L; Rowland-Jones S; Laloo D; Phillips R; Edwards A; Giangrande P; Brown AL; Gotch F; et al  
Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses.  
*J Immunol* 155: 2729-36 (1995)
- McAlarney T; Ogino M; Apostolski S; Latov N  
Specificity and cross-reactivity of anti-galactocerebroside antibodies.  
*Immunol Invest* 24: 595-606 (1995)
- McClain KL; Leach CT; Jenson HB; Joshi VV; Pollock BH; Parmley RT; DiCarlo FJ; Chadwick EG; Murphy SB  
Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS [see comments]  
*N Engl J Med* 332: 12-8 (1995)
- McCormack SJ; Samuel CE  
Mechanism of interferon action: RNA-binding activity of full-length and R-domain forms of the RNA-dependent protein kinase PKR—determination of KD values for VAI and TAR RNAs.  
*Virology* 206: 511-9 (1995)
- McCreary C; Bergin C; Pilkington R; Kelly G; Mulcahy F  
Clinical parameters associated with recalcitrant oral candidosis in HIV infection: a preliminary study.  
*Int J STD AIDS* 6: 204-7 (1995)

- McCullough M; Hume S  
A longitudinal study of the change in resistance patterns and genetic relationship of oral *Candida albicans* from HIV-infected patients.  
*J Med Vet Mycol* 33: 33-7 (1995)
- McCullough M; Ross B; Reade PC  
Oral *Candida albicans* from patients infected with the human immunodeficiency virus and characterization of a genetically distinct subgroup of *Candida albicans*.  
*Aust Dent J* 40: 91-7 (1995)
- McCullough MJ; Ross BC; Reade PC  
Genetic differentiation of *Candida albicans* strains by mixed-linker polymerase chain reaction.  
*J Med Vet Mycol* 33: 77-80 (1995)
- McCune JM  
Viral latency in HIV disease.  
*Cell* 82: 183-8 (1995)
- McElhinney LM; Cooper RJ; Morris DJ  
Multiplex polymerase chain reaction for human herpesvirus-6, human cytomegalovirus, and human beta-globin DNA.  
*J Virol Methods* 53: 223-33 (1995)
- McElhinny JA; MacMorran WS; Bren GD; Ten RM; Israel A; Paya CV  
Regulation of I kappa B alpha and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus.  
*J Virol* 69: 1500-9 (1995)
- McGrath MS; Shiramizu BT; Herndier BG  
Identification of a clonal form of HIV in early Kaposi's sarcoma: evidence for a novel model of oncogenesis, "sequential neoplasia".  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 379-85 (1995)
- McGuire D; Barhite S; Hollander H; Miles M  
JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy.  
*Ann Neurol* 37: 395-9 (1995)
- McIlroy D; Autran B; Cheynier R; Wain-Hobson S; Clauvel JP; Oksenhendler E; Debre P; Hosmalin A  
Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients.  
*J Virol* 69: 4737-45 (1995)
- McKee TC; Cardellina JH 2nd; Dreyer GB; Boyd MR  
The pseudocalanolides: structure revision of calanolides C and D.  
*J Nat Prod* 58: 916-20 (1995)
- McKnight A; Weiss RA; Shotton C; Takeuchi Y; Hoshino H; Clapham PR  
Change in tropism upon immune escape by human immunodeficiency virus.  
*J Virol* 69: 3167-70 (1995)
- McLain L; Porta C; Lomonosoff GP; Durrani Z; Dimmock NJ  
Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.  
*AIDS Res Hum Retroviruses* 11: 327-34 (1995)
- McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM  
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.  
*J Clin Invest* 96: 456-64 (1995)
- Mehta J; Diaz C; Guha B; Harvill L; Krishnaswamy G  
Appearance of drug-resistant tuberculosis in rural Tennessee.  
*South Med J* 88: 60-4 (1995)
- el-Mekkawy S; Meselhy MR; Kusumoto IT; Kadota S; Hattori M; Namba T  
Inhibitory effects of Egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase.  
*Chem Pharm Bull (Tokyo)* 43: 641-8 (1995)
- Mellors JW; Bazmi HZ; Schinazi RF; Roy BM; Hsiou Y; Arnold E; Weir J; Mayers DL  
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.  
*Antimicrob Agents Chemother* 39: 1087-92 (1995)
- Mely Y; de Rocquigny H; Sorinas-Jimeno M; Keith G; Roques BP; Marquet R; Gerard D  
Binding of the HIV-1 nucleocapsid protein to the primer tRNA(3Lys), in vitro, is essentially not specific.  
*J Biol Chem* 270: 1650-6 (1995)
- Mercure L; Phaneuf D; Wainberg MA  
Differential effect of the immunomodulatory hormone somatostatin on replication of human immunodeficiency virus type 1 in CD4+ and CD8+ T lymphocytes.  
*Clin Diagn Lab Immunol* 2: 192-8 (1995)

## References (1995)

- Metlas R; Veljkovic V  
Does the HIV-1 manipulate immune network via gp120 immunoglobulin-like domain involving V3 loop?  
Vaccine 13: 355-9 (1995)
- Mhashilkar AM; Bagley J; Chen SY; Szilvay AM; Helland DG; Marasco WA  
Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies.  
EMBO J 14: 1542-51 (1995)
- Michael NL; Chang G; d'Arcy LA; Ehrenberg PK; Mariani R; Busch MP; Birx DL; Schwartz DH  
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus.  
J Virol 69: 4228-36 (1995)
- Michael NL; Mo T; Merzouki A; O'Shaughnessy M; Oster C; Burke DS; Redfield RR; Birx DL; Cassol SA  
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort.  
J Virol 69: 1868-77 (1995)
- Michne WF; Schroeder JD; Bailey TR; Neumann HC; Cooke D; Young DC; Hughes JV; Kingsley SD; Ryan KA; Putz HS; et al  
Keto/enol epoxy steroids as HIV-1 Tat inhibitors: structure-activity relationships and pharmacophore localization.  
J Med Chem 38: 3197-206 (1995)
- Mihm S; Galter D; Droge W  
Modulation of transcription factor NF kappa B activity by intracellular glutathione levels and by variations of the extracellular cysteine supply.  
FASEB J 9: 246-52 (1995)
- Mihm S; Galter D; Droge W  
Modulation of transcription factor NF kappa B activity by intracellular glutathione levels and by variations of the extracellular cysteine supply.  
FASEB J 9: 246-52 (1995)
- Miller MD; Bushman FD  
HIV integration. Ini1 for integration?  
Curr Biol 5: 368-70 (1995)
- Miller MD; Wang B; Bushman FD  
Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro.  
J Virol 69: 3938-44 (1995)
- Miller MD; Warmerdam MT; Page KA; Feinberg MB; Greene WC  
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.  
J Virol 69: 579-84 (1995)
- Mischianti C; Feriotto G; Fiorentino D; Gambari R  
Chromatography in DNA radiolabeling: hands-off automation using a robotic workstation.  
J Chromatogr B Biomed Appl 664: 303-10 (1995)
- Mishima Y; Steitz JA  
Site-specific crosslinking of 4-thiouridine-modified human tRNA(3Lys) to reverse transcriptase from human immunodeficiency virus type I.  
EMBO J 14: 2679-87 (1995)
- Misselwitz R; Hausdorf G; Welfle K; Hohne WE; Welfle H  
Conformation and stability of recombinant HIV-1 capsid protein p24 (rp24).  
Biochim Biophys Acta 1250: 9-18 (1995)
- Miyao Y; Shimizu K; Tamura M; Yamada M; Tamura K; Nakahira K; Kuriyama S; Hayakawa T; Ikenaka K  
A simplified general method for determination of recombinant retrovirus titers.  
Cell Struct Funct 20: 177-83 (1995)
- Miyazaki Y; Takamatsu T; Nosaka T; Fujita S; Martin TE; Hatanaka M  
The cytotoxicity of human immunodeficiency virus type 1 Rev: implications for its interaction with the nucleolar protein B23.  
Exp Cell Res 219: 93-101 (1995)
- Mizel SB; Kucera LS; Richardson SH; Ciacci F; Iyer NP  
Regulation of macrophage activation and human immunodeficiency virus production by invasive Salmonella strains.  
Infect Immun 63: 1820-6 (1995)
- Monken CE; Wu B; Srinivasan A  
High resolution analysis of HIV-1 quasispecies in the brain.  
AIDS 9: 345-9 (1995)
- Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; et al  
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm<sup>3</sup>. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.  
Ann Intern Med 123: 561-71 (1995)

- Montaner LJ; Gordon S  
TH2 downregulation of macrophage HIV-1 replication [letter]  
*Science* 267: 538-9 (1995)
- Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA 3rd; Swanstrom R  
A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.  
*Virology* 207: 475-85 (1995)
- Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF 3rd; Burton DR; Ho DD  
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.  
*J Virol* 69: 101-9 (1995)
- Moore JP; Trkola A; Korber B; Boots LJ; Kessler JA 2nd; McCutchan FE; Mascola J; Ho DD; Robinson J; Conley AJ  
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.  
*J Virol* 69: 122-30 (1995)
- Moore PS; Chang Y  
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection [see comments]  
*N Engl J Med* 332: 1181-5 (1995)
- Moore PS; Jones CJ; Mahmood N; Evans IG; Goff M; Cooper R; Hay AJ  
Anti-(human immunodeficiency virus) activity of polyoxotungstates and their inhibition of human immunodeficiency virus reverse transcriptase.  
*Biochem J* 307 ( Pt 1): 129-34 (1995)
- Morikawa Y; Kishi T; Zhang WH; Nermut MV; Hockley DJ; Jones IM  
A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17.  
*J Virol* 69: 4519-23 (1995)
- Morrison HG; Kirchhoff F; Desrosiers RC  
Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus.  
*Virology* 210: 448-55 (1995)
- Morrison HG; Kirchhoff F; Desrosiers RC  
Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus.  
*Virology* 210: 448-55 (1995)
- Moss PA; Rowland-Jones SL; Frodsham PM; McAdam S; Giangrande P; McMichael AJ; Bell JI  
Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.  
*Proc Natl Acad Sci U S A* 92: 5773-7 (1995)
- Mouzaki A; Serfling E; Zubler RH  
Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor- $\chi$  B.  
*Eur J Immunol* 25: 2177-82 (1995)
- Moyle G  
Influence of emergence of viral resistance on HIV treatment choice [letter]  
*Int J STD AIDS* 6: 225-6 (1995)
- Mucke L; Abraham CR; Ruppe MD; Rockenstein EM; Toggas SM; Mallory M; Alford M; Maslah E  
Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein.  
*J Exp Med* 181: 1551-6 (1995)
- Mulder-Kampinga GA; Simonon A; Kuiken CL; Dekker J; Scherpbier HJ; van de Perre P; Boer K; Goudsmit J  
Similarity in env and gag genes between genomic RNAs of human immunodeficiency virus type 1 (HIV-1) from mother and infant is unrelated to time of HIV-1 RNA positivity in the child.  
*J Virol* 69: 2285-96 (1995)
- Muller H; Rehmann-Sutter C  
[Gene therapy and ethics]  
*Schweiz Med Wochenschr* 125: 34-41 (1995)
- Muller JR; Janz S; Goedert JJ; Potter M; Rabkin CS  
Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men.  
*Proc Natl Acad Sci U S A* 92: 6577-81 (1995)
- Munch-Petersen B; Tyrsted G; Cloos L; Beck RA; Eger K  
Different affinity of the two forms of human cytosolic thymidine kinase towards pyrimidine analogs.  
*Biochim Biophys Acta* 1250: 158-62 (1995)
- Muriaux D; Girard PM; Bonnet-Mathoniere B; Paoletti J  
Dimerization of HIV-1Lai RNA at low ionic strength. An autocomplementary sequence in the 5' leader region is evidenced by an antisense oligonucleotide.  
*J Biol Chem* 270: 8209-16 (1995)

## References (1995)

- Muro-Cacho CA; Pantaleo G; Fauci AS  
Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden.  
*J Immunol* 154: 5555-66 (1995)
- Murray MF; Srinivasan A  
Nicotinamide inhibits HIV-1 in both acute and chronic in vitro infection.  
*Biochem Biophys Res Commun* 210: 954-9 (1995)
- Musiani M; Zerbini M; Gentilomi G; Rodorigo G; De Rosa V; Gibellini D; Venturoli S; Gallinella G  
Persistent B19 parvovirus infections in haemophilic HIV-1 infected patients.  
*J Med Virol* 46: 103-8 (1995)
- Nacken W; Kingsman AJ; Kingsman SM; Sablitzky F; Sorg C  
A homologue of the human MSS1 gene, a positive modulator of HIV-1 gene expression, is massively expressed in *Xenopus* oocytes.  
*Biochim Biophys Acta* 1261: 293-5 (1995)
- Nahreini P; Mathews MB  
Effects of the simian virus 40 origin of replication on transcription from the human immunodeficiency virus type 1 promoter.  
*J Virol* 69: 1296-301 (1995)
- Najera I; Holguin A; Quinones-Mateu ME; Munoz-Fernandez MA; Najera R; Lopez-Galindez C; Domingo E  
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.  
*J Virol* 69: 23-31 (1995)
- Ndimbie OK; Nedjar S; Kingsley L; Riddle P; Rinaldo C  
Long-term serologic follow-up of hepatitis C virus-seropositive homosexual men.  
*Clin Diagn Lab Immunol* 2: 219-24 (1995)
- Neal TF; Holland HK; Baum CM; Villinger F; Ansari AA; Saral R; Wingard JR; Fleming WH  
CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.  
*Blood* 86: 1749-56 (1995)
- Neenhold HR; Rana TM  
Major groove opening at the HIV-1 Tat binding site of TAR RNA evidenced by a rhodium probe.  
*Biochemistry* 34: 6303-9 (1995)
- Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ  
Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIIB gp 120.  
*Cell Immunol* 160: 217-23 (1995)
- Nehete PN; Murthy KK; Satterfield WC; Arlinghaus RB; Sastry KJ  
Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIIB.  
*AIDS* 9: 567-72 (1995)
- Neumann M; Felber BK; Kleinschmidt A; Froese B; Erfle V; Pavlakis GN; Brack-Werner R  
Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function.  
*J Virol* 69: 2159-67 (1995)
- Neurath AR; Lin K; Strick N; Jiang S  
Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the trans-membrane region, affect the glycoprotein 41 fusion domain [letter]  
*AIDS Res Hum Retroviruses* 11: 189-90 (1995)
- Newell ML; Gibb DM  
A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission.  
*Drug Saf* 12: 274-82 (1995)
- Newman MA; McPherson SA; Fletcher TM 3rd; Kappes JC; Hahn BH  
Polyclonal rabbit antisera that detect the Vpr protein of SIVSM and SIVMAC on immunoblots of purified virions.  
*AIDS Res Hum Retroviruses* 11: 405-8 (1995)
- Newman MA; McPherson SA; Fletcher TM 3rd; Kappes JC; Hahn BH  
Polyclonal rabbit antisera that detect the Vpr protein of SIVSM and SIVMAC on immunoblots of purified virions.  
*AIDS Res Hum Retroviruses* 11: 405-8 (1995)
- Ng TT; Guntermann C; Nye KE; Parkin JM; Anderson J; Norman JE; Morrow WJ  
Adhesion co-receptor expression and intracellular signalling in HIV disease: implications for immunotherapy.  
*AIDS* 9: 337-43 (1995)
- Nicholson LK; Yamazaki T; Torchia DA; Grzesiek S; Bax A; Stahl SJ; Kaufman JD; Wingfield PT; Lam PY; Jadhav PK; et al  
Flexibility and function in HIV-1 protease [see comments]  
*Nat Struct Biol* 2: 274-80 (1995)

- Nielsen K; Wei LS; Sim MS; Deveikis A; Keller M; Stiehm ER; Frenkel LM; Bryson YJ  
Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay.  
*J Infect Dis* 172: 359-64 (1995)
- Nietfield W; Bauer M; Fevrier M; Maier R; Holzwarth B; Frank R; Maier B; Riviere Y; Meyerhans A  
Sequence constraints and recognition by CTL of an HLA-B27-restricted HIV-1 gag epitope.  
*J Immunol* 154: 2189-97 (1995)
- Nir-Paz R; Israel S; Honigman A; Kahane I  
Mycoplasmas regulate HIV-LTR-dependent gene expression.  
*FEMS Microbiol Lett* 128: 63-8 (1995)
- Nolan CM; Williams DL; Cave MD; Eisenach KD; el-Hajj H; Hooton TM; Thompson RL; Goldberg SV  
Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis.  
*Am J Respir Crit Care Med* 152: 1067-71 (1995)
- Nosaka T; Miyazaki Y; Takamatsu T; Sano K; Nakai M; Fujita S; Martin TE; Hatanaka M  
The post-transcriptional regulator Rex of the human T-cell leukemia virus type I is present as nucleolar speckles in infected cells.  
*Exp Cell Res* 219: 122-9 (1995)
- Nottet HS; Jett M; Flanagan CR; Zhai QH; Persidsky Y; Rizzino A; Bernton EW; Genis P; Baldwin T; Schwartz J; et al  
A regulatory role for astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-alpha by activated HIV-1-infected monocytes is attenuated by primary human astrocytes.  
*J Immunol* 154: 3567-81 (1995)
- Nowak MA; May RM; Phillips RE; Rowland-Jones S; Lalloo DG; McAdam S; Klenerman P; Koppe B; Sigmund K; Bangham CR; et al  
Antigenic oscillations and shifting immunodominance in HIV-1 infections [see comments]  
*Nature* 375: 606-11 (1995)
- Nowak MA; McMichael AJ  
How HIV defeats the immune system.  
*Sci Am* 273: 58-65 (1995)
- O'Brien MC; Ueno T; Jahan N; Zajac-Kaye M; Mitsuya H  
HIV-1 expression induced by anti-cancer agents in latently HIV-1-infected ACH2 cells.  
*Biochem Biophys Res Commun* 207: 903-9 (1995)
- O'Neil LL; Burkhard MJ; Diehl LJ; Hoover EA  
Vertical transmission of feline immunodeficiency virus.  
*AIDS Res Hum Retroviruses* 11: 171-82 (1995)
- Okada T; Patterson BK; Gurney ME  
Inhibition of anti-V3 domain antibody binding to human immunodeficiency virus type-1-infected cells by sulfated polysaccharides.  
*Biochem Biophys Res Commun* 209: 850-8 (1995)
- Oksuz S; Gurek F; Gil RR; Pengsuparp T; Pezzuto JM; Cordell GA  
Four diterpene esters from *Euphorbia myrsinites*.  
*Phytochemistry* 38: 1457-62 (1995)
- Oldfield EC 3rd  
Increasing resistance of *Candida albicans* to fluconazole.  
*Am J Gastroenterol* 90: 1182 (1995)
- Olivares I; Menendez-Arias L; Rodriguez-Bernabe A; Martin MJ; Dopazo J; Lopez-Galindez C  
Sequence analysis of HIV-1 vif gene in Spanish isolates.  
*Virus Genes* 9: 283-8 (1995)
- Ometto L; Zanutto C; Maccabruni A; Caselli D; Truscia D; Gi-aquinto C; Ruga E; Chieco-Bianchi L; De Rossi A  
Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission.  
*AIDS* 9: 427-34 (1995)
- Opalenik SR; Shin JT; Wehby JN; Mahesh VK; Thompson JA  
The HIV-1 TAT protein induces the expression and extracellular appearance of acidic fibroblast growth factor.  
*J Biol Chem* 270: 17457-67 (1995)
- Orloff SL; Bandea CI; Kennedy MS; Allaway GP; Maddon PJ; McDougal JS  
Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.  
*AIDS Res Hum Retroviruses* 11: 335-42 (1995)
- Oshiro CM; Kuntz ID; Dixon JS  
Flexible ligand docking using a genetic algorithm.  
*J Comput Aided Mol Des* 9: 113-30 (1995)
- Otsuka M; Fujita M; Aoki T; Ishii S; Sugiura Y; Yamamoto T; Inoue J  
Novel zinc chelators with dual activity in the inhibition of the kappa B site-binding proteins HIV-EP1 and NF-kappa B.  
*J Med Chem* 38: 3264-70 (1995)

## References (1995)

- Ott DE; Nigida SM Jr; Henderson LE; Arthur LO  
The majority of cells are superinfected in a cloned cell line that produces high levels of human immunodeficiency virus type 1 strain MN.  
*J Virol* 69: 2443-50 (1995)
- Ottmann M; Gabus C; Darlix JL  
The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity.  
*J Virol* 69: 1778-84 (1995)
- Ou SH; Wu F; Harrich D; Garcia-Martinez LF; Gaynor RB  
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs.  
*J Virol* 69: 3584-96 (1995)
- Ou WJ; Bergeron JJ; Li Y; Kang CY; Thomas DY  
Conformational changes induced in the endoplasmic reticulum luminal domain of calnexin by Mg-ATP and Ca<sup>2+</sup>.  
*J Biol Chem* 270: 18051-9 (1995)
- Oxford JS  
Quo vadis antiviral agents for herpes, influenza and HIV? [editorial]  
*J Med Microbiol* 43: 1-3 (1995)
- Pachl C; Todd JA; Kern DG; Sheridan PJ; Fong SJ; Stempien M; Hoo B; Besemer D; Yeghiazarian T; Irvine B; et al  
Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 446-54 (1995)
- Paganelli R; Scala E; Ansotegui IJ; Ausiello CM; Halapi E; Fanales-Belasio E; D'Offizi G; Mezzaroma I; Pandolfi F; Fiorilli M; et al  
CD8<sup>+</sup> T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE [see comments]  
*J Exp Med* 181: 423-8 (1995)
- Pahl A; Flugel RM  
Characterization of the human spuma retrovirus integrase by site-directed mutagenesis, by complementation analysis, and by swapping the zinc finger domain of HIV-1.  
*J Biol Chem* 270: 2957-66 (1995)
- Paik SY; Banerjee AC; Harmison GG; Chen CJ; Schubert M  
Inducible and conditional inhibition of human immunodeficiency virus proviral expression by vesicular stomatitis virus matrix protein.  
*J Virol* 69: 3529-37 (1995)
- Palaniappan C; Fay PJ; Bambara RA  
Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase.  
*J Biol Chem* 270: 4861-9 (1995)
- Pancino G; Camoin L; Sonigo P  
Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein.  
*J Virol* 69: 2110-8 (1995)
- Pantaleo G; Demarest JF; Vaccarezza M; Graziosi C; Bansal GP; Koenig S; Fauci AS  
Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.  
*Eur J Immunol* 25: 226-31 (1995)
- Pantaleo G; Fauci AS  
New concepts in the immunopathogenesis of HIV infection.  
*Annu Rev Immunol* 13: 487-512 (1995)
- Parada CA; Yoon JB; Roeder RG  
A novel LBP-1-mediated restriction of HIV-1 transcription at the level of elongation in vitro.  
*J Biol Chem* 270: 2274-83 (1995)
- Pardridge WM; Boado RJ; Kang YS  
Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo.  
*Proc Natl Acad Sci U S A* 92: 5592-6 (1995)
- Parent LJ; Bennett RP; Craven RC; Nelle TD; Krishna NK; Bowzard JB; Wilson CB; Puffer BA; Montelaro RC; Wills JW  
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.  
*J Virol* 69: 5455-60 (1995)
- Park IW; Sodroski J  
Functional analysis of the vpx, vpr, and nef genes of simian immunodeficiency virus.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 335-44 (1995)
- Parmantier E; Monge M; Yagello M; Cabon F; Demerens C; Gluckman JC; Zalc B  
HIV-1 envelope glycoprotein gp120 does not bind to galactosylceramide-expressing rat oligodendrocytes.  
*Virology* 206: 1084-91 (1995)

- Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB; et al  
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.  
*J Virol* 69: 5228-35 (1995)
- Patel PH; Jacobo-Molina A; Ding J; Tantilio C; Clark AD Jr; Raag R; Nanni RG; Hughes SH; Arnold E  
Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase.  
*Biochemistry* 34: 5351-63 (1995)
- Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF  
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.  
*J Virol* 69: 2148-52 (1995)
- Patterson S; Gross J; English N; Stackpoole A; Bedford P; Knight SC  
CD4 expression on dendritic cells and their infection by human immunodeficiency virus.  
*J Gen Virol* 76 ( Pt 5): 1155-63 (1995)
- Pedrol E; Grau JM; Casademont J; Cid MC; Masanes F; Fernandez-Sola J; Urbano-Marquez A  
Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers.  
*Clin Neuropathol* 14: 179-84 (1995)
- Peeters M; Janssens W; Vanden Haesevelde M; Fransen K; Willems B; Heyndrickx L; Kestens L; Piot P; Van der Groen G; Heeney J  
Virologic and serologic characteristics of a natural chimpanzee lentivirus infection.  
*Virology* 211: 312-5 (1995)
- Peeters M; Janssens W; Vanden Haesevelde M; Fransen K; Willems B; Heyndrickx L; Kestens L; Piot P; Van der Groen G; Heeney J  
Virologic and serologic characteristics of a natural chimpanzee lentivirus infection.  
*Virology* 211: 312-5 (1995)
- Pelletier E; Saurin W; Cheynier R; Letvin NL; Wain-Hobson S  
The tempo and mode of SIV quasispecies development in vivo calls for massive viral replication and clearance.  
*Virology* 208: 644-52 (1995)
- Peng H; Reinhart TA; Retzel EF; Staskus KA; Zupancic M; Haase AT  
Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to productive infection.  
*Virology* 206: 16-27 (1995)
- Pengue G; Caputo A; Rossi C; Barbanti-Brodano G; Lania L  
Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Kruppel-associated box repressor domain targeted to the transactivating response element.  
*J Virol* 69: 6577-80 (1995)
- Peranteau AG; Kuzmic P; Angell Y; Garcia-Echeverria C; Rich DH  
Increase in fluorescence upon the hydrolysis of tyrosine peptides: application to proteinase assays.  
*Anal Biochem* 227: 242-5 (1995)
- Pereira FB; Goni FM; Nieva JL  
Liposome destabilization induced by the HIV-1 fusion peptide effect of a single amino acid substitution.  
*FEBS Lett* 362: 243-6 (1995)
- Perham RN; Terry TD; Willis AE; Greenwood J; di Marzo Veronese F; Appella E  
Engineering a peptide epitope display system on filamentous bacteriophage.  
*FEMS Microbiol Rev* 17: 25-31 (1995)
- Petit PL; Haarlem JV; Poelman M; Haverkamp MC; Wamola IA  
Bacteraemia in patients presenting with fever.  
*East Afr Med J* 72: 116-20 (1995)
- Petry H; Dittmer U; Stahl-Hennig C; Coulibaly C; Makoschey B; Fuchs D; Wachter H; Tolle T; Morys-Wortmann C; Kaup FJ; et al  
Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.  
*J Virol* 69: 1564-74 (1995)
- Petry H; Dittmer U; Stahl-Hennig C; Coulibaly C; Makoschey B; Fuchs D; Wachter H; Tolle T; Morys-Wortmann C; Kaup FJ; et al  
Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.  
*J Virol* 69: 1564-74 (1995)
- Phipps DJ; Reed-Doob P; MacFadden DK; Piovesan JP; Mills GB; Branch DR  
An octapeptide analogue of HIV gp120 modulates protein tyrosine kinase activity in activated peripheral blood T lymphocytes.  
*Clin Exp Immunol* 100: 412-8 (1995)



## References (1995)

- Pinto LA; Sullivan J; Berzofsky JA; Clerici M; Kessler HA; Landay AL; Shearer GM  
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.  
*J Clin Invest* 96: 867-76 (1995)
- Piret B; Legrand-Poels S; Sappey C; Piette J  
NF-kappa B transcription factor and human immunodeficiency virus type 1 (HIV-1) activation by methylene blue photosensitization.  
*Eur J Biochem* 228: 447-55 (1995)
- Pise-Masison CA; Holland CA  
Restricted replication of the HIV-1 T-lymphotropic isolate NL4-3 in HL-60 cells.  
*Virology* 206: 641-5 (1995)
- Planelles V; Bachelerie F; Jowett JB; Haislip A; Xie Y; Banooni P; Masuda T; Chen IS  
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr.  
*J Virol* 69: 5883-9 (1995)
- Plasterk RH  
The HIV integrase catalytic core [news]  
*Nat Struct Biol* 2: 87-90 (1995)
- Pogue RR; Eron J; Frelinger JA; Matsui M  
Amino-terminal alteration of the HLA-A\*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.  
*Proc Natl Acad Sci U S A* 92: 8166-70 (1995)
- Polacino PS; Liang HA; Clark EA  
Formation of simian immunodeficiency virus long terminal repeat circles in resting T cells requires both T cell receptor- and IL-2-dependent activation.  
*J Exp Med* 182: 617-21 (1995)
- Porter DC; Ansardi DC; Morrow CD  
Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans.  
*J Virol* 69: 1548-55 (1995)
- Poumbourios P; el Ahmar W; McPhee DA; Kemp BE  
Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.  
*J Virol* 69: 1209-18 (1995)
- Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ; et al  
Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.  
*AIDS Res Hum Retroviruses* 11: 203-9 (1995)
- Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM; et al  
Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H-pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.  
*J Med Chem* 38: 898-905 (1995)
- Pratt RD; Shapiro JF; McKinney N; Kwok S; Spector SA  
Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury.  
*J Infect Dis* 172: 851-4 (1995)
- Priel E; Aflalo E; Seri I; Henderson LE; Arthur LO; Aboud M; Segal S; Blair DG  
DNA binding properties of the zinc-bound and zinc-free HIV nucleocapsid protein: supercoiled DNA unwinding and DNA-protein cleavable complex formation.  
*FEBS Lett* 362: 59-64 (1995)
- Priestle JP; Fassler A; Rosel J; Tintelnot-Blomley M; Strop P; Grutter MG  
Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.  
*Structure* 3: 381-9 (1995)
- Prieto I; Hervas-Stubbs S; Garcia-Granero M; Berasain C; Riezu-Boj JJ; Lasarte JJ; Sarobe P; Prieto J; Borrás-Cuesta F  
Simple strategy to induce antibodies of distinct specificity: application to the mapping of gp120 and inhibition of HIV-1 infectivity.  
*Eur J Immunol* 25: 877-83 (1995)
- Puri RK; Leland P; Aggarwal BB  
Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits interleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line.  
*AIDS Res Hum Retroviruses* 11: 31-40 (1995)
- Purvis SF; Jacobberger JW; Sramkoski RM; Patki AH; Lederman MM  
HIV type 1 Tat protein induces apoptosis and death in Jurkat cells.  
*AIDS Res Hum Retroviruses* 11: 443-50 (1995)
- Puyal C; Milhaud P; Bienvenue A; Philippot JR  
A new cationic liposome encapsulating genetic material. A potential delivery system for polynucleotides.  
*Eur J Biochem* 228: 697-703 (1995)

- Qavi HB; Green MT; Lewis DE; Hollinger FB; Pearson G; Ablashi DV  
HIV-1 and HHV-6 antigens and transcripts in retinas of patients with AIDS in the absence of human cytomegalovirus. *Invest Ophthalmol Vis Sci* 36: 2040-7 (1995)
- Quiros E; Garcia F; Maroto MC; Bernal MC; Cabezas T; Piedrola G  
Human immunodeficiency virus type-1 can be detected in monocytes by polymerase chain reaction. *J Med Microbiol* 42: 411-4 (1995)
- Rabehi L; Ferriere F; Saffar L; Gattegno L  
alpha 1-Acid glycoprotein binds human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein via N-linked glycans. *Glycoconj J* 12: 7-16 (1995)
- Rabin RL; Roederer M; Maldonado Y; Petru A; Herzenberg LA; Herzenberg LA  
Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. *J Clin Invest* 95: 2054-60 (1995)
- Race E; Frezza P; Stephens DM; Davis D; Polyanskaya N; Cranage M; Oxford JS  
An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. *Vaccine* 13: 54-60 (1995)
- Raghavan K; Buolamwini JK; Fesen MR; Pommier Y; Kohn KW; Weinstein JN  
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. *J Med Chem* 38: 890-7 (1995)
- Ramzaoui S; Jouen-Beades F; Michot F; Borsa-Lebas F; Humbert G; Tron F  
Comparison of activation marker and TCR V beta gene product expression by CD4+ and CD8+ T cells in peripheral blood and lymph nodes from HIV-infected patients. *Clin Exp Immunol* 99: 182-8 (1995)
- Rando RF; Ojwang J; Elbaggari A; Reyes GR; Tinder R; McGrath MS; Hogan ME  
Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. *J Biol Chem* 270: 1754-60 (1995)
- Rasmussen L; Morris S; Zipeto D; Fessel J; Wolitz R; Dowling A; Merigan TC  
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. *J Infect Dis* 171: 177-82 (1995)
- Rasuli AM; Rasuli ShM; Klepikov NN; Andreev SM; Meshcheriakova DV; Tarasova SO; Seniuta NB; Syrtsev AV; Gurtsevich VE  
[Cross reactivity and amino acid structural homology of immunodominant peptide fragments of structural viruses from the human retroviruses HTLV-I, HTLV-II, HIV-1, and HIV-2] *Mol Biol (Mosk)* 29: 225-38 (1995)
- Raszka WV Jr; Skillman LP; McEvoy PL; Robb ML  
Isolation of nontuberculous, non-avium mycobacteria from patients infected with human immunodeficiency virus. *Clin Infect Dis* 20: 73-6 (1995)
- Ratner L; Niederman TM  
Nef. *Curr Top Microbiol Immunol* 193: 169-208 (1995)
- Ratner L; Niederman TM  
Nef. *Curr Top Microbiol Immunol* 193: 169-208 (1995)
- Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL  
Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients. *J Infect Dis* 171: 1420-30 (1995)
- Reddy TR; Kraus G; Suhasini M; Leavitt MC; Wong-Staal F  
Identification and mapping of inhibitory sequences in the human immunodeficiency virus type 2 vif gene. *J Virol* 69: 5167-70 (1995)
- Reddy TR; Kraus G; Yamada O; Looney DJ; Suhasini M; Wong-Staal F  
Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. *J Virol* 69: 3549-53 (1995)
- Refaeli Y; Levy DN; Weiner DB  
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. *Proc Natl Acad Sci U S A* 92: 3621-5 (1995)

## References (1995)

- Reich SH; Melnick M; Davies JF 2nd; Appelt K; Lewis KK; Fuhry MA; Pino M; Trippe AJ; Nguyen D; Dawson H; et al  
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.  
*Proc Natl Acad Sci U S A* 92: 3298-302 (1995)
- Reicin AS; Kalpana G; Paik S; Marmon S; Goff S  
Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration.  
*J Virol* 69: 5904-7 (1995)
- Reicin AS; Paik S; Berkowitz RD; Luban J; Lowy I; Goff SP  
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity.  
*J Virol* 69: 642-50 (1995)
- Reimann KA; Cate RL; Wu Y; Palmer L; Olson D; Waite BC; Letvin NL; Burkly LC  
In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques.  
*AIDS Res Hum Retroviruses* 11: 517-25 (1995)
- Reimann KA; Cate RL; Wu Y; Palmer L; Olson D; Waite BC; Letvin NL; Burkly LC  
In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques.  
*AIDS Res Hum Retroviruses* 11: 517-25 (1995)
- Reinhardt PP; Reinhardt B; Lathey JL; Spector SA  
Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates.  
*J Clin Microbiol* 33: 292-7 (1995)
- Ren J; Esnouf R; Garman E; Somers D; Ross C; Kirby I; Keeling J; Darby G; Jones Y; Stuart D; et al  
High resolution structures of HIV-1 RT from four RT-inhibitor complexes.  
*Nat Struct Biol* 2: 293-302 (1995)
- Renwick SB; Critchley AD; Adams CJ; Kelly SM; Price NC; Stockley PG  
Probing the details of the HIV-1 Rev-Rev-responsive element interaction: effects of modified nucleotides on protein affinity and conformational changes during complex formation.  
*Biochem J* 308 ( Pt 2): 447-53 (1995)
- Resnick DA; Smith AD; Gesiler SC; Zhang A; Arnold E; Arnold GF  
Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.  
*J Virol* 69: 2406-11 (1995)
- Resti M; Azzari C; Lega L; Rossi ME; Zammarchi E; Novembre E; Vierucci A  
Mother-to-infant transmission of hepatitis C virus.  
*Acta Paediatr* 84: 251-5 (1995)
- Rezikyan S; Kaaya EE; Ekman M; Voevodin AF; Feichtinger H; Putkonen P; Castanos-Velez E; Biberfeld G; Biberfeld P  
B-cell lymphomagenesis in SIV-immunosuppressed cynomolgus monkeys.  
*Int J Cancer* 61: 574-9 (1995)
- Rhim H; Rice AP  
HIV-1 Tat protein is able to efficiently transactivate the HIV-2 LTR through a TAR RNA element lacking both dinucleotide bulge binding sites.  
*Virology* 206: 673-8 (1995)
- Rice P; Mizuuchi K  
Structure of the bacteriophage Mu transposase core: a common structural motif for DNA transposition and retroviral integration.  
*Cell* 82: 209-20 (1995)
- Richards OC; Hanson JL; Schultz S; Ehrenfeld E  
Identification of nucleotide binding sites in the poliovirus RNA polymerase.  
*Biochemistry* 34: 6288-95 (1995)
- Richardson JH; Kaye JF; Child LA; Lever AM  
Helper virus-free transfer of human immunodeficiency virus type 1 vectors.  
*J Gen Virol* 76 ( Pt 3): 691-6 (1995)
- Richardson JH; Marasco WA  
Intracellular antibodies: development and therapeutic potential.  
*Trends Biotechnol* 13: 306-10 (1995)
- Richman DD  
Human immunodeficiency virus. Protease uninhibited [news; comment]  
*Nature* 374: 494 (1995)
- Rieckmann P; Albrecht M; Ehrenreich H; Weber T; Michel U  
Semi-quantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction.  
*Res Exp Med (Berl)* 195: 17-29 (1995)
- Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J; et al  
Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.  
*Arch Virol* 140: 1393-404 (1995)

- Rittinger K; Divita G; Goody RS  
Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.  
*Proc Natl Acad Sci U S A* 92: 8046-9 (1995)
- Rittner K; Churcher MJ; Gait MJ; Karn J  
The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.  
*J Mol Biol* 248: 562-80 (1995)
- Robbins PA; Garboczi DN; Strominger JL  
HLA-A\*0201 complexes with two 10-Mer peptides differing at the P2 anchor residue have distinct refolding kinetics.  
*J Immunol* 154: 703-9 (1995)
- Robertson DL; Hahn BH; Sharp PM  
Recombination in AIDS viruses.  
*J Mol Evol* 40: 249-59 (1995)
- Robertson DL; Hahn BH; Sharp PM  
Recombination in AIDS viruses.  
*J Mol Evol* 40: 249-59 (1995)
- Robertson DL; Sharp PM; McCutchan FE; Hahn BH  
Recombination in HIV-1 [letter]  
*Nature* 374: 124-6 (1995)
- Rodgers DW; Gamblin SJ; Harris BA; Ray S; Culp JS; Hellmig B; Woolf DJ; Debouck C; Harrison SC  
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.  
*Proc Natl Acad Sci U S A* 92: 1222-6 (1995)
- Rodriguez-Rodriguez L; Tsuchihashi Z; Fuentes GM; Bambara RA; Fay PJ  
Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro.  
*J Biol Chem* 270: 15005-11 (1995)
- Rogel ME; Wu LI; Emerman M  
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.  
*J Virol* 69: 882-8 (1995)
- Rolo FM; Miranda L; Wainberg MA; Gu Z; Lobaina L; Noa E; Mato J; Machado F; Martin Z  
Envelope V3 region sequences of Cuban HIV-1 isolates.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 123-5 (1995)
- Romines KR; Watenpaugh KD; Tomich PK; Howe WJ; Morris JK; Lovasz KD; Mulichak AM; Finzel BC; Lynn JC; Horng MM; et al  
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.  
*J Med Chem* 38: 1884-91 (1995)
- Root-Bernstein RS  
Preliminary evidence for idiotype-antiidiotype immune complexes cross-reactive with lymphocyte antigens in AIDS and lupus.  
*Med Hypotheses* 44: 20-7 (1995)
- Root-Bernstein RS; DeWitt SH  
Semen alloantigens and lymphocytotoxic antibodies in AIDS and ICL.  
*Genetica* 95: 133-56 (1995)
- Rose J; Silvera P; Flanagan B; Kitchin P; Almond N  
The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo.  
*J Virol Methods* 51: 229-39 (1995)
- Rose JR; Babe LM; Craik CS  
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.  
*J Virol* 69: 2751-8 (1995)
- Rosenblatt JD; Miles S; Gasson JC; Prager D  
Transactivation of cellular genes by human retroviruses.  
*Curr Top Microbiol Immunol* 193: 25-49 (1995)
- Rothblum CJ; Jackman J; Mikovits J; Shukla RR; Kumar A  
Interaction of nuclear protein p140 with human immunodeficiency virus type 1 TAR RNA in mitogen-activated primary human T lymphocytes.  
*J Virol* 69: 5156-63 (1995)
- Rowell JF; Ruff AL; Guarnieri FG; Staveley-O'Carroll K; Lin X; Tang J; August JT; Siliciano RF  
Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells.  
*J Immunol* 155: 1818-28 (1995)
- Royer RE; Deck LM; Vander Jagt TJ; Martinez FJ; Mills RG; Young SA; Vander Jagt DL  
Synthesis and anti-HIV activity of 1,1'-dideoxygossypol and related compounds.  
*J Med Chem* 38: 2427-32 (1995)

## References (1995)

- Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrahi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ  
Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.  
*AIDS* 9: 243-51 (1995)
- Rudensey LM; Kimata JT; Benveniste RE; Overbaugh J  
Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population.  
*Virology* 207: 528-42 (1995)
- Rudensey LM; Kimata JT; Benveniste RE; Overbaugh J  
Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population.  
*Virology* 207: 528-42 (1995)
- Sabbioni S; Negrini M; Rimessi P; Manservigi R; Barbanti-Brodano G  
A BK virus episomal vector for constitutive high expression of exogenous cDNAs in human cells.  
*Arch Virol* 140: 335-9 (1995)
- Sabin CA; Mocroft AA; Phillips AN  
The association between HIV phenotype, virus burden, codon 215 mutation and CD4 cell decline [letter]  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 101-2 (1995)
- Saib A; Peries J; de The H  
Recent insights into the biology of the human foamy virus.  
*Trends Microbiol* 3: 173-8 (1995)
- Sakai H; Furuta RA; Tokunaga K; Kawamura M; Hatanaka M; Adachi A  
Rev-dependency of expression of human immunodeficiency virus type 1 gag and env genes.  
*FEBS Lett* 365: 141-5 (1995)
- Sakihama T; Smolyar A; Reinherz EL  
Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120.  
*Proc Natl Acad Sci U S A* 92: 6444-8 (1995)
- Saksela K; Cheng G; Baltimore D  
Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4.  
*EMBO J* 14: 484-91 (1995)
- Sakuragi J; Sakai H; Kawamura M; Tokunaga K; Ueda S; Adachi A  
Generation and characterization of a host cell-dependent gag gene mutant of human immunodeficiency virus type 1.  
*Virology* 212: 251-4 (1995)
- Salemi S; Caporossi AP; Boffa L; Longobardi MG; Barnaba V  
HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing [see comments]  
*J Exp Med* 181: 2253-7 (1995)
- Salghetti S; Mariani R; Skowronski J  
Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail.  
*Proc Natl Acad Sci U S A* 92: 349-53 (1995)
- Sampaio EP; Caneshi JR; Nery JA; Duppre NC; Pereira GM; Vieira LM; Moreira AL; Kaplan G; Sarno EN  
Cellular immune response to *Mycobacterium leprae* infection in human immunodeficiency virus-infected individuals.  
*Infect Immun* 63: 1848-54 (1995)
- Samuelsson A; Chiodi F; Ohman P; Putkonen P; Norrby E; Persson MA  
Chimeric macaque/human Fab molecules neutralize simian immunodeficiency virus.  
*Virology* 207: 495-502 (1995)
- Sanguinetti M; Posteraro B; Rossolini GM; Satta G  
Development of a yeast retrotransposon-based system useful for screening of potentially active anti-retroviral compounds.  
*Microbiologica* 18: 117-25 (1995)
- Sappey C; Boelaert JR; Legrand-Poels S; Grady RW; Piette J  
NF-kappa B transcription factor activation by hydrogen peroxide can be decreased by 2,3-dihydroxybenzoic acid and its ethyl ester derivative.  
*Arch Biochem Biophys* 321: 263-70 (1995)
- Sarafianos SG; Pandey VN; Kaushik N; Modak MJ  
Glutamine 151 participates in the substrate dNTP binding function of HIV-1 reverse transcriptase.  
*Biochemistry* 34: 7207-16 (1995)
- Sargueil B; Pecchia DB; Burke JM  
An improved version of the hairpin ribozyme functions as a ribonucleoprotein complex.  
*Biochemistry* 34: 7739-48 (1995)

- Sarma RH; Sarma MH; Rein R; Shibata M; Setlik RS; Ornstein RL; Kazim AL; Cairo A; Tomasi TB  
Secondary structure in solution of two anti-HIV-1 hammer-head ribozymes as investigated by two-dimensional 1H 500 MHz NMR spectroscopy in water.  
FEBS Lett 357: 317-23 (1995)
- Sawai ET; Baur AS; Peterlin BM; Levy JA; Cheng-Mayer C  
A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity.  
J Biol Chem 270: 15307-14 (1995)
- Scanlon MJ; Fairlie DP; Craik DJ; Englebretsen DR; West ML  
NMR solution structure of the RNA-binding peptide from human immunodeficiency virus (type 1) Rev.  
Biochemistry 34: 8242-9 (1995)
- Schaal H; Klein M; Gehrman P; Adams O; Scheid A  
Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion.  
J Virol 69: 3308-14 (1995)
- Schmitz ML; Stelzer G; Altmann H; Meisterernst M; Baeuerle PA  
Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators.  
J Biol Chem 270: 7219-26 (1995)
- Schneider DJ; Feigon J; Hostomsky Z; Gold L  
High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus.  
Biochemistry 34: 9599-610 (1995)
- Schreck S; Panozzo J; Milton J; Libertin CR; Woloschak GE  
The effects of multiple UV exposures on HIV-LTR expression.  
Photochem Photobiol 61: 378-82 (1995)
- Schreier H; Ausborn M; Gunther S; Weissig V; Chander R  
(Patho)physiologic pathways to drug targeting: artificial viral envelopes.  
J Mol Recognit 8: 59-62 (1995)
- Schrier RD; Freeman WR; Wiley CA; McCutchan JA  
Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.  
J Clin Invest 95: 1741-6 (1995)
- Schroder HC; Muller WE; Agutter PS  
Kinetic models for nucleocytoplasmic transport of messenger RNA.  
J Theor Biol 174: 169-77 (1995)
- Schuitemaker H; Fouchier RA; Broersen S; Groenink M; Koot M; van 't Wout AB; Huisman HG; Tersmette M; Miedema F  
Envelope V2 configuration and HIV-1 phenotype: clarification [letter]  
Science 268: 115 (1995)
- Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P; Danner SA; Mulder J; Loveday C; Christopherson C; et al  
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).  
J Infect Dis 171: 1411-9 (1995)
- Schwartz DH; Sharma UK; Perlman EJ; Blakemore K  
Adherence of human immunodeficiency virus-infected lymphocytes to fetal placental cells: a model of maternal -> fetal transmission.  
Proc Natl Acad Sci U S A 92: 978-82 (1995)
- Schweizer M; Turek R; Hahn H; Schliephake A; Netzer KO; Eder G; Reinhardt M; Rethwilm A; Neumann-Haefelin D  
Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans.  
AIDS Res Hum Retroviruses 11: 161-70 (1995)
- Scotiniotis I; Brass CA; Malet PF  
Hepatitis C: diagnosis and treatment.  
J Gen Intern Med 10: 273-82 (1995)
- Secchiero P; Carrigan DR; Asano Y; Benedetti L; Crowley RW; Komaroff AL; Gallo RC; Lusso P  
Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction.  
J Infect Dis 171: 273-80 (1995)
- Sei S; Saito K; Stewart SK; Crowley JS; Brouwers P; Kleiner DE; Katz DA; Pizzo PA; Heyes MP  
Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy.  
J Infect Dis 172: 638-47 (1995)
- Selvin PR  
Fluorescence resonance energy transfer.  
Methods Enzymol 246: 300-34 (1995)
- Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC  
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.  
J Infect Dis 172: 70-8 (1995)

## References (1995)

- Shafer RW; Merigan TC  
New virologic tools for the design and analysis of clinical trials [editorial; comment]  
*J Infect Dis* 171: 1325-8 (1995)
- Shafer RW; Small PM; Larkin C; Singh SP; Kelly P; Sierra MF; Schoolnik G; Chirgwin KD  
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment.  
*J Infect Dis* 171: 170-6 (1995)
- Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T; et al  
Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.  
*Biochem Biophys Res Commun* 211: 159-65 (1995)
- Shapshak P; Nagano I; Xin K; Bradley W; McCoy CB; Sun NC; Stewart RV; Yoshioka M; Petito C; Goodkin K; et al  
HIV-1 heterogeneity and cytokines. Neuropathogenesis.  
*Adv Exp Med Biol* 373: 225-38 (1995)
- Sharma V; Knobloch TJ; Benjamin D  
Differential expression of cytokine genes in HIV-1 tat transfected T and B cell lines.  
*Biochem Biophys Res Commun* 208: 704-13 (1995)
- Shaw LC; Lewin AS  
Protein-induced folding of a group I intron in cytochrome b pre-mRNA.  
*J Biol Chem* 270: 21552-62 (1995)
- Sheridan PL; Schorpp M; Voz ML; Jones KA  
Cloning of an SNF2/SWI2-related protein that binds specifically to the SPH motifs of the SV40 enhancer and to the HIV-1 promoter.  
*J Biol Chem* 270: 4575-87 (1995)
- Sheridan PL; Sheline CT; Cannon K; Voz ML; Pazin MJ; Kadonaga JT; Jones KA  
Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro.  
*Genes Dev* 9: 2090-104 (1995)
- Sherman MP; Dock NL; Ehrlich GD; Sninsky JJ; Brothers C; Gillsdorf J; Bryz-Gornia V; Poiesz BJ  
Evaluation of HIV type 1 western blot-indeterminate blood donors for the presence of human or bovine retroviruses.  
*AIDS Res Hum Retroviruses* 11: 409-14 (1995)
- Shibata R; Hoggan MD; Broscius C; Englund G; Theodore TS; Buckler-White A; Arthur LO; Israel Z; Schultz A; Lane HC; et al  
Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.  
*J Virol* 69: 4453-62 (1995)
- Shirasaka T; Kavlick MF; Ueno T; Gao WY; Kojima E; Alcaide ML; Choekijchai S; Roy BM; Arnold E; Yarchoan R; et al  
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.  
*Proc Natl Acad Sci U S A* 92: 2398-402 (1995)
- Shirokova EA; Shipitsyn AV; Semizarov DG  
[Study of reverse transcriptase selectivity. Substrate properties of new 2',3'-unsaturated acyclic nucleotide analogs]  
*Mol Biol (Mosk)* 29: 461-71 (1995)
- Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA  
Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.  
*J Virol* 69: 222-30 (1995)
- Shterman N; Elroy-Stein O; Morad I; Amitsur M; Kaufmann G  
Cleavage of the HIV replication primer tRNA<sup>Lys,3</sup> in human cells expressing bacterial anticodon nuclease.  
*Nucleic Acids Res* 23: 1744-9 (1995)
- Siddiqi SM; Chen X; Rao J; Schneller SW; Ikeda S; Snoeck R; Andrei G; Balzarini J; De Clercq E  
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.  
*J Med Chem* 38: 1035-8 (1995)
- Sidhu MK; Rashidbaigi A; Liao MJ; Testa D  
Distinction between HIV-1 and HIV-2 nucleotide sequences by PCR and restriction enzyme analysis.  
*Biotechniques* 18: 20, 22, 24 (1995)
- Sidorov AV; Zdanovskii AG; Shumina NR; Zverev VV; Andzharidze OG  
[Stability and virus-inhibiting effect of recombinant receptor toxins based on the human CD4 receptor and diphtheria toxin]  
*Vopr Virusol* 40: 103-5 (1995)
- Sieczkowski L; Chandran B; Wood C  
The human immunodeficiency virus tat gene enhances replication of human herpesvirus-6.  
*Virology* 211: 544-53 (1995)

- Siegel F; Kurth R; Norley S  
Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 217-26 (1995)
- Siegel F; Kurth R; Norley S  
Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 8: 217-26 (1995)
- Sierra-Honigmann AM; Carbone KM; Yolken RH  
Polymerase chain reaction (PCR) search for viral nucleic acid sequences in schizophrenia.  
*Br J Psychiatry* 166: 55-60 (1995)
- Sierzputowska-Gracz H; McKenzie RA; Theil EC  
The importance of a single G in the hairpin loop of the iron responsive element (IRE) in ferritin mRNA for structure: an NMR spectroscopy study.  
*Nucleic Acids Res* 23: 146-53 (1995)
- Silver SA; Arthur RR; Erozan YS; Sherman ME; McArthur JC; Uematsu S  
Diagnosis of progressive multifocal leukoencephalopathy by stereotactic brain biopsy utilizing immunohistochemistry and the polymerase chain reaction.  
*Acta Cytol* 39: 35-44 (1995)
- Silvestris F; Ribatti D; Nico B; Silvestris N; Romito A; Dammacco F  
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms (editorial)]  
*Ann Ital Med Int* 10: 7-13 (1995)
- Silvestris F; Williams RC Jr; Dammacco F  
Autoreactivity in HIV-1 infection: the role of molecular mimicry.  
*Clin Immunol Immunopathol* 75: 197-205 (1995)
- Simm M; Shahabuddin M; Chao W; Allan JS; Volsky DJ  
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.  
*J Virol* 69: 4582-6 (1995)
- Simon JH; Southerling TE; Peterson JC; Meyer BE; Malim MH  
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.  
*J Virol* 69: 4166-72 (1995)
- Skinner MH; Blaschke TF  
Clinical pharmacokinetics of rifabutin.  
*Clin Pharmacokinet* 28: 115-25 (1995)
- Smith AB 3rd; Akaishi R; Jones DR; Keenan TP; Guzman MC; Holcomb RC; Sprengeler PA; Wood JL; Hirschmann R; Holloway MK  
Design and synthesis of nonpeptide peptidomimetic inhibitors of renin.  
*Biopolymers* 37: 29-53 (1995)
- Smythe JA; Symonds G  
Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.  
*Inflamm Res* 44: 11-5 (1995)
- Snyder BW; Vitale J; Milos P; Gosselin J; Gillespie F; Ebert K; Hague BF; Kindt TJ; Wadsworth S; Leibowitz P  
Developmental and tissue-specific expression of human CD4 in transgenic rabbits.  
*Mol Reprod Dev* 40: 419-28 (1995)
- Sobol RW; Henderson EE; Kon N; Shao J; Hitzges P; Mordechai E; Reichenbach NL; Charubala R; Schirmeister H; Pfeleiderer W; et al  
Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2',5'-oligoadenylate derivatives.  
*J Biol Chem* 270: 5963-78 (1995)
- Sodano P; Hartmann B; Rose T; Wain-Hobson S; Delepierre M  
Solution structure of a homopyrimidine: homopurine dodecamer encoded by the HIV-1 envelope gene: NMR and molecular simulation studies.  
*Biochemistry* 34: 6900-10 (1995)
- Soderberg LS; Barnett JB  
Inhalation exposure to isobutyl nitrite inhibits macrophage tumoricidal activity and modulates inducible nitric oxide.  
*J Leukoc Biol* 57: 135-40 (1995)
- Sodora DL; Courcelle J; Brojatsch J; Berson A; Wang YC; Dow SW; Hoover EA; Mullins JI  
Analysis of a feline immunodeficiency virus provirus reveals patterns of gene sequence conservation distinct from human immunodeficiency virus type 1.  
*AIDS Res Hum Retroviruses* 11: 531-3 (1995)
- Sommadossi JP  
Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues.  
*J Infect Dis* 171 Suppl 2: S88-92 (1995)



## References (1995)

- Song CZ; Loewenstein PM; Green M  
Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.  
*J Virol* 69: 2907-11 (1995)
- Soukchareun S; Tregear GW; Haralambidis J  
Preparation and characterization of antisense oligonucleotide-peptide hybrids containing viral fusion peptides.  
*Bioconjug Chem* 6: 43-53 (1995)
- Soulier J; Grollet L; Oksenhendler E; Cacoub P; Cazals-Hatem D; Babinet P; d'Agay MF; Clauvel JP; Raphael M; Degos L; et al  
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.  
*Blood* 86: 1276-80 (1995)
- Soulier J; Grollet L; Oksenhendler E; Miclea JM; Cacoub P; Baruchel A; Brice P; Clauvel JP; d'Agay MF; Raphael M; et al  
Molecular analysis of clonality in Castleman's disease.  
*Blood* 86: 1131-8 (1995)
- Southgate CD; Green MR  
Delineating minimal protein domains and promoter elements for transcriptional activation by lentivirus Tat proteins.  
*J Virol* 69: 2605-10 (1995)
- Sova P; van Ranst M; Gupta P; Balachandran R; Chao W; Itescu S; McKinley G; Volsky DJ  
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo.  
*J Virol* 69: 2557-64 (1995)
- Spence RA; Kati WM; Anderson KS; Johnson KA  
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.  
*Science* 267: 988-93 (1995)
- Spina CA; Guatelli JC; Richman DD  
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.  
*J Virol* 69: 2977-88 (1995)
- Spira AI; Ho DD  
Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro.  
*J Virol* 69: 422-9 (1995)
- Srinivasakumar N; Hammariskjold ML; Rekosh D  
Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation.  
*J Virol* 69: 6106-14 (1995)
- Srivastava SP; Davies MV; Kaufman RJ  
Calcium depletion from the endoplasmic reticulum activates the double-stranded RNA-dependent protein kinase (PKR) to inhibit protein synthesis.  
*J Biol Chem* 270: 16619-24 (1995)
- Staffa A; Cochrane A  
Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.  
*Mol Cell Biol* 15: 4597-605 (1995)
- Stahl G; Bidou L; Rousset JP; Cassan M  
Versatile vectors to study recoding: conservation of rules between yeast and mammalian cells.  
*Nucleic Acids Res* 23: 1557-60 (1995)
- Stamatatos L; Cheng-Mayer C  
Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.  
*J Virol* 69: 6191-8 (1995)
- Staszewski S; Massari FE; Kober A; Gohler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI; et al  
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.  
*J Infect Dis* 171: 1159-65 (1995)
- Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E; et al  
Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.  
*J Virol* 69: 814-24 (1995)
- Steinkasserer A; Jones T; Sheer D; Koettnitz K; Hauber J; Bevec D  
The eukaryotic cofactor for the human immunodeficiency virus type 1 (HIV-1) rev protein, eIF-5A, maps to chromosome 17p12-p13: three eIF-5A pseudogenes map to 10q23.3, 17q25, and 19q13.2.  
*Genomics* 25: 749-52 (1995)

- Stephens EB; McClure HM; Narayan O  
The proteins of lymphocyte- and macrophage-tropic strains of simian immunodeficiency virus are processed differently in macrophages.  
*Virology* 206: 535-44 (1995)
- Stern TL; Reitz MS Jr; Robert-Guroff M  
Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.  
*J Virol* 69: 1860-7 (1995)
- Stoiber H; Ebenbichler C; Schneider R; Janatova J; Dierich MP  
Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.  
*AIDS* 9: 19-26 (1995)
- Stoiber H; Ebenbichler CF; Thielens NM; Arlaud GJ; Dierich MP  
HIV-1 rsgp41 depends on calcium for binding of human c1q but not for binding of gp120.  
*Mol Immunol* 32: 371-4 (1995)
- Stricker RB; Zhu YS; Elsworth BF  
A simplified method for quantitation of human immunodeficiency virus type 1 (HIV1) RNA in plasma: clinical correlates.  
*Res Virol* 146: 151-8 (1995)
- Stutz F; Neville M; Rosbash M  
Identification of a novel nuclear pore-associated protein as a functional target of the HIV-1 Rev protein in yeast.  
*Cell* 82: 495-506 (1995)
- Su L; Kaneshima H; Bonyhadi M; Salimi S; Kraft D; Rabin L; McCune JM  
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo.  
*Immunity* 2: 25-36 (1995)
- Su SF; Amidon GL  
Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery.  
*Biochim Biophys Acta* 1245: 62-8 (1995)
- Su Y; Popik W; Pitha PM  
Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells.  
*J Virol* 69: 110-21 (1995)
- Sugiyama Y; Hamamoto H; Takemoto S; Watanabe Y; Okada Y  
Systemic production of foreign peptides on the particle surface of tobacco mosaic virus.  
*FEBS Lett* 359: 247-50 (1995)
- Sun LQ; Pyati J; Smythe J; Wang L; Macpherson J; Gerlach W; Symonds G  
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs.  
*Proc Natl Acad Sci U S A* 92: 7272-6 (1995)
- Sun LQ; Wang L; Gerlach WL; Symonds G  
Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.  
*Nucleic Acids Res* 23: 2909-13 (1995)
- Sun XW; Ellerbrock TV; Lungu O; Chiasson MA; Bush TJ; Wright TC Jr  
Human papillomavirus infection in human immunodeficiency virus-seropositive women.  
*Obstet Gynecol* 85: 680-6 (1995)
- Sune C; Garcia-Blanco MA  
Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.  
*J Virol* 69: 3098-107 (1995)
- Sune C; Garcia-Blanco MA  
Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.  
*J Virol* 69: 6572-6 (1995)
- Sutton JA; Braddock M; Kingsman AJ; Kingsman SM  
Requirement for HIV-1 TAR sequences for Tat activation in rodent cells.  
*Virology* 206: 690-4 (1995)
- Switzer WM; Heneine W  
Rapid screening of open reading frames by protein synthesis with an in vitro transcription and translation assay.  
*Biotechniques* 18: 244-8 (1995)
- Szebeni A; Herrera JE; Olson MO  
Interaction of nucleolar protein B23 with peptides related to nuclear localization signals.  
*Biochemistry* 34: 8037-42 (1995)

## References (1995)

- Szilvay AM; Brokstad KA; Kopperud R; Haukenes G; Kalland KH  
Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants.  
*J Virol* 69: 3315-23 (1995)
- Tachedjian G; Hooker DJ; Gurusinge AD; Bazmi H; Deacon NJ; Mellors J; Birch C; Mills J  
Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.  
*Virology* 212: 58-68 (1995)
- Takahashi H; Matsuda M; Kojima A; Sata T; Andoh T; Kurata T; Nagashima K; Hall WW  
Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.  
*Proc Natl Acad Sci U S A* 92: 5694-8 (1995)
- Takaku H; Kim SG; Hatta T; Takai K  
[Inhibition of gene expression by antisense DNA]  
*Nippon Rinsho* 53: 771-8 (1995)
- Takeda S; Dorfman NA; Robert-Guroff M; Notkins AL; Rando RF  
Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in *Escherichia coli*.  
*Hybridoma* 14: 9-18 (1995)
- Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH; et al  
Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.  
*J Immunol* 154: 1973-86 (1995)
- Tamaki H; Beaulieu BL; Somasundaran M; Sullivan JL  
Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children.  
*J Infect Dis* 172: 739-46 (1995)
- Tamamura H; Otaka A; Takada W; Terakawa Y; Yoshizawa H; Masuda M; Ibuka T; Murakami T; Nakashima H; Waki M; et al  
Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection.  
*Chem Pharm Bull (Tokyo)* 43: 12-8 (1995)
- Tan R; Frankel AD  
Structural variety of arginine-rich RNA-binding peptides.  
*Proc Natl Acad Sci U S A* 92: 5282-6 (1995)
- Tan W; Felber BK; Zolotukhin AS; Pavlakis GN; Schwartz S  
Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1.  
*J Virol* 69: 5607-20 (1995)
- Tan W; Schwartz S  
The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3' untranslated region.  
*J Virol* 69: 2932-45 (1995)
- Tanaka H; Takashima H; Ubasawa M; Sekiya K; Inouye N; Baba M; Shigeta S; Walker RT; De Clercq E; Miyasaka T  
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.  
*J Med Chem* 38: 2860-5 (1995)
- Tanaka Y; Galinski MS  
Human parainfluenza virus type 3: analysis of the cytoplasmic tail and transmembrane anchor of the hemagglutinin-neuraminidase protein in promoting cell fusion.  
*Virus Res* 36: 131-49 (1995)
- Tanchou V; Sgro-Serpente P; Durand H; Aubertin AM; Dormont D; Venet A; Benarous R  
B-cell continuous epitopes of the SIVmac-251 envelope protein in experimentally infected macaques.  
*Res Virol* 146: 19-32 (1995)
- Tang J; Hartsuck JA  
A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.  
*FEBS Lett* 367: 112-6 (1995)
- Tang S; Patterson B; Levy JA  
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.  
*J Virol* 69: 5659-65 (1995)
- Tao B; Fultz PN  
Molecular and biological analyses of quasispecies during evolution of a virulent simian immunodeficiency virus, SIVsmmPBj14.  
*J Virol* 69: 2031-7 (1995)
- Taylor JP; Pomerantz RJ; Oakes JW; Khalili K; Amini S  
A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat.  
*Oncogene* 10: 395-400 (1995)

- Tencza SB; Miller MA; Islam K; Mietzner TA; Montelaro RC  
Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.  
*J Virol* 69: 5199-202 (1995)
- Teruya-Feldstein J; Temeck BK; Sloas MM; Kingma DW; Raffeld M; Pass HI; Mueller B; Jaffe ES  
Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient.  
*Am J Surg Pathol* 19: 357-63 (1995)
- Terwilliger EF  
Biology of HIV-1 and treatment strategies.  
*Emerg Med Clin North Am* 13: 27-42 (1995)
- Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW; et al  
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.  
*J Med Chem* 38: 3624-37 (1995)
- Thomas DL; Vlahov D; Solomon L; Cohn S; Taylor E; Garfein R; Nelson KE  
Correlates of hepatitis C virus infections among injection drug users.  
*Medicine (Baltimore)* 74: 212-20 (1995)
- Thomas DL; Zenilman JM; Alter HJ; Shih JW; Galai N; Carella AV; Quinn TC  
Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore—an analysis of 309 sex partnerships.  
*J Infect Dis* 171: 768-75 (1995)
- Thomas MG; Ellis-Pegler RB  
Antiretroviral treatment of HIV infection.  
*N Z Med J* 108: 181-2 (1995)
- Thompson JD; Ayers DF; Malmstrom TA; McKenzie TL; Ganousis L; Chowrira BM; Couture L; Stinchcomb DT  
Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.  
*Nucleic Acids Res* 23: 2259-68 (1995)
- Tinkle BT; Ueda H; Jay G  
The pathogenic role of human immunodeficiency virus accessory genes in transgenic mice.  
*Curr Top Microbiol Immunol* 193: 133-56 (1995)
- Tirelli U; Errante D; Dolcetti R; Gloghini A; Serraino D; Vaccher E; Franceschi S; Boiocchi M; Carbone A  
Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.  
*J Clin Oncol* 13: 1758-67 (1995)
- Tissot C; Mechti N  
Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression.  
*J Biol Chem* 270: 14891-8 (1995)
- Tokunaga K; Furuta R; Kawamura M; Adachi A  
[Functions of human immunodeficiency virus regulatory genes]  
*Tanpakushitsu Kakusan Koso* 40: 1079-91 (1995)
- Tong L; Pav S; Mui S; Lamarre D; Yoakim C; Beaulieu P; Anderson PC  
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.  
*Structure* 3: 33-40 (1995)
- Tornevik Y; Ullman B; Balzarini J; Wahren B; Eriksson S  
Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.  
*Biochem Pharmacol* 49: 829-37 (1995)
- Toth FD; Mosborg-Petersen P; Kiss J; Aboagye-Mathiesen G; Hager H; Juhl CB; Gergely L; Zdravkovic M; Aranyosi J; Lampe L; et al  
Interactions between human immunodeficiency virus type 1 and human cytomegalovirus in human term syncytiotrophoblast cells coinfecting with both viruses.  
*J Virol* 69: 2223-32 (1995)
- Towers G; Harris J; Lang G; Collins MK; Latchman DS  
Retinoic acid inhibits both the basal activity and phorbol ester-mediated activation of the HIV long terminal repeat promoter.  
*AIDS* 9: 129-36 (1995)
- Tran AC; Zhang D; Byrn R; Roberts MR  
Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes.  
*J Immunol* 155: 1000-9 (1995)

## References (1995)

- Trial J; Birdsall HH; Hallum JA; Crane ML; Rodriguez-Barradas MC; de Jong AL; Krishnan B; Lacke CE; Figdor CG; Rossen RD  
Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.  
*J Clin Invest* 95: 1690-701 (1995)
- Trischmann H; Davis D; Lachmann PJ  
Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4.  
*AIDS Res Hum Retroviruses* 11: 343-52 (1995)
- Trono D  
HIV accessory proteins: leading roles for the supporting cast.  
*Cell* 82: 189-92 (1995)
- Trono D  
HIV accessory proteins: leading roles for the supporting cast.  
*Cell* 82: 189-92 (1995)
- Tsuchie H; Saraswathy TS; Sinniah M; Vijayamalar B; Maniar JK; Monzon OT; Santana RT; Paladin FJ; Wasi C; Thongcharoen P; et al  
HIV-1 variants in South and South-East Asia.  
*Int J STD AIDS* 6: 117-20 (1995)
- Tsunakawa M; Hu SL; Hoshino Y; Detlefson DJ; Hill SE; Furumai T; White RJ; Nishio M; Kawano K; Yamamoto S; et al  
Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization [letter]  
*J Antibiot (Tokyo)* 48: 433-4 (1995)
- Tsunetsugu-Yokota Y; Akagawa K; Kimoto H; Suzuki K; Iwasaki M; Yasuda S; Hausser G; Hultgren C; Meyerhans A; Take-mori T  
Monocyte-derived cultured dendritic cells are susceptible to human immunodeficiency virus infection and transmit virus to resting T cells in the process of nominal antigen presentation.  
*J Virol* 69: 4544-7 (1995)
- Tummino PJ; Ferguson D; Jacobs CM; Tait B; Hupe L; Lunney E; Hupe D  
Competitive inhibition of HIV-1 protease by biphenyl carboxylic acids.  
*Arch Biochem Biophys* 316: 523-8 (1995)
- Tung CH; Wang J; Leibowitz MJ; Stein S  
Dual-specificity interaction of HIV-1 TAR RNA with Tat peptide-oligonucleotide conjugates.  
*Bioconjug Chem* 6: 292-5 (1995)
- Uberla K; Stahl-Hennig C; Bottiger D; Matz-Rensing K; Kaup FJ; Li J; Haseltine WA; Fleckenstein B; Hunsmann G; Oberg B; et al  
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.  
*Proc Natl Acad Sci U S A* 92: 8210-4 (1995)
- Uda T; Hifumi E; Kobayashi T; Shimizu K; Sata T; Ogino K  
An approach for an immunoaffinity AIDS sensor using the conservative region of the HIV envelope protein (gp41) and its monoclonal antibody.  
*Biosens Bioelectron* 10: 477-83 (1995)
- Vandamme AM; Fransen K; Debaisieux L; Marissens D; Sprecher S; Vaira D; Vandenbroucke AT; Verhofstede C  
Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. The Belgian AIDS Reference Laboratories.  
*J Virol Methods* 51: 305-16 (1995)
- Vandamme AM; Van Dooren S; Kok W; Goubau P; Fransen K; Kievits T; Schmit JC; De Clercq E; Desmyter J  
Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR.  
*J Virol Methods* 52: 121-32 (1995)
- Vanhee-Brossollet C; Thoreau H; Serpente N; D'Auriol L; Levy JP; Vaquero C  
A natural antisense RNA derived from the HIV-1 env gene encodes a protein which is recognized by circulating antibodies of HIV+ individuals.  
*Virology* 206: 196-202 (1995)
- Vanhoof G; Goossens F; De Meester I; Hendriks D; Scharpe S  
Proline motifs in peptides and their biological processing.  
*FASEB J* 9: 736-44 (1995)
- Velge-Roussel F; Breton P; Lescure F; Guillon X; Bout D; Hoebeke J  
Analysis of human CD4-antibody interaction using the BIA-core system.  
*J Immunol Methods* 183: 141-8 (1995)
- Vellutini C; Horschowski N; Philippon V; Gambarelli D; Nave KA; Filippi P  
Development of lymphoid hyperplasia in transgenic mice expressing the HIV tat gene.  
*AIDS Res Hum Retroviruses* 11: 21-9 (1995)

- Veschambre P; Simard P; Jalinot P  
Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo.  
*J Mol Biol* 250: 169-80 (1995)
- Viard JP; Hennequin C; Fortineau N; Pertuiset N; Rothschild C; Zylberberg H  
Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole [letter]  
*Lancet* 346: 118 (1995)
- Vingerhoets JH; Vanham GL; Kestens LL; Penne GG; Colebunders RL; Vandenbruaene MJ; Goeman J; Gigase PL; De Boer M; Ceuppens JL  
Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects.  
*Clin Exp Immunol* 100: 425-33 (1995)
- Vlach J; Garcia A; Jacque JM; Rodriguez MS; Michelson S; Virelizier JL  
Induction of Sp1 phosphorylation and NF-kappa B-independent HIV promoter domain activity in T lymphocytes stimulated by okadaic acid.  
*Virology* 208: 753-61 (1995)
- Vogel T; Norley S; Beer B; Kurth R  
Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.  
*Immunology* 84: 482-7 (1995)
- Vogt G; le Grand R; Vaslin B; Boussin F; Auboyer MH; Riviere Y; Putkonen P; Sonigo P; Kieny MP; Girard M; et al  
Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins.  
*Vaccine* 13: 202-8 (1995)
- Volkman S; Jendis J; Frauendorf A; Moelling K  
Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA.  
*Nucleic Acids Res* 23: 1204-12 (1995)
- Volsky DJ; Potash MJ; Simm M; Sova P; Ma XY; Chao W; Shahabuddin M  
The human immunodeficiency virus type 1 vif gene: the road from an accessory to an essential role in human immunodeficiency virus type 1 replication.  
*Curr Top Microbiol Immunol* 193: 157-68 (1995)
- Voss G; Li J; Manson K; Wyand M; Sodroski J; Letvin NL  
Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys.  
*Virology* 208: 770-5 (1995)
- Voss G; Li J; Manson K; Wyand M; Sodroski J; Letvin NL  
Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys.  
*Virology* 208: 770-5 (1995)
- Vyas RR; Basu AK  
DNA polymerase action on an oligonucleotide containing a site-specifically located N-(deoxyguanosin-8-yl)-1-aminopyrene.  
*Carcinogenesis* 16: 811-6 (1995)
- Wagner G  
The importance of being floppy [news; comment]  
*Nat Struct Biol* 2: 255-7 (1995)
- Wainberg MA; Gu Z; Salomon H; Arts EJ; Kleiman L; Parniak MA; Morin N  
[Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds]  
*C R Acad Sci III* 318: 315-28 (1995)
- Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J; et al  
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.  
*AIDS* 9: 351-7 (1995)
- Wakefield JK; Wolf AG; Morrow CD  
Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).  
*J Virol* 69: 6021-9 (1995)
- Walker WL; Kopka ML; Filipowsky ME; Dickerson RE; Goodsell DS  
Design of B-DNA cross-linking and sequence-reading molecules.  
*Biopolymers* 35: 543-53 (1995)
- Walling DM; Clark NM; Markovitz DM; Frank TS; Braun DK; Eisenberg E; Krutchkoff DJ; Felix DH; Raab-Traub N  
Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia [see comments]  
*J Infect Dis* 171: 1122-30 (1995)
- Wan M; Loh BN  
Expression and purification of active form of HIV-1 protease from *E.coli*.  
*Biochem Mol Biol Int* 35: 899-912 (1995)

## References (1995)

- Wan M; Takagi M; Loh BN; Imanaka T  
Comparison of HIV-1 protease expression in different fusion forms.  
*Biochem Mol Biol Int* 36: 411-9 (1995)
- Wang B; Boyer J; Srikantan V; Ugen K; Gilbert L; Phan C; Dang K; Merva M; Agadjanyan MG; Newman M; et al  
Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.  
*Virology* 211: 102-12 (1995)
- Wang CC; Hwang LH; Yang PM; Chiang BL; Chen PJ; Chen DS  
Unbiased usage of T-cell receptor beta variable region genes in peripheral blood cells of hepatitis C patients: no correlation with superantigen effect.  
*J Med Virol* 45: 24-8 (1995)
- Wang GT; Li S; Wideburg N; Krafft GA; Kempf DJ  
Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.  
*J Med Chem* 38: 2995-3002 (1995)
- Wang H; Nishanian P; Fahey JL  
Characterization of immune suppression by a synthetic HIV gp41 peptide.  
*Cell Immunol* 161: 236-43 (1995)
- Wang N; Zhu T; Ho DD  
Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.  
*J Virol* 69: 2708-15 (1995)
- Wang QL; Wang HT; Blalock E; Muller S; Kohler H  
Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals.  
*J Clin Invest* 96: 775-80 (1995)
- Wang WK; Essex M; Lee TH  
Uncommon gp120 cysteine residues found in primary HIV-1 isolates.  
*AIDS Res Hum Retroviruses* 11: 185-8 (1995)
- Wang WK; Essex M; Lee TH  
The highly conserved aspartic acid residue between hyper-variable regions 1 and 2 of human immunodeficiency virus type 1 gp120 is important for early stages of virus replication.  
*J Virol* 69: 538-42 (1995)
- Ward GA; Stover CK; Moss B; Fuerst TR  
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.  
*Proc Natl Acad Sci U S A* 92: 6773-7 (1995)
- Ward NE; Gravitt KR; O'Brian CA  
Inhibition of protein kinase C by a synthetic peptide corresponding to cytoplasmic domain residues 828-848 of the human immunodeficiency virus type 1 envelope glycoprotein.  
*Cancer Lett* 88: 37-40 (1995)
- Warfel AH; Thorbecke GJ; Belsito DV  
Synergism between interferon-gamma and cytokines or lipopolysaccharide in the activation of the HIV-LTR in macrophages.  
*J Leukoc Biol* 57: 469-76 (1995)
- Warren RQ; Wong MT; Melcher GP; Blatt SP; Cahn P; Perez H; Zapiola I; Bouzas MB; Muchnik G; Anderson SA; et al  
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates.  
*J Clin Microbiol* 33: 481-3 (1995)
- Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH; et al  
Viral dynamics in human immunodeficiency virus type 1 infection [see comments]  
*Nature* 373: 117-22 (1995)
- Weinberg JB; Misukonis MA; Shami PJ; Mason SN; Sauls DL; Dittman WA; Wood ER; Smith GK; McDonald B; Bachus KE; et al  
Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages.  
*Blood* 86: 1184-95 (1995)
- Weissman D; Li Y; Ananworanich J; Zhou LJ; Adelsberger J; Tedder TF; Baseler M; Fauci AS  
Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1.  
*Proc Natl Acad Sci U S A* 92: 826-30 (1995)
- Weissman D; Poli G; Fauci AS  
IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage.  
*J Acquir Immune Defic Syndr Hum Retrovirol* 9: 442-9 (1995)

- Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M  
Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.  
*Blood* 86: 2321-8 (1995)
- Weltman AC; Righi SP; DiFerdinando GT Jr; Jovell RJ; Driscoll JR  
Rifampicin-resistant *Mycobacterium tuberculosis* [letter]  
*Lancet* 345: 1513 (1995)
- Wen W; Meinkoth JL; Tsien RY; Taylor SS  
Identification of a signal for rapid export of proteins from the nucleus.  
*Cell* 82: 463-73 (1995)
- West ML; Fairlie DP  
Targeting HIV-1 protease: a test of drug-design methodologies.  
*Trends Pharmacol Sci* 16: 67-75 (1995)
- Westendorp MO; Shatrov VA; Schulze-Osthoff K; Frank R; Kraft M; Los M; Krammer PH; Droge W; Lehmann V  
HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state.  
*EMBO J* 14: 546-54 (1995)
- Whatmore AM; Cook N; Hall GA; Sharpe S; Rud EW; Cranage MP  
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence.  
*J Virol* 69: 5117-23 (1995)
- White MR; Masuko M; Amet L; Elliott G; Braddock M; Kingsman AJ; Kingsman SM  
Real-time analysis of the transcriptional regulation of HIV and hCMV promoters in single mammalian cells.  
*J Cell Sci* 108 ( Pt 2): 441-55 (1995)
- Wild C; Greenwell T; Shugars D; Rimsky-Clarke L; Matthews T  
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure [letter]  
*AIDS Res Hum Retroviruses* 11: 323-5 (1995)
- Wilson CC; Wong JT; Girard DD; Merrill DP; Dynan M; An DD; Kalams SA; Johnson RP; Hirsch MS; D'Aquila RT; et al  
Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents.  
*J Infect Dis* 172: 88-96 (1995)
- Wilt SG; Milward E; Zhou JM; Nagasato K; Patton H; Rusten R; Griffin DE; O'Connor M; Dubois-Dalcq M  
In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy.  
*Ann Neurol* 37: 381-94 (1995)
- Winslow DL; Stack S; King R; Scarnati H; Bincsik A; Otto MJ  
Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors.  
*AIDS Res Hum Retroviruses* 11: 107-13 (1995)
- Winter N; Lagranderie M; Gangloff S; Leclerc C; Gheorghiu M; Gicquel B  
Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice.  
*Vaccine* 13: 471-8 (1995)
- Winter N; Lagranderie M; Gangloff S; Leclerc C; Gheorghiu M; Gicquel B  
Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice.  
*Vaccine* 13: 471-8 (1995)
- Wiskerchen M; Muesing MA  
Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene.  
*J Virol* 69: 597-601 (1995)
- Wiskerchen M; Muesing MA  
Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.  
*J Virol* 69: 376-86 (1995)
- Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D; et al  
Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.  
*Nat Struct Biol* 2: 480-8 (1995)
- Wohrl BM; Georgiadis MM; Telesnitsky A; Hendrickson WA; Le Grice SF  
Footprint analysis of replicating murine leukemia virus reverse transcriptase.  
*Science* 267: 96-9 (1995)
- Wohrl BM; Tantillo C; Arnold E; Le Grice SF  
An expanded model of replicating human immunodeficiency virus reverse transcriptase.  
*Biochemistry* 34: 5343-56 (1995)



## References (1995)

- Wolf L  
A tuberculosis control plan for ambulatory care centers.  
*Nurse Pract* 20: 34-6, 39-40 (1995)
- Wolff B; Cohen G; Hauber J; Meshcheryakova D; Rabeck C  
Nucleocytoplasmic transport of the Rev protein of human immunodeficiency virus type 1 is dependent on the activation domain of the protein.  
*Exp Cell Res* 217: 31-41 (1995)
- Woloschak GE; Panozzo J; Schreck S; Libertin CR  
Salicylic acid inhibits ultraviolet- and cis-platinum-induced human immunodeficiency virus expression.  
*Cancer Res* 55: 1696-700 (1995)
- Wray V; Federau T; Henklein P; Klabunde S; Kunert O; Schomburg D; Schubert U  
Solution structure of the hydrophilic region of HIV-1 encoded virus protein U (Vpu) by CD and 1H NMR spectroscopy.  
*Int J Pept Protein Res* 45: 35-43 (1995)
- Wrin T; Loh TP; Vennari JC; Schuitemaker H; Nunberg JH  
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.  
*J Virol* 69: 39-48 (1995)
- Wu BY; Woffendin C; Duckett CS; Ohno T; Nabel GJ  
Regulation of human retroviral latency by the NF-kappa B/I kappa B family: inhibition of human immunodeficiency virus replication by I kappa B through a Rev-dependent mechanism.  
*Proc Natl Acad Sci U S A* 92: 1480-4 (1995)
- Wu H; Yang WP; Barbas CF 3rd  
Building zinc fingers by selection: toward a therapeutic application.  
*Proc Natl Acad Sci U S A* 92: 344-8 (1995)
- Wu W; Blumberg BM; Fay PJ; Bambara RA  
Strand transfer mediated by human immunodeficiency virus reverse transcriptase in vitro is promoted by pausing and results in misincorporation.  
*J Biol Chem* 270: 325-32 (1995)
- Wu X; Liu H; Xiao H; Kim J; Seshiah P; Natsoulis G; Boeke JD; Hahn BH; Kappes JC  
Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.  
*J Virol* 69: 3389-98 (1995)
- Wu Z; Kayman SC; Honnen W; Revesz K; Chen H; Vijn-Warrier S; Tilley SA; McKeating J; Shotton C; Pinter A  
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.  
*J Virol* 69: 2271-8 (1995)
- Wu-Baer F; Sigman D; Gaynor RB  
Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.  
*Proc Natl Acad Sci U S A* 92: 7153-7 (1995)
- Wyatt PG; Bethell RC; Cammack N; Charon D; Dodic N; Dumaitre B; Evans DN; Green DV; Hopewell PL; Humber DC; et al  
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.  
*J Med Chem* 38: 1657-65 (1995)
- Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J  
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.  
*J Virol* 69: 5723-33 (1995)
- Wyss-Coray T; Feng L; Masliah E; Ruppe MD; Lee HS; Toggas SM; Rockenstein EM; Mucke L  
Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1.  
*Am J Pathol* 147: 53-67 (1995)
- Xie L; Xie JX; Kashiwada Y; Cosentino LM; Liu SH; Pai RB; Cheng YC; Lee KH  
Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents.  
*J Med Chem* 38: 3003-8 (1995)
- Yadav PN; Yadav JS; Modak MJ  
Nucleoside drug resistance in HIV-1 reverse transcriptase [letter]  
*Nat Struct Biol* 2: 193-5 (1995)
- Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J  
Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.  
*J Virol* 69: 320-5 (1995)

- Yamada K; Morozumi H; Okamoto T  
LTR-directed homologous recombination of full-length HIV-1 provirus clone in recA(-) bacteria.  
*Arch Virol* 140: 1007-14 (1995)
- Yamasaki K; Saito M; Oobatake M; Kanaya S  
Characterization of the internal motions of Escherichia coli ribonuclease HI by a combination of 15N-NMR relaxation analysis and molecular dynamics simulation: examination of dynamic models.  
*Biochemistry* 34: 6587-601 (1995)
- Yang W; Steitz TA  
Recombining the structures of HIV integrase, RuvC and RNase H.  
*Structure* 3: 131-4 (1995)
- Yang WP; Wu H; Barbas CF 3rd  
Surface plasmon resonance based kinetic studies of zinc finger-DNA interactions.  
*J Immunol Methods* 183: 175-82 (1995)
- Yang Y; Bailey J; Vacchio MS; Yarchoan R; Ashwell JD  
Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells.  
*Proc Natl Acad Sci U S A* 92: 3051-5 (1995)
- Yang ZH; Mtoni I; Chonde M; Mwasekaga M; Fuursted K; Askgard DS; Bennedsen J; de Haas PE; van Soolingen D; van Embden JD; et al  
DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients in Tanzania.  
*J Clin Microbiol* 33: 1064-9 (1995)
- Yao FL; Klein MH; Loosmore S; Rovinski B  
Gene assembly-aided mutagenesis (GAAM).  
*Biotechniques* 18: 372-4, 376 (1995)
- Yao XJ; Friberg J; Checroune F; Gratton S; Boisvert F; Sekaly RP; Cohen EA  
Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity.  
*Virology* 209: 615-23 (1995)
- Yao Y; Hoffer A; Chang CY; Puga A  
Dioxin activates HIV-1 gene expression by an oxidative stress pathway requiring a functional cytochrome P450 CYP1A1 enzyme.  
*Environ Health Perspect* 103: 366-71 (1995)
- Yasutomi Y; Koenig S; Woods RM; Madsen J; Wassef NM; Alving CR; Klein HJ; Nolan TE; Boots LJ; Kessler JA; et al  
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.  
*J Virol* 69: 2279-84 (1995)
- Yasutomi Y; McAdam SN; Boyson JE; Piekarczyk MS; Watkins DI; Letvin NL  
A MHC class I B locus allele-restricted simian immunodeficiency virus envelope CTL epitope in rhesus monkeys.  
*J Immunol* 154: 2516-22 (1995)
- Yawetz S; Cumberland WG; van der Meyden M; Martinez-Maza O  
Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma.  
*Blood* 85: 1843-9 (1995)
- Yeung MC; Pulliam L; Lau AS  
The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha.  
*AIDS* 9: 137-43 (1995)
- Yoshida H; Ikeda K; Achiwa K; Hoshino H  
Synthesis of sulfated cerebroside analogs having mimicks of ceramide and their anti-human immunodeficiency virus type 1 activities.  
*Chem Pharm Bull (Tokyo)* 43: 594-602 (1995)
- Yoshinaga T; Fujiwara T  
Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro.  
*J Virol* 69: 3233-6 (1995)
- Yu G; Shen FS; Sturch S; Aquino A; Glazer RI; Felsted RL  
Regulation of HIV-1 gag protein subcellular targeting by protein kinase C.  
*J Biol Chem* 270: 4792-6 (1995)
- Yu L; Loewenstein PM; Zhang Z; Green M  
In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP.  
*J Virol* 69: 3017-23 (1995)
- Yu L; Zhang Z; Loewenstein PM; Desai K; Tang Q; Mao D; Symington JS; Green M  
Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain.  
*J Virol* 69: 3007-16 (1995)

## References (1995)

- Yu M; Leavitt MC; Maruyama M; Yamada O; Young D; Ho AD; Wong-Staal F  
Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1.  
Proc Natl Acad Sci U S A 92: 699-703 (1995)
- Yu M; Poeschla E; Yamada O; Degrandis P; Leavitt MC; Heusch M; Yees JK; Wong-Staal F; Hampel A  
In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1.  
Virology 206: 381-6 (1995)
- Yu WH; Wolfgang W; Forte M  
Subcellular localization of human voltage-dependent anion channel isoforms.  
J Biol Chem 270: 13998-4006 (1995)
- Yu XF; Wang Z; Beyrer C; Celentano DD; Khamboonruang C; Allen E; Nelson K  
Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand.  
J Virol 69: 4649-55 (1995)
- Yuan T; Mietzner TA; Montelaro RC; Vogel HJ  
Characterization of the calmodulin binding domain of HIV transmembrane glycoprotein by NMR and CD spectroscopy.  
Biochemistry 34: 10690-6 (1995)
- Yusa K; Oh-hara T; Tsuruo T  
Induction of resistance to 1-beta-D-arabinofuranosylcytosine in human H9 cell line by simian immunodeficiency virus.  
Biochem Biophys Res Commun 206: 486-91 (1995)
- Zaaijer HL; Kok W; ten Veen JH; Reesink HW; Foolen H; Winkel IN; Huisman JG; Cuypers HT; Kievits T; Lelie PN  
Detection of HIV-1 RNA in plasma by isothermal amplification (NASBA) irrespective of the stage of HIV-1 infection.  
J Virol Methods 52: 175-81 (1995)
- Zacharias M; Hagerman PJ  
The bend in RNA created by the trans-activation response element bulge of human immunodeficiency virus is straightened by arginine and by Tat-derived peptide.  
Proc Natl Acad Sci U S A 92: 6052-6 (1995)
- Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA  
Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.  
Proc Natl Acad Sci U S A 92: 631-5 (1995)
- Zakharova OD; Tarrago-Litvak L; Fournier M; Andreola ML; Repkova MN; Venyaminova AG; Litvak S; Nevinsky GA  
Interaction of primer tRNA(Lys3) with the p51 subunit of human immunodeficiency virus type 1 reverse transcriptase: a possible role in enzyme activation.  
FEBS Lett 361: 287-90 (1995)
- Zambello R; Loughran TP Jr; Trentin L; Pontisso P; Battistella L; Raimondi R; Facco M; Sancetta R; Agostini C; Pizzolo G; et al  
Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes.  
Leukemia 9: 1207-11 (1995)
- Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A  
Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.  
Virology 206: 807-16 (1995)
- Zhang D; Zhang N; Wick MM; Byrn RA  
HIV type 1 protease activation of NF-kappa B within T lymphoid cells.  
AIDS Res Hum Retroviruses 11: 223-30 (1995)
- Zhang H; Zhang Y; Spicer T; Henrard D; Poiesz BJ  
Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle.  
J Virol 69: 3675-82 (1995)
- Zhang P; Chiriboga L; Jacobson M; Marsh E; Hennessey P; Schinella R; Feiner H  
Mycosis fungoideslike T-cell cutaneous lymphoid infiltrates in patients with HIV infection.  
Am J Dermatopathol 17: 29-35 (1995)
- Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S  
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.  
Biochem Pharmacol 49: 929-39 (1995)
- Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S  
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.  
Clin Chem 41: 836-43 (1995)

- Zhang R; Yan J; Shahinian H; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR; et al  
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.  
*Clin Pharmacol Ther* 58: 44-53 (1995)
- Zhang Y; Barklis E  
Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation.  
*J Virol* 69: 5716-22 (1995)
- Zhang Y; Nakata K; Weiden M; Rom WN  
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat.  
*J Clin Invest* 95: 2324-31 (1995)
- Zhong P; Peeters M; Janssens W; Franssen K; Heyndrickx L; Vanham G; Willems B; Piot P; van der Groen G  
Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D.  
*AIDS Res Hum Retroviruses* 11: 239-48 (1995)
- Zhou Q; Sharp PA  
Novel mechanism and factor for regulation by HIV-1 Tat.  
*EMBO J* 14: 321-8 (1995)
- Zhu T; Wang N; Carr A; Wolinsky S; Ho DD  
Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconverter.  
*J Virol* 69: 1324-7 (1995)
- Zolla-Pazner S; O'Leary J; Burda S; Gorny MK; Kim M; Mascola J; McCutchan F  
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.  
*J Virol* 69: 3807-15 (1995)
- Zoumadakis M; Tabler M  
Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.  
*Nucleic Acids Res* 23: 1192-6 (1995)
- Zvi A; Kustanovich I; Feigelson D; Levy R; Eisenstein M; Matsushita S; Richalet-Secordel P; Regenmortel MH; Anglister J  
NMR mapping of the antigenic determinant recognized by an anti-gp120, human immunodeficiency virus neutralizing antibody.  
*Eur J Biochem* 229: 178-87 (1995)
- Zvi A; Kustanovich I; Hayek Y; Matsushita S; Anglister J  
The principal neutralizing determinant of HIV-1 located in V3 of gp120 forms a 12-residue loop by internal hydrophobic interactions.  
*FEBS Lett* 368: 267-70 (1995)
- Zybarth G; Carter C  
Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing.